HPLC Method Development and Quantitation for Pharmaceutical Compounds by Patel, Hitesh B.
          Saurashtra University 
     Re – Accredited Grade ‘B’ by NAAC 
     (CGPA 2.93) 
 
 
 
 
Patel, Hitesh B., 2008, “HPLC Method Development and Quantitation for 
Pharmaceutical Compounds”,  thesis PhD, Saurashtra University 
  
http://etheses.saurashtrauniversity.edu/id/eprint/439 
  
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author. 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given.  
 
 
 
 
 
 
 
 
 
Saurashtra University Theses Service 
http://etheses.saurashtrauniversity.edu 
repository@sauuni.ernet.in 
 
© The Author 
  
HPLC METHOD DEVELOPMENT AND QUANTITATION  
FOR PHARMACEUTICAL COMPOUNDS 
  
A  
THESIS 
SUBMITTED TO THE 
SAURASHTRA UNIVERSITY 
 FOR THE DEGREE OF  
 
Doctor of Philosophy 
IN 
THE FACULTY OF SCIENCE (CHEMISTRY) 
BY 
 Hitesh B. Patel   
 
UNDER THE GUIDANCE 
   OF   
Dr. H. S. Joshi 
 
DEPARTMENT OF CHEMISTRY 
(DST-FUNDED, UGC-SAP SPONSORED) 
SAURASHTRA UNIVERSITY 
(  BY NAAC) 
RAJKOT : 360 005, INDIA 
 2008  
 
 
Gram: UNIVERSITY Phone: (R) 0281-2584221
Fax: 0281-2577633 (O) 0281-2578512
SAURASHTRA UNIVERSITY
University Road
Rajkot - 360 005
Dr. H. S. Joshi Residence:
M.Sc., Ph.D., F.I.C.S. B-1, Amidhara Appartment
Associate Professor 2- Jalaram Plot
Department of Chemistry University Road
Rajkot - 360 005
GUJARAT (INDIA)
               Statement under o. Ph. D. 7 of Saurashtra University
The work included in the thesis is my own work under the supervision of Dr. H. S. Joshi and
leads to some contribution in chemistry subsidized by a number of references.
Date :              2008
Place : Rajkot Hitesh B. Patel
This is to certify that the present work submitted for the Ph.D. Degree of Saurashtra University
by Hitesh B. Patel is his own work and leads to advancement in the  knowledge of chemistry.
The thesis has been prepared under my supervision.
Date :              2008
Place : Rajkot Dr. H. S. Joshi
Associate Professor
Department of Chemistry
Saurashtra University
Rajkot-360 005
ACKNOWLEDGEMENTS 
 
With the blessing of God let me write that the source of honors for the completion 
of the work embodied in the present thesis is due to numerous persons by whom I have 
been inspired, helped by many ways. 
 
First of all I would like to express my sincere gratitude to my supervisor Associate 
Professor Dr. H. S. Joshi for accepting me as his research student and who made this 
research a success. It is with Dr. Joshi’s enthusiasm and integral view on research 
combined with his willingness to provide quality chemistry and not less that kept me 
going and I wish to say thank you for showing me this way of research. Besides being a 
wonderful Supervisor, Dr. Joshi is very good friend and I am deeply honored to have 
known him in my life. I wish to say thank you so much again Dr. Joshi for all the help 
you offered over the years both in and out of my academic life. It is with no doubt that 
without your help I would not be where I am now and where I will in future. 
 
I pay my homage and devote my emotions to my father Mr. Balubahi L. Patel and 
mother Mrs. Labhuben B. Patel without their blessing this task would not have been 
accomplished. I bow my head with utter humility to them for their continuous source of 
energy, inspirations, and motivation. 
 
 I also owe to, from the deepest corner of heart, deepest sense of gratitude and 
indebtedness to Professor P. H. Parshania, Department Head to allowing me for research 
work at department of chemistry as well as at Torrent research Center. I am thankful to 
Professor Anamik Shah, Department of Chemistry for motivation. 
 
I can never forget my younger brother Bhavesh and my elder sisters 
Dr.Pareshaben, Bhartiben, Nayana and Heena for many ways they supported me for this 
work.  
 
How could I ever forget to my wife Harsha? By her, I was constant encouraged 
and motivated for this work. I am thankful to my daughter Devisha to allow me happily to 
do work on off days and late night that was also the great support for me. 
 
I cherish the affection and help rendered by my best friends like Dr.Hitesh Jogia 
and Dr.Tushar Mehta who ever stood beside me with their helping hands and moral 
support with research environment in my life. I am very thankful to Mr.Hemal Gajjar for 
supporting me for research work permission from the Torrent Research Center. I am 
thankful to Mr.Pranav Shah and Mr. Ronak Rami for supporting me for analytical method 
validation. 
 
I am thankful to Mr. Anirban chowdhury to support me at the beginning of this 
work and I am also thankful to Mr. Jitendra Baria to support me at the end of this work. 
  
I am very thankful to Mr. Arivozhi Mohan for his primary approval from 
analytical development department and for providing all kind of support for this work 
from beginning to end. 
 
I would like to reserve special thanks for Dr. Dutt. Without his permission I can 
not accomplish this task and I also thankful to Dr.Sunil Nadkarni, Mr.P.C.Gandhi and all 
research committee members’ behalf of all research students of the TRC for their great 
support. 
 
I would like to acknowledge the owner of Torrent Research Center Mr. Sudhir 
Mehta and his family and to the founder of the Torrent group, Late Shri Mr.U. N. Mehta 
for creating the space for the people, without that platform I can not accomplish this task. 
 
Thanks to my best friends of research team of Dr. H. S. Joshi; like Dr. Dushyant, 
Dr.Pankaj Kachhadia, Ashish Doshi, Satish Tala, Kaushik Joshi, Manoj Dhaduk Vijay 
Ram, Kapil Dubal Govind Kher, Bhavesh Dodia and Renish Ghetia for their many kind 
of support. 
 
I express my grateful acknowledgment to Department of Chemistry and 
Saurashtra University for their consideration to me as research student and registered me 
for research work. 
 
I wish to acknowledge the people who surrounded to me and supported me behind 
the screen for this entire research, without their greatness I can not accomplish this task. 
 
 
 
 
Hitesh B. Patel 
 
CONTENT  
SYNOPSIS……………………………………………………………………………. 001
PART-[A] 
HPLC METHOD DEVELOPMENT AND QUANTITATION OF API AND 
FORMULATION 
 
General Introduction…………………………………………………………………. 007
References……………………………………………………………………………. 024
Section-I: HPLC Method development and validation for determination of 
related impurities in Olanzapine OD tablets 
 
1. Introduction………………………………………………………………….. 026
2. Literature review……………………………………………………………. 027
3. Aim of present study…………………………………………………………. 032
4. Experimental…………………………………………………………………. 033
5. Result and discussion………………………………………………………… 036
6. Quantitation and calculation formulae………………………………………. 055
7. References………………………….. ……………………………………….. 058
Section-II: HPLC Method development and validation for determination of 
related impurities in Quetiapine fumarate 
 
1. Introduction…………………………………………………………………… 060
2. Literature review…………………………………………………………….. 063
3. Aim of present study…………………………………………………………. 067
4. Experimental………………………………………………………………….. 069
5. Result and discussion………………………………………………………… 073
6. Quantitation and calculation formulae……………………………………….. 097
7. References …………………………..……………………………………….. 100
Section-III: HPLC Method development and validation for assay of 
Pramipexole in Pramipexole tablets 
 
1. Introduction…………………………………………………………………… 102
2. Literature review…………………………………………………………….. 105
3. Aim of present study…………………………………………………………. 107
4. Experimental………………………………………………………………….. 108
5. Result and discussion………………………………………………………… 109
6. Quantitation and calculation formulae………………………………………. 124
7. References …………………………..……………………………………….. 126
 
   
PART-[B]:  
CHIRAL SEPARATION AND METHOD DEVELOPMENT OF API BY 
HPLC 
 
Introduction to chiral chromatography………………………………………………. 128
References…………………………...……………………………………………….. 137
Section-I: Chiral RP-HPLC method development and validation for 
determination of R-isomer in Pramipexole 
 
1. Introduction…………………………………………………………………… 138
2. Literature review…………………………………………………………….. 138
3. Aim of present study…………………………………………………………. 139
4. Experimental…………………………………………………………………. 140
5. Result and discussion………………………………………………………… 142
6. Quantitation and calculation formulae………………………………………. 155
7. References…………………………...……………………………………….. 157
PART-[C]:  
METHOD DEVELOPMENT AND QUANTITATION OF FORMULATION 
BY UPLC 
 
Introduction to UPLC………………………………………………………………… 158
References…………………………………………………………………………..... 163
Section-I: UPLC Method development and validation for determination of 
related impurities in Torsemide tablets 
 
1. Introduction…………………………………………………………………… 164
2. Literature review…………………………………………………………….. 165
3. Aim of present study…………………………………………………………. 168
4. Experimental…………………………………………………………………. 169
5. Result and discussion………………………………………………………… 173
6. Quantitation and calculation formulae………………………………………. 193
7. References ………………………….………………………………………… 195
Glossary………………………………………………………………………………. 197
 
 
  
  1  
 
 
 SYNOPSIS  
A comprehensive summary of the work to be incorporated in the thesis entitled 
“HPLC method development and quantitation for pharmaceutical compounds” has 
been described as under. 
 
PART-[A] HPLC METHOD DEVELOPMENT AND QUANTITATION OF 
API AND FORMULATION 
PART-[B] CHIRAL SEPARATION AND METHOD DEVELOPMENT OF 
API BY HPLC 
PART-[C] METHOD DEVELOPMENT AND QUANTITATION OF 
FORMULATION BY UPLC 
 
Experimental approach based on several considerations for each section 
mentioned as under: 
Development of analytical method  Validation parameters for analytical method 
Separation goal and information  Specificity 
Selection of mobile phase  Linearity and range  
Selection of stationary phase  Precision and intermediate precision 
Selection of flow-mode and flow rate  Accuracy 
Selection of wave-length  Robustness 
Selection of diluent  Solution stability 
Injection volume / Concentration  Limit of detection and limit of quantification 
 
PART-[A]:  
HPLC METHOD DEVELOPMENT AND QUANTITATION OF API AND 
FORMULATION 
 
Aim of present studies 
The research work undertaken in these studies in the area of pharmaceuticals and 
mainly addresses method development for determination of assay of pharmaceutical 
compound and determination of related impurities in active pharmaceutical substances as 
well as in its products by HPLC. Each developed analytical method was validated for its 
intended application as per ICH guideline. 
 
 
Synopsis 
 
________________________________________________________________________ 
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Section-I: HPLC Method development and validation for determination of related 
impurities in Olanzapine OD tablets 
N
NN
S
CH3
CH3
 
Olanzapine, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5] benzodiazepine 
Developed chromatographic conditions 
Buffer Buffer, 6.24 gm sodium dihydrogen orthophosphate dehydrate 
in 800 ml of water, pH was adjusted to 6.8 with dilute sodium 
hydroxide solution, filtered through 0.45µm membrane  
Mobile phase-A Buffer : Acetonitrile: Methanol, 500:200:300 (v/v/v) 
Mobile phase-B Water : Acetonitrile, 20:80 (v/v) 
Diluent Water : Acetonitrile, 20:80 (v/v) 
Column oven temp. 27°C 
Detection UV at 250 nm 
Injection volume 20 µl 
Time (min) Mobile phase-A (%) Mobile phase-B (%) 
0.01 100 0 
20 100 0 
25 70 30 
30 40 60 
35 20 80 
40 10 90 
45 10 90 
50 40 60 
55 100 0 
Gradient 
programme 
60 100 0 
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________________________________________________________________________ 
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Section-II: HPLC Method development and validation for determination of related 
impurities in Quetiapine fumarate 
OH
OH
O
OS
N N
N
O
OH
 2  
Quetiapine fumarate 
Developed chromatographic conditions 
Mobile phase-A Buffer : Acetonitrile : Methanol, 70: 13: 17 (v/v/v) 
(Buffer, 40 mM ammonium acetate, pH was adjusted with ammonia  
solution to 9.2, filtered through 0.45µm PVDF membrane) 
Mobile phase-B Acetonitrile 
Column X terra RP -8 ,150 mm X 4.6mm 5µm 
Column oven temp 45°C 
Detection UV at 250 nm  
Flow rate 1.5ml/min 
Injection volume 20µl 
Run time 80 min 
Time (min) Mobile phase-A (%) Mobile phase-B (%) 
0.0 100 0 
40 100 0 
65 50 50 
75 50 50 
76 100 0 
Gradient program 
80 100 0 
Diluent 0.1ml of perchloric acid (70%) in 1000 ml of mixture of water and 
Acetonitrile in ratio of 20:80 
 
 
 
 
 
Synopsis 
 
________________________________________________________________________ 
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Section-III: HPLC Method development and validation for assay of Pramipexole in 
Pramipexole tablets 
N
SNH
H3C
H
NH2 2HCl H2O
S-isomer  
Pramipexole, (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole as 2HCl H2O 
 
Developed chromatographic conditions 
Mobile phase 0.1% ammonia solution:acetonitrile:methanol,70:15:15 (v/v/v) 
Column X terra RP -8 ,150 mm X 4.6mm 5µm 
Column oven temp 25°C 
Detection UV at 260 nm  
Flow rate 1.0 ml/min 
Injection volume 10µl 
Run time 10 min 
Diluent Water: Methanol, 50:50 (v/v) 
 
PART-[B]: 
CHIRAL SEPARATION AND METHOD DEVELOPMENT OF API BY HPLC 
 
Aim of study 
 
The research work undertaken in this study in the area of pharmaceuticals and 
addresses method development for determination chiral purity or determination of R-
isomer as an impurity for active pharmaceutical substances by HPLC. Developed 
analytical method was validated for its intended application as per ICH guideline. 
 
 
Synopsis 
 
________________________________________________________________________ 
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Section-I: Chiral RP-HPLC method development and validation for determination 
of R-isomer in Pramipexole  
N
SNH
H3C
H
NH2 2HCl H2O
N
SNH
H3C
H
NH2 2HCl H2O
S-Isomer of Pramipexole (API)
R-Isomer of Pramipexole (Impurity)  
Developed chromatographic conditions 
Mobile phase Buffer: Acetonitrile in ratio of 70: 30 (v/v)  
Column CHIRAL PACK AD-RH 150 mm x 4.6 mm with 10 x 4 mm 
guard cartridge as of same CSP in gourd holder 
Column oven temp 25°C 
Detection UV at 260 nm  
Flow rate 0.6 ml/min 
Injection volume 20µl 
Run time 45 min 
Diluent 40:60, Methanol: 0.1% v/v ammonia solution 
 
PART-[C]:  
METHOD DEVELOPMENT AND QUANTITATION OF FORMULATION BY 
UPLC 
 
Aim of study 
The research work undertaken in these studies in the area of pharmaceuticals and 
mainly addresses method development for determination of related impurities in drug 
products by UPLC. Developed analytical method was validated for its intended 
application as per ICH guideline. 
 
 
Synopsis 
 
________________________________________________________________________ 
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Section-I: UPLC Method development and validation for determination of related 
impurities in Torsemide tablets 
CH3
CH3
N
H
N
H
O
S
O O
N
NH
CH3  
Torsemide, 1-isopropyl-3-[(4-m-toludino-3-pyridyl)sulfonyl]urea 
Developed chromatographic conditions 
Buffer 20 mM potassium dihydrogen phosphate, pH adjusted to 3.5 with 
orthophosphoric acid, filtered through 0.22µm 
Mobile phase-A Buffer : Acetonitrile, 90:10 (v/v) 
Mobile phase-B Buffer : Acetonitrile, 50:50 (v/v) 
Diluent Buffer : Acetonitrile : Methanol, 25:25:50 (v/v/v) 
Column oven temp. 30°C 
Detection UV at 288 nm 
Injection volume 6 µl 
Time (min) Mobile phase-A (%) Mobile phase-B (%) 
0.0 75 25 
2.5 65 35 
4.0 25 75 
4.6 25 75 
5.0 75 25 
Gradient programme 
6.0 75 25 
 
The developed procedure has been evaluated for the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness. It has been 
proved that it was specific, linear, precise, accurate and robust and stability indicating. 
Hence, the method could be of use for routine quality control analysis and also for 
analysis of stability samples. 
 
 
Hitesh B. Patel      Dr. H.S. Joshi 
Place :        Place  : 
Date  :        Date   : 
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GENERAL INTRODUCTION 
 
History of chromatography 
In 1903 a Russian botanist Mikhail Tswett produced a colorful separation of plant 
pigments through calcium carbonate column. Chromatography word came from Greek 
language chroma = color and graphein = to write i.e. color writing or chromatography [1-
2]. 
 
History of HPLC
Prior to the 1970's, few reliable chromatographic methods were commercially 
available to the laboratory scientist. During 1970's, most chemical separations were 
carried out using a variety of techniques including open-column chromatography, paper 
chromatography, and thin-layer chromatography. However, these chromatographic 
techniques were inadequate for quantification of compounds and resolution between 
similar compounds. During this time, pressure liquid chromatography began to be used to 
decrease flow through time, thus reducing purification times of compounds being isolated 
by column chromatography. However, flow rates were inconsistent, and the question of 
whether it was better to have constant flow rate or constant pressure was debated [3].  
 
High pressure liquid chromatography was developed in the mid-1970's and 
quickly improved with the development of column packing materials and the additional 
convenience of on-line detectors. In the late 1970's, new methods including reverse phase 
liquid chromatography allowed for improved separation between very similar 
compounds.  
 
By the 1980's HPLC was commonly used for the separation of chemical 
compounds. New techniques improved separation, identification, purification and 
quantification far above the previous techniques. Computers and automation added to the 
convenience of HPLC. Improvements in type of columns and thus reproducibility were 
made as such terms as micro-column, affinity columns, and Fast HPLC began to 
immerge. 
 
By the 2000 very fast development was undertaken in the area of column material 
with small particle size technology and other specialized columns. The dimensions of the 
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typical HPLC column are 100-300 mm in length with an internal diameter between 3-5 
mm. The usual diameter of micro-columns, or capillary columns, ranges from 3 µm to 
200 µm [4]. 
 
In this decade sub 2 micron particle size technology (column material packed with 
silica particles of < 2µm size) with modified or improved HPLC instrumentation becomes 
a popular with different instrument brand name like UPLC (Ultra Performance Liquid 
Chromatography) of Waters and RRLC (Rapid Resolution Liquid Chromatography) of 
Agilent. 
 
Modern High Performance Liquid Chromatography (HPLC) 
The highly sophisticated reliable and fast liquid chromatographic (LC) separation 
techniques are become a requirement in many industries like pharmaceuticals, 
agrochemicals, dyes, petrochemicals, natural products and others. Early LC used gravity 
fed open tubular columns with particles 100s of microns in size; the human eye was used 
for a detector and separations often took hours (days?) to develop. Today's HPLC requires 
very special apparatus which includes the following. 
 
1. Extremely precise gradient mixers. 
2. HPLC high pressure pumps with very constant flow.  
3. Unique high accuracy, low dispersion, HPLC sample valves.  
4. Very high efficiency HPLC columns with inert packing materials.  
5. High sensitivity low dispersion HPLC detectors.  
6. High speed data acquisition systems.  
7. Low dispersion connecting tubes for valve to column and column to detector. 
 
HPLC Gradient mixtures 
HPLC gradient mixers must provide a very precise control of solvent composition 
to maintain a reproducible gradient profile. This can be complicated in HPLC by the 
small elution volumes required by many systems. It is much more difficult to produce a 
constant gradient when mixing small volumes then when mixing large volumes. For low 
pressure systems this requires great precision in the operation of the miniature mixing 
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valves used and low dispersion flows throughout the mixer. For multi-pump high pressure 
systems it requires a very precise control of the flow rate while making very small 
changes of the flow rate.  
 
HPLC Pumps 
Because of the small particles used in modern HPLC, modern LC pumps need to 
operate reliably and precisely at pressures of 10,000 p.s.i. or at least 6,000 p.s.i. To 
operate at these pressures and remain sensibly inert to the wide variety of solvents used 
HPLC pumps usually have sapphire pistons, stainless steel cylinders and return valves 
fitted with sapphire balls and stainless steel seats. For analytical purposes HPLC pumps 
should have flow rates that range from 0 to 10 ml/min., but for preparative HPLC, flow 
rates in excess of 100 ml/min may be required. It is extremely difficult to provide a very 
constant flow rate at very low flow rates. If 1% is considered acceptable then for 1ml/min 
a flow variation of less then 10µl/min is required. This level of constancy is required 
because most HPLC detectors are flow sensitive and errors in quantization will result 
from change in flow rate. 
 
HPLC Sample Valves 
Since sample valves come between the pump and the column it follows that 
HPLC sample valves must also tolerate pressures up to 10,000 p.s.i. For analytical HPLC, 
the sample volume should be selectable from sub micro liter to a few micro liters, 
whereas in preparative HPLC the sample volume may be even greater than 10 ml. To 
maintain system efficiency the sample valve must be designed to have very low 
dispersion characteristics, this is true not only for flow dispersion but also for the less 
obvious problems of dispersion caused by sample adsorption/desorption on valve surfaces 
and diffusion of sample into and out of the mating surfaces between valve moving parts. 
It goes without saying that the valves must deliver a very constant sample size but this is 
usually attained by the use of a constant size sample loop.  
 
HPLC Columns 
HPLC columns are packed with very fine particles (usually a few microns in 
diameter). The very fine particles are required to attain the low dispersion that give the 
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high plate counts expected of modern HPLC. Plate counts in excess of 25,000 plates per 
column are possible with modern columns, however, these very high efficiencies are very 
rarely found with real samples because of the dispersion associated with injection valves, 
detectors, data acquisition systems and the dispersion due to the higher molecular weight 
of real samples as opposed to the common test samples. Packing these small particles into 
the column is a difficult technical problem but even with good packing a great amount of 
care must be given to the column end fittings and the inlet and outlet connection to keep 
dispersion to a minimum. The main consideration with HPLC is the much wider variety 
of solvents and packing materials that can be utilized because of the much lower 
quantities of both which are required. In particular very expensive optically pure 
compounds can be used to make Chiral HPLC stationary phases and may even be used as 
(disposable) HPLC solvents.  
 
HPLC Detectors 
In order to give an accurate chromatographic profile the detector sampling (cell) 
volume must be a small fraction of the solute elution volume. If the detector volume were 
larger then the elution volume then you would have peaks that appeared with flat tops as 
the whole peak would be resident in the detector at the same time. This means that as 
column volumes decrease and system efficiencies increase the volume of the detector cell 
volume must also decrease. It is odds for the requirement for detector to maintain high 
sensitivity as this is usually dependant on having a larger cell volume. Again, this requires 
the very careful design of modern detectors. Many types of detectors can use with HPLC 
system like UV-Visible or PDA (Photo Diode Array), RI (Refractive Index), 
Fluorescence, ECD (Electro Chemical Detector), ELSD (Evaporative Light Scattering 
Detector), and many others hyphenated techniques like MS, MS/MS and NMR as well as 
evaporative IR. 
 
HPLC Data acquisition 
In HPLC data acquisition system the higher sampling rate needed for the rapidly 
eluting narrow peaks of the HPLC chromatogram. Although the theoretical number of 
samples needed for good quantization are actually quite small, for real systems a hundred 
samples or more per peak is recommended; thus, for a 4 sec wide peak, a rate of 25 
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samples per second may be required. The same data analysis and reporting software can 
be used as in ordinary LC.  
Conclusion 
HPLC is probably the most universal type of analytical procedure; its application 
areas include quality control, process control, forensic analysis, environmental monitoring 
and clinical testing. In addition HPLC also ranks as one of the most sensitive analytical 
procedures and is unique in that it easily copes with multi-component mixtures. It has 
achieved this position as a result of the constant evolution of the equipment used in LC to 
provide higher and higher efficiencies at faster and faster analysis times with a constant 
incorporation of new highly selective column packings. 
 
(I) EFFECT OF VARIABLES ON COLUMN EFFICIENCY 
A mathematical approximation of the behavior of chromatographic column 
efficiency is obtained from the Van Deemter equation: 
 
uC
u
BAH ⋅++=  
Where, H is the plate height, u is the linear velocity of the mobile phase, A is the 
eddy diffusion term, B is the longitudinal diffusion coefficient, and C is the coefficient of 
the mass transfer term. The lower the value of H, the more efficient the column. 
 
The eddy diffusion term A, represents the multitude of pathways by which a 
component finds its way through the column. In a poorly packed column, the retention 
time for molecules of the same component can vary significantly depending on the 
numerous flow paths that could be taken. This effect results in band-broadening. The 
mobile phase velocity also affects the eddy diffusion parameter, and at moderate to high 
flow rates the zone-broadening is greater. At low flow rates, the molecules of a 
component are not significantly dispersed by multi-channeling; diffusion averaging 
results in this case. 
 
The longitudinal diffusion term, B/u, describes a band-broadening process that is 
inversely related to the mobile phase velocity. The analyte is in the column for a shorter 
 11  
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time when the flow rate is high; hence the diffusion term is less. In HPLC, this term is 
negligible since diffusion coefficients of liquids are very small relative to gases (as in 
GC).  
The mass transfer term, C.u, describes the time available for equilibrium of an 
analyte to be established between the mobile and stationary phases. At high mobile flow 
rates there is less time for this equilibrium to take place and a contribution to the 
broadening effect is observed.  
 
(II) SEPARATION MECHANISMS 
A useful classification of the various LC techniques is based on the type of 
distribution (or equilibrium) that is responsible for the separation. The common 
interaction mechanisms encountered in LC are classified as adsorption, partition, ion-
exchange, gel permeation or size exclusion, and chiral interaction. In practice, most LC 
separations are the result of mixed mechanisms. A brief description of the separation 
mechanisms is as under.  
 
Adsorption 
When the stationary phase in HPLC is a solid, the type of equilibrium between 
this phase and the liquid mobile phase is termed adsorption. All of the pioneering work in 
chromatography was based upon adsorption methods, in which the stationary phase is a 
finely divided polar solid that contains surface sites for retention of analytes. The 
composition of the mobile phase is the main variable that affects the partitioning of 
analytes. Silica and alumina are the only stationary phases used, the former being 
preferred for most applications. Applications of adsorption chromatography include the 
separation of relatively non-polar water-insoluble organic compounds. Because of the 
polar nature of the stationary phase and the impact of slight variations in mobile phase 
composition on the retention time, adsorption chromatography is very useful for the 
separation of isomers in a mixture. 
 
Partition 
The equilibrium between the mobile phase and a stationary phase comprising of 
either a liquid adsorbed on a solid or an organic species bonded to a solid is described as 
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partition. The predominant type of separation in HPLC today is based on partition using 
bonded stationary phases. Bonded stationary phases are prepared by reaction of 
organochlorosilane with the reactive hydroxyl groups on silica. The organic functional 
group is often a straight chain octyl (C-8) or octyldecyl (C-18); in some cases a polar 
functional group such as cyano, diol, or amino may be part of the siloxane structure. Two 
types of partition chromatography may be distinguished, based on the relative polarities 
of the phases. 
 
When the stationary phase is polar and the mobile phase relatively less polar (n-
hexane, ethyl ether, chloroform), this type of chromatography is referred to as normal-
phase chromatography. For this reason, the use of silica as the stationary phase (as in 
adsorption chromatography) is also considered to be a normal phase separation method. 
When the mobile phase is more polar than the stationary phase (which may be a C-8 or C-
18 bonded phase), this type of chromatography is called reversed-phase chromatography. 
Reversed-phase chromatography separations are carried out using a polar aqueous-based 
mobile phase mixture that contains an organic polar solvent such as methanol or 
acetonitrile. Because of its versatility and wide range of applicability, reversed-phased 
chromatography is the most frequently used HPLC method. Applications include non-
ionic compounds, polar compounds, and in certain cases ionic compounds. 
  
Ion-exchange 
Ion-exchange separations are carried out using a stationary phase that is an ion-
exchange resin. Packing materials are based either on chemically modified silica or on 
styrene-divinylbenzene copolymers, onto which ionic side groups are introduced. 
Examples of the ionic groups include (a) Sulfonic acid (strong cation exchanger), (b) 
Carboxylic acid (weak cation exchanger), (c) Quaternary ammonium groups (strong 
anion exchanger), and (d) Tertiary amine group (weak anion exchanger). The most 
important parameters that govern the retention are the type of counter-ion, the ionic 
strength, pH of the mobile phase, and temperature. Ion chromatography is the term 
applied for the chromatographic separation of inorganic anions/cations, low molecular 
weight organic acids, drugs, serums, preservatives, vitamins, sugars, ionic chelates, and 
certain organometallic compounds. 
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The separation can be based on ion-exchange, ion-exclusion effects, or ion 
pairing. Conductivity detectors in ion chromatography provide universal and sensitive 
detection of charged species. The employment of some form of ion-suppression 
immediately after the analytical column eliminates the limitation of high background 
signal from the mobile phase in conductivity detection. 
 
Size Exclusion 
High molecular weight solutes (>10,000) are typically separated using size 
exclusion chromatography – gel filtration or gel permeation. In size-exclusion LC, the 
components of a mixture are separated according to their ability to penetrate into the 
pores of the stationary phase material. Packing materials used are wide-pore silica gel, 
polysaccharides, and synthetic polymers like polyacrylamide or styrene-divinylbenzene 
copolymer. In gel filtration the mobile phase is aqueous and the packing material is 
hydrophilic, while in gel permeation an organic mobile phase is used and the stationary 
phase is hydrophobic. Size-exclusion applications include the separation of large 
molecular weight biomolecules, and molecular weight distribution studies of large 
polymers and natural products. For a homologous series of oligomers, the retention time 
(volume) can be related to the logarithm of the molecular mass.  
 
Chiral Interaction 
Chiral compounds or enantiomers have identical molecular structures that are non 
superposable mirror images of each other. Rapid and accurate stereochemical resolution 
of enantiomers is a challenge in the field of pharmaceuticals and drug discovery. A chiral 
stationary phase contains one form of an enantiomeric compound immobilized on the 
surface of the support material. Typically, derivatives of optically active polysaccharides 
that are chemically bonded to silica form the packing material. A chiral separation is 
based on differing degrees of stereochemical interaction between the components of an 
enantiomeric sample mixture and the stationary phase. 
 
Method development 
Method development should be based on several considerations. It is preferable to 
have maximum sample information to make development fast and desired for intended  
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analytical method application, physical and chemical properties are most preferable as 
primary information. Moreover, separation goal needs to define at beginning so; 
appropriate method can be developed for the purpose. An LC method development is 
very huge area for even pharmaceuticals with regulatory requirement of international 
standards. So, prior to method validation and usage at quality control many aspects need 
to focus as per ICH guideline. Method development can be based on sample and goal as 
well as available resources for chromatography but few basic steps for method 
development are can be discussed as below [5]. 
 
Steps in method development 
 
1. Sample information, define separation goals 
2. Sample pretreatment, need of special HPLC procedure 
3. Selection of detector and detector settings 
4. Selection of LC method; preliminary run; estimate best separation conditions 
5. Optimize separation conditions 
6. Check for problems or requirement for special procedure 
7. Method validation 
 
Sample information 
 
1.  Number of compounds present 
2.  Chemical structure of compounds 
3.  Chemical nature 
4.  Molecular weight of compounds 
5.  pKa Value(s) of compounds 
6.  Sample solubility 
7.  Sample stability and storage 
8.  Concentration range of compounds in sample 
9.  UV spectra of compounds or properties for detection of compounds 
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Separation goals 
Goal Comment 
Resolution Precise and rugged quantitative analysis requires that 
resolution be greater than 1.5 
Separation time < 5-10 minutes is desirable for routine procedure (e.g. 
Dissolution profile) 
Quantitation < 2% RSD for assays 
Pump pressure < 150 Bar is desirable, < 200 bar is usually essential 
(For UPLC-waters and RRLC-agilent these values are 5 fold 
and 3 fold respectively) 
Peak height Narrow peaks are desirable for large signal/noise ratio 
Solvent consumption Minimum mobile phase use per run is desirable 
Sample preparation 
Select the optimum sample amount 
Determine the diluent that gives the best; 
-Solution stability 
-Solubility for sample or it’s component (s) 
Investigate the effect of diluent in terms of  
-Organic and aqueous solvent ratio 
-pH 
-Extraction volume 
-Extraction procedure and time 
-Chromatographic changes like peak shape and resolution 
Note: As a diluent mobile phase is preferable with consideration of above points for 
better baseline 
Solution may require dilution or buffering  
Determine sample concentration which gives LOQ below  the identification threshold 
in case of related substances 
Sample may require sample pretreatment to remove  interferences and/or protect the 
column and equipment 
As a part of sample pretreatment; filter compatibility study  is required 
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Detection 
Before the first sample is injected during the HPLC  method development we must 
be reasonably sure that the detector selected will sense all sample components of interest. 
Normally variable wavelength UV detector  is the first choice of the chromatographers, 
because of their convenience and applicability for most organic samples. UV spectra can 
be obtained by PDA detector. When the UV response of the sample is inadequate, other 
detector or derivative HPLC method can be used. 
 
Selection of LC method and mobile phase selection in partition chromatography  
Successful chromatography requires a proper balance of the intermolecular forces 
between the solute, the mobile phase, and the stationary phase. The important criteria to 
consider for method development are resolution, sensitivity, precision, accuracy, limit of 
detection, limit of quantitation, linearity, reproducibility, and time of analysis and 
robustness of the method. In all of these, the column quality plays an important role since 
the peak shape affects all criteria required for optimum separation. The factors that affect 
the column efficiency have already been described above.  
 
Column dimensions and particle size affect the speed of analysis, resolution, 
column backpressure, detection limit, and solvent consumption. HPLC methods have 
traditionally been developed using columns measuring 10, 15 or 25 cm in length and 4.6 
mm ID. Short columns of 5 cm or less in length and 1 or 2 mm ID are now available; 
when packed with particles of size 5 micron or less, very high efficiency columns are 
obtained. The advantages of using shorter columns are lower backpressures, dramatic 
solvent savings, greater sensitivity, reduced analysis time, and applicability to small 
sample quantities - all achieved without compromising resolution. Using these columns, 
gradient methods may be used to achieve very rapid analyses of samples that contain a 
wide polarity range of analytes. The future of reversed-phase HPLC method development 
will involve a significant increase in the use of use narrow-bore and micro-bore columns. 
 
Often in choosing a column for partition chromatography, the polarity of the 
stationary phase is matched roughly to that of the analytes in the sample; a mobile phase 
of different polarity is used for elution. The analytes must be soluble in the mobile phase 
and the solvent must be compatible with the analytical method.  
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As a general guide, use normal phase chromatography for the separation of polar 
compounds and reversed-phase chromatography for components that are in the 
moderately polar to non-polar range.  
 
Normal phase chromatography commonly involves the use of silica, aminopropyl, 
diol, and cyanopropyl stationary phases. These columns may be used to separate polar 
compounds such as amines, anilines, nitroaromatics, phenols, and pesticides.  
 
Isocratic elution in reversed-phase chromatography is typically accomplished 
using a mobile phase mixture of water and another solvent of lower eluting strength 
(acetonitrile, methanol). In cases where the time of analysis is compromised or when the 
resolution is poor, gradient elution using 2 or 3 different solvents is recommended.  
 
The relative polarity of a solvent is a useful guide to solvent selection in partition 
chromatography. The relative polarities of the listed solvents may differ slightly 
depending on the literature source, since the scale used to measure polarity may be 
different. The following should suffice as a general reference for relative solvent polarity.  
 
1 Fluoroalkanes (least polar)  10 Acetone  
2 Hexane 11 Ethyl acetate  
3 Isooctane 12 Dioxane  
4 Carbon tetrachloride 13 Isopropanol  
5 Toluene  14 Ethanol  
6 Diethyl ether (ether)  15 Acetic acid  
7 Chloroform  16 Methanol  
8 Methylene chloride  17 Acetonitrile  
9 Tetrahydrofuran (THF)  18 Water (most polar)  
 
There is a strong dependence of the retention time on the mobile phase 
composition, and the retention parameter may be easily altered by variation of solvent 
polarity. This is the easiest way to improve chromatographic resolution of two 
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overlapping species or to decrease overall separation time for components with widely 
differing retention values. A good starting point is a mixture of water and a polar organic 
solvent (methanol or acetonitrile). The effect of mobile phase polarity on elution time can 
be tested at a few different solvent proportions. If greater selectivity is required, a mobile 
phase comprising of 3-4 solvents may be used. Theoretical calculations have indicated 
that a mobile phase mixture of water, THF, methanol, and acetonitrile may be used to 
resolve most reversed-phase applications within a reasonable length of time. 
 
The various analytes to be separated may also be arranged based on the polarities 
of their functional groups. A general guide to relative solute polarity going from non-
polar to the most polar group is as follows: 
1 Hydocarbons (least polar)  6 Amides 
2 Ethers  7 Amines 
3 Esters  8 Alcohols  
4 Ketones  9 Water (most polar)  
5 Aldehydes    
 
Stationary Phases: 
Many types of stationary phases available commercially with different column 
material chemistry start from C-18 for reversed phase to silica for Normal phase 
chromatography. Chromatographers may needs to consider many aspects before selection 
column. 
Type of column Remark 
C-18 ("octadecyl", "ODS") Rugged; retentive; widely used 
C-8 ("octyl") Similar to C18, but slightly less retentive 
C-3 and C-4 Less retentive; less stable; used mainly for peptides and proteins 
C-1 ("trimethylsilyl") Least retentive; least stable 
Phenyl and phenethyl Moderately retentive; selectivity change 
CN ("cyano") Moderately retentive; also normal-phase 
NH2 ("amino") Weakly retentive; more often used for normal-phase; less stable 
Polystyrene Stable for 1 < pH < 13; good peak shape and lifetime ; 
selectivity change; selectivity change; often less efficient 
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The most widely used HPLC packings are the long-chain alkyls such as C18 or 
C8. These differ somewhat in their overall retentivity, although most separations can be 
carried out on either material. Shorter-chain alkyl packings are less retentive, but are also 
less stable. The silyl ether bonds are labile to hydrolysis at low pH. With long-chain 
packings, the hydrophobicity of the chain limits the rate of hydrolysis as well as 
protecting the underlying silica from dissolution in basic solution.  
 
Aromatic bonded phases typically have an overall retentivity comparable to that 
of C8 material, but with an added selectivity for samples which can differ in their 
interactions with aromatic groups. More polar groups, such as cyano or amino can also be 
bonded to silica to provide selectivity differences compared to the alkyl phases. The 
resulting packings are more commonly used for normal- phase than for reversed-phase 
LC. 
Finally, polystyrene based packings provide a viable alternative to silica for 
applications in which silanol interactions must be avoided altogether or for which high-
pH operation is required. Because such packings have no silanol groups, their selectivity 
can be quite different from that of silica-based materials. 
 
Beyond the very tenuous guidelines given above, there is no way to make 
sweeping generalizations concerning initial column choices for particular samples. 
Because selectivity is based on differences is molecular structure and depends on 
secondary interactions, the only effective way to establish suitability of a particular 
column for a particular sample is empirical: try it. 
 
The most common type of HPLC column is the C18 or C8 bonded phase silica. 
These provide a good compromise among retention, selectivity, lifetime, operating 
pressure, etc. In most applications, either a C8 or C18 will do equally well. There is often 
more selectivity difference between the “same” columns from different manufacturers 
than between “different” columns from the same source. 
 
Silica columns are the most commonly used type because they tend to be more 
efficient and reproducible than their polymeric equivalents. The latter can be quite useful 
when an extended pH range is required, or when silanol interactions give rise to excessive 
tailing on silica based column. 
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Variables that affect N  
Flow rate, column length, particle size, column quality and operating temperature, 
these variables also affect the run time and pressure. 
 
Because HPLC hardware is limited to operating pressures of about 5,000 psi, it is 
rarely feasible to generate extremely large column plate numbers. HPLC columns today 
provide 5,000 - 15,000 plates for well behaved samples. This number has remained 
roughly constant for over twenty years, but the column length needed to achieve it has 
decreased by a factor of about 5, with a corresponding decrease in run time. 
 
A rough approximation of the plate number expected from a given column is 
provided by: N = 3000 L/dp where, L is the column length in cm and dp is the packing 
particle size in μm. 
 
The column in current routine practice consists of a 5-μm bonded-phase silica in a 
10 or 15-cm column. 3-μm packings in shorter columns give faster analysis but are not as 
rugged as their 5-μm counterparts. Either configuration can generate the 10,000 or so 
plates required for general-purpose HPLC method development. 
Column dimensions can be arbitrarily divided into the following categories based on 
internal diameter (this terminology is not universal): 
 
Preparative ≥10 mm Analytical 3-5 mm Microbore ≤ 1 mm 
Semi-preparative 5 - 10 mm Narrow bore 2-3 mm  
 
Standard analytical scale columns are typically available in 5, 10, 15, and 25-cm lengths. 
 
Through most of our discussion, we have assumed symmetrical, Gaussian peak 
shape. Real chromatographic peaks, however, are rarely symmetrical. Although 
mathematically elegant general expressions for quantifying peak symmetry can been 
developed, practical difficulties have led chromatographers to the “rough and ready” 
definition of asymmetry shown here.10% of peak height is typically but not universally 
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used for the measurement. The asymmetry factor generally increases as the measurement 
is made further down the peak. 
USP (pharmacopoeial) methods commonly specify a tailing factor of the peak 
measured by formula: 
 
AB
CB
factorTailing
2=   
 
It is measured at 5% of peak height. Tailing factor at 5% and asymmetry factor at 
10% give (very) roughly equivalent numbers overall, but may be quite different in 
specific cases (depending on the exact shape of the peak). 
 
 
A bad column can lead to tailing bands in one of two ways. A plugged frit or a 
void will cause tailing for all bands in the chromatogram. A column packed with “acidic 
silica” particles will cause tailing of basic (amine) components of the sample. In this 
example, compound #3 is basic (dimethylaniline), and it is seen to tail in the top 
chromatogram — but not the bottom. The reason is that the top separation is carried out 
with an acidic silica packing. 
 
By far the major contributor to peak tailing is the existence of secondary retention 
effects. On silica based columns, these come primarily from interactions with 
underivatized silanol groups. 
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Some silanols are quite acidic (pKa’s can range down to 3.5 or lower) which 
means that they can interact via ion exchange at most reasonable pH values. Even at low 
pH (or with neutral silanols) , a sufficiently aggressive base can remove the proton to 
generate an ion-exchange interaction. Just to make life interesting, there is a non-bonding 
electron pair on the oxygen that can also interact with acids via hydrogen bonding. 
 
Actually, the problem is not interactions with silanols, but rather hindered 
interactions with silanols such that some sample molecules become strongly held via a 
two-point interaction (ion exchange + hydrophobic). The characteristics required for 
tailing are the existence of a low concentration of highly retentive active sites. As a result, 
these sites are quickly overloaded and attachment / release from these sites may be slow. 
Each of these latter effects can result in peak tailing. 
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Unfortunately, theoretical predictions of mobile phase and stationary phase 
interactions with a given set of sample components are not always accurate, but they do 
help to narrow down the choices for method development. The separation scientist must 
usually perform a series of trial-and-error experiments with different mobile phase 
compositions until a satisfactory separation is achieved [6-7]. 
 
Method Validation 
A developed analytical method for routine use needs to be validated as per ICH 
guideline for following validation parameters based on its intended application [8]: 
 
1. Specificity  
2. Linearity & Range 
3. Precision 
(A) Method precision (Repeatability)  
(B) Intermediate precision (Ruggedness) 
4. Accuracy (Recovery)  
5. Robustness 
6. Solution stability 
7. System suitability 
 
Method validation is vast area which includes many validation parameters with 
different approaches for different level of requirement based on intended use of analytical 
method, criticality and regulatory requirements. Validated method also can give the 
unpredicted or unknown problem during the course of routine usage, because validated 
method is also limited confidence, as method was validated for known or predicted 
variable parameters or every method can fail sooner or later [9]. But still after method 
development it needs to be validated as per requirement which gives certain level of 
confidence for its intended use. 
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Section-I: HPLC Method development and validation for determination of 
related impurities in Olanzapine OD tablets 
 
1. Introduction to Olanzapine 
Olanzapine is chemically 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] 
[1,5] benzodiazepine,  a thienobenzodiazepine derivative [Fig.1], belongs to class of 
second generation derivative antipsychotic agents, the so-called atypical antipsychotics. 
They have greater affinity for erotonin 5-HT2 serotonin receptors than for dopamine D2 
receptors and cause fewer extra pyramidal symptoms (EPS) in contrast with classical 
antipsychotics (e.g. haloperidol). The efficacy and safety of olanzapine has been 
demonstrated in randomised, placebo-controlled and comparative trials in positive and 
negative symptoms of schizophrenia, and also as monotherapy or in combination with 
mood stabilizers in the treatment of acute manic or mixed episodes associated with 
bipolar disorder [1]. 
 
Its molecular weight is 312.43 g/mole with molecular formula of C17H20N4S. Its 
dissociation constants (pKa) 4.69 and 7.37 are reported. Its melting point is 190°C to 
195°C [2]. 
N
NN
S
CH3
CH3
 
Fig.1: Olanzapine 
 
Strengths: Olanzapine OD tablets are available in four strengths as 2.5 mg, 5 mg, 7.5 mg, 
10 mg and 20 mg of Olanzapine as an active ingredient for oral administration. 
 
1.1 Active substance 
The active substance olanzapine is a yellow crystalline powder. Olanzapine can exist 
as five possible polymorphic forms (I, II, III, IV and V). The control of polymorphism has 
been achieved and was found to be stable during stability studies. The structure has been 
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fully elucidated by 1H-NMR, UV, IR and mass spectroscopy, and elemental analysis. 
Physico-chemical characterization includes appearance, solubility, loss on drying, tapped 
density, DSC scan and X-ray diffraction to identify polymorphic form. The active 
substance has no chiral centres and no isomerism could be found in the literature [3]. 
 
2. Literature review 
The literature reviews regarding Olanzapine suggest that various analytical 
methods were reported for drug substance as well as in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of Olanzapine are as under. 
 
2.1 Pierre M. Llorca, François Coudore, Christophe Corpelet, Aurelie Buyens, 
Monique Hoareau and Alain Eschalier have developed a method for  Olanzapine in 
blood plasma using the Dionex HPLC system used consisted of a Dionex injector 
(Model ASI-100), an isocratic pump (Model P-580A), and a photodiode array detector 
(Model UVD-170S). Chromatograms were processed using the ChromeleonTM 
chromatographic data collection and analysis system and Ultremex silica column [250 
x 4.6 mm (i.d.); Phenomenex]. The mobile phase consisted of a methanol-deionized 
water mixture (70:30 by volume) containing 0.110 mL/L butylamine. The mobile 
phase was filtered through a 0.22 µm filter and degassed before use. The 
chromatography was carried out at ambient temperature at a flow rate of 1 mL/min. 
Peaks were monitored at 273 nm [4]. 
2.2 M. A. Raggi, G. Casamenti, R. Mandrioli, S. Fanali, D. De Ronchi and 
V. Volterra have developed a sensitive high performance liquid chromatograpic 
method for the analysis of the novel antipsychotic drug, olanzapine, in human plasma. 
Chromatography was performed on a reversed-phase column (C8, 150×4.6 mm i.d., 5 
μm) with acetonitrile-phosphate buffer (pH=2.5) as the mobile phase. The detection 
voltage was +900 mV and the cell and column temperature were 50°C. The flow rate 
was 1 mL min−1. The method provides a linear response over an olanzapine 
concentration range of 2–100 ng mL−1. Isolation of olanzapine from plasma was 
accomplished by a solid phase extraction procedure, using C8 cartridges, which gave 
high extraction yield and needed a small amount of human plasma (only 0.25 mL). 
The results obtained analysing plasma samples from patients in therapy with 
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olanzapine were satisfactory in terms of precision and sensitivity, and were compared 
to those obtained by means of a method based on HPLC with UV detection [5]. 
2.3 B. Venkateswara Reddy et al. have developed a rapid, specific reversed phase 
HPLC method for simultaneous determination of olanzapine and fluoxetine in their 
formulations. Chromatographic separation of these two pharmaceuticals was carried 
out on an Inertsil C18 reversed phase column (150 mm × 4.6 mm, 5 μm) with a 
40:30:30 (v/v/v) mixture of 9.5 mM sodium dihydrogen phosphate (pH adjusted to 
6.8 ± 0.1 with triethylamine), acetonitrile and methanol as mobile phase. The flow 
rate 1.2 mL min−1 and the analytes are monitored at 225 nm. Paroxetine was used as 
internal standard. The assay results were linear from 25 to 75 μg mL−1 for olanzapine 
(r 2 ≥ 0.995) and 100–300 μg mL−1 for fluoxetine (r 2 ≥ 0.995), showed intra- and 
inter-day precision less than 1.0%, and accuracy of 97.7–99.1% and 97.9–99.0%. 
LOQ was 0.005 and 0.001 μg mL−1 for olanzapine and fluoxetine, respectively. 
Separation was complete in less than 10 min. Validation of the method showed it to 
be robust, precise, accurate and linear over the range of analysis [6]. 
2.4 Catlow J. T., Barton R. D., Clemens M., Gillespie T. A., Goodwin M., Swanson S. 
P. have developed a sensitive reversed-phase HPLC method for the analysis of 
olanzapine in human plasma is described. Isolation of olanzapine from plasma was 
accomplished by solid-phase extraction utilizing an ion-exchange/reversed-phase 
cartridge designed for basic drug extraction. The drug was subsequently separated by 
reversed-phase HPLC and monitored by electrochemical detection (ED). 
Electrochemical analysis was used to detect olanzapine due to its uniquely low 
oxidative potential. Ascorbic acid was added to prevent oxidation during extraction. 
The limit of quantitation for the assay was established at 0.25 ng/ml utilizing a 1-ml 
human plasma sample. The average inter-day accuracy was 96.6% with a average 
precision (%C.V.) of 3.22% over the concentration range of 0.25 to 100 ng/ml. This 
method was applied to human plasma samples from human clinical trials with 
olanzapine. The HPLC-ED method compared favorably with a negative chemical 
ionization GC-MS method previously utilized for analysis of olanzapine in human 
plasma [7]. 
2.5 Dasandi B., Shah P., Gandhi C., Bhat K. M., Shivprakash have developed a new 
method for the estimation of olanzapine in human plasma and validated. They utilized 
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RP column and amperometric detector. The mobile phase consisted of 75mM sodium 
dihydrogen phosphate buffer of pH 7.0, acetonitrile and methanol in 55:22.5:22.5 
%v/v ratios in an isocratic mode at 1.5ml-1 flow rate. The drug is extracted in to 3ml 
each of Tertiary Butyl Methyl Ether (TBME) twice from plasma, evaporated and the 
residue dissolved in mobile phase. The percentage extraction is found to be more than 
79% and the linearity range from 0.5ng to 50.0ng ml-1. The method has been validated 
extensively and found to have good interday and intraday precision. This method has 
been applied to study pharmacokinetics in 12 healthy human volunteers [8]. 
2.6 Jingqi Bao and Brian D. Potts have developed a sensitive assay method for the 
measurement of Olanzapine in rat brain tissue using HPLC with electrochemical 
detection. The assay has a lower limit of quantitation of 0.5 ng/ml in tissue 
homogenate and utilizes a liquid–liquid extraction followed by reversed-phase HPLC 
for the quantitative analysis of Olanzapine. The method provided a linear response for 
Olanzapine over a concentration range of 0.5–100 ng/ml with a coefficient of 
determination (r2) greater than 0.9995. The extraction efficiencies of Olanzapine and 
internal standard (LY170158) were greater than 82% in brain tissue. The intra-assay 
and inter-assay relative errors ranged from −5.38 to 17.60% and −3.25 to 10.53%, 
respectively. The intra-assay and inter-assay RSD values were in the range of 1.12 to 
6.96% and 3.78 to 6.68%. Long-term stability studies showed that brain tissue 
homogenate samples spiked with Olanzapine and internal standard are stable at −70°C 
for at least 110 days. However, a room temperature stability study showed that 
Olanzapine was not stable in brain homogenate if the sample was exposed at 25°C 
longer than 2 h. This method has been used for the study of the disposition and 
pharmacokinetics of Olanzapine in male Sprague Dawley rats [9]. 
2.7 Ramisetti Nageswara Rao and co-workers have developed an RP-HPLC method for 
the simultaneous separation and determination of olanzapine (OLZ) and its process 
impurities in bulk drugs and pharmaceutical formulations. The separation was 
accomplished on Inertsil ODS 3V (4.6 mm×250 mm; particle size 5 µm) column 
using 0.2 M ammonium acetate (pH = 4.50) and ACN as mobile phase in gradient 
elution mode. The analytes were monitored by a photo diode array (PDA) detector set 
at 254 nm and the flow rate was kept at 1.0 mL/min. The chromatographic behavior of 
all the compounds was examined under variable compositions of different solvents, 
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buffer concentrations, and pH. The method was validated in terms of accuracy, 
precision, and linearity. Four unknown process impurities observed consistently 
during the analysis of different batches of OLZ were isolated and characterized by 
ESI-MS/MS, 1H NMR, and FT-IR. The proposed RP-HPLC method was successfully 
applied to the analysis of commercial formulations. The method could be of use not 
only for rapid and routine evaluation of the quality of OLZ in bulk drug 
manufacturing units but also for the detection of its impurities in pharmaceutical 
formulations [10]. 
2.8 E. J. Harvey, R. J. Flanagan, and D. M. Taylor worked on stability of a suspension 
of olanzapine in Guy's hospital paediatric formula base for oral administration in 
hospitals for that they used an HPLC method  based on that developed for the 
measurement of clozapine in Guy's hospital paediatric base.3 A 150 x 4.6mm internal 
diameter stainless steel column packed with Spherisorb S5 SCX (Phase Separations) 
was used with methanolic ammonium perchlorate (35mmol/L, pH 6.7) at a flow-rate 
of 1.5ml/min as eluent. Sample injection was performed using a Perkin-Elmer ISS-
101 autosampler and detection was by UV absorption (260nm). Peak heights were 
recorded using a Hewlett-Packard 3392A integrator. A methanolic stock solution of 
olanzapine pure compound (LY170053; Eli Lilly, Indianapolis, United States) (50mg 
olanzapine/50ml, ie, 1g/L) was prepared and stored at 2–8C. Portions of this solution 
were diluted in methanol:deionised water (93.5+6.5) to give calibration solutions 
containing 5mg, 10mg and 15mg olanzapine per litre. Portions (100µl) of each of the 
calibration standards were added to portions (100µl) of internal standard solution 
(10mg/L methanolic LY170222 [Eli Lilly])4 in autoinjector vials and vortex-mixed 
for 10 seconds. These solutions (20µl portions) were analysed in duplicate by HPLC 
as described above. The retention times of the internal standard and of olanzapine 
were approximately 10.0 min and 11.5 min, respectively. The olanzapine calibration 
solutions were freshly prepared by dilution from the stock solution on each analysis 
day [11]. 
2.9 Chiu J A and Franklin R B have developed a sensitive HPLC assay for 
measurement of the antipsychotic drug, olanzapine, in plasma. The assay has a limit 
of quantitation of 1 ng ml-1 in plasma and utilizes solid-phase extraction and 
electrochemical detection. The method provides a linear response for olanzapine over 
 
 
Method development olanzapine OD tablets 
 
 
31 
 
 
a concentration range of 1-100 ng ml-1 with coefficients of determination greater than 
0.9912. The inter-assay precision was 15.9% at the limit of detection and ranged from 
7.33% to 8.47% over the range of 5-100 ng ml-1. The intra-assay precision was in the 
range 0.97%-26.0%. The inter-assay accuracy ranged from 98.9 to 118% and the 
intra-assay accuracy ranged from 92.5% to 125% of the theoretical value. In addition, 
the assay was extended to measure the plasma levels of two metabolites of 
olanzapine, namely the N-desmethyl- and the 2-hydroxymethyl analogs. The utility of 
the assay was demonstrated following the administration of a single oral dose of 14C-
olanzapine to rats where, at several time-points after dosing, the plasma was assayed 
for total radioactivity, levels of olanzapine, and the two metabolites. Olanzapine and 
two of its metabolites accounted for less than 50% of the total plasma radiocarbon; 
olanzapine accounting for approximately 39% at the Cmax, N-desmethyl for 5% and 
2-hydroxymethyl for 8% respectively. The plasma elimination half-times for 
olanzapine and the two metabolites were approximately the same, ranging from 3.3 to 
4.4 h [12]. 
2.10 C. R. Shah, B.N. Suhagia, N.J. Shah, D.R. Patel, N.M. Patel have developed a 
rapid, selective and stability-indicating high performance thin layer chromatographic 
method and validated for the simultaneous estimation of olanzapine and fluoxetine in 
combined tablet dosage form. Olanzapine and fluoxetine were chromatographed on 
silica gel 60 F 254 TLC plate using methanol:toluene (4:2 v/v) as the mobile phase and 
spectrodensitometric scanning-integration was performed at a wavelength of 233 nm 
using a Camag TLC Scanner III. This system was found to give compact spots for 
both olanzapine (R f value of 0.63±0.01) and fluoxetine (R f value of 0.31±0.01). The 
polynomial regression data for the calibration plots showed good linear relationship 
with r 2 =0.9995 in the concentration range of 100-800 ng/spot for olanzapine and 
1000-8000 ng/spot for fluoxetine with r 2 =0.9991. The method was validated in terms 
of linearity, accuracy, precision, recovery and specificity. The limit of detection and 
the limit of quantification for the olanzapine were found to be 30 and 100 ng/spot, 
respectively and for fluoxetine 300 and 1000 ng/spot, respectively. Olanzapine and 
fluoxetine were degraded under acidic, basic and oxidation degradation conditions 
which showed all the peaks of degraded product were well resolved from the active 
pharmaceutical ingredient. Both drugs were not further degraded after thermal and 
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photochemical degradation. The method was found to be reproducible and selective 
for the simultaneous estimation of olanzapine and fluoxetine. As the method could 
effectively separate the drugs from their degradation products, it can be employed as a 
stability-indicating method [13]. 
2.11 Poornachander Thatipalli, Ramesh Kumar, Chandrasekhar Bulusu, Ramesh 
Chakka, Pratap R. Padi, Anjaneyulu Yerra, and Satyanarayana Bollikonda 
reported synthesis and characterization of impurities of an anti-psychotic drug 
substance, Olanzapine HPLC analysis of olanzapine, a known anti-psychotic drug, 
showed impurity peaks ranging from 0.05 to 0.15 % during process development. 
These samples were analyzed by LCMS and the peaks were identified at m/z 230, 
341, 511, 326, 361 and 329. All six impurities were synthesized individually and 
characterized based on their spectral data (IR, NMR and Mass). The structure of these 
impurities were assigned as 2-methyl-4,9-dihydro-3-thia-4,9- diazabenzo [f]azulen-
10-one 4,1-[4-(2-methyl-4H-3-thia-4,9-diazabenzo[f]azulen-10-yl) piperazin-1-yl] 
ethanone 5,bis-[10-(2-methyl-4H-3-thia-4,9-diazabenzo[f]azulene)]-1,4- piperazine 6, 
2,4-dimethyl-10-(4-methylpiperazin-1-yl)-4H-3-thia-4,9-diazabenzo[f]azulene 7, 10-
(4-chloromethyl-4-methylpiperazin-1-ylium)-2-methyl-4H-3-thia-4,9-diazabenzo[f] 
azulene chloride 8 and 2-methyl-10-(4-methyl-N-oxopiperazin-1-yl)-4H-3-thia-4,9-
diazabenzo[f]azulene 9 respectively. The formation, synthesis and characterisation of 
the olanzapine impurities are discussed [14]. 
2.12 R. Ravichandran briefing in pharmacopeial forum  about method for Olanzapine 
drug substance using Zorbax RX-C8 or Zorbax SB-C8 brand of L7 column 
manufactured by Agilent Technologies, RT of Olanzapine in Related substances is 13 
minute in gradient elution while 6.7 minute in Assay test for isocratic mode [15]. 
 
3. Aim of present study 
 
Literature reveals that the Olanzapine OD tablet is official in any pharmacopeia 
[16-21]. Many methods for Olanzapine assay for drug substance and formulation as well 
as related substances for drug substances were reported. Few methods for Olanzapine in 
biological fluids also reported [4-15]. But none of method was reported for determination 
of related substances in Olanzapine OD tablets. The present communication describes 
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method for determination of related impurities for Olanzapine OD tablets with established 
relative response factor (RRF) and relative retention time (RRT) for known impurities. 
Simple and precise analytical method for determination of related impurities for 
Olanzapine OD tablets was developed and validated as per ICH guideline [22]. Hence, 
this HPLC method could be of use for formulation development and stability testing as 
well as at quality control laboratory for routine use. 
 
The aim and scope of the proposed work are as under 
 
? LC Method development for determination of related impurities in Olanzapine 
OD tablets formulation 
? Forced degradation study under stress condition 
? To resolve all known impurities and generated during the force degradation 
studies 
? Perform analytical method validation for the proposed method as per ICH 
guideline. 
 
4. Experimental 
4.1 Materials, chemicals and reagents 
Materials, chemicals and reagents were used as mentioned in Table 1 and Table 2 
 Table 1: Materials  
S. No Material Name 
Lot. No./ 
Batch no. 
Mfg. by 
Potency/ 
Purity 
1 Olanzapine working standard OTV/2007/543 TRC, Bhat 99.72% 
2 Olanzapine orodispersible tablets 20mg BA 527001 TPL, 
Chattral 
-- 
3 Placebo of olanzapine orodispersible 
Tablets 20mg 
P/20/050 TRC, Bhat -- 
4 
 
2-methyl -4-(methyl-4-oxide-1-
piperazinyl)10H-thieno-[2,3-b] [1,5]-
benzodiazepine (Impurity 1) 
OTV/2007/1491 TRC, Bhat 99.37% 
5 2-methyl-4 oxo-10 H-thieno-[2,3-b] [1,5]-
benzodiazepine (Impurity 2) 
OLA 
IMP/XIX/010 
TRC, Bhat 88.75% 
6 TBD (4-Amino-2-methyl-10H-thieno[2,3-
b][15]benzodiazepine HCl) 
1311ST03-
131700104 
TEVA 99.7% 
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Table 2: Chemicals and reagents 
S. No. Chemical/Reagent Grade S. No. Chemical/Reagent Grade 
1 Acetonitrile HPLC 5 Sodium hydroxide AR 
2 Sodium dihydrogen ortho 
phosphate dehydrate 
AR 6 Hydrogen peroxide AR 
3 Water  Milli-Q 7 Glacial acetic acid GR 
4 Hydrochloric Acid AR 8 Methanol HPLC 
 
4.2 Instrumentation 
The HPLC system of Waters separations module 2695, PDA detector 2996, UV 
detector 2487 with  Empower pro- empower 2 software  and Shimadzu LC-2010C HT 
with LC solution version 1.22 SP1 were used for this entire study and chromatographic 
separation was achieved on YMC-Pack ODS-A-303 (250 mmX4.6 mm; 5µm) column as 
stationary phase with binary gradient mode. 
 
4.3 Diluted standard solution:  
Accurately weighed and transferred 25 mg of olanzapine reference/working 
standard in 100ml volumetric flask, 70ml of diluent was added to dissolve with aid of 
sonication and diluted to volume with diluent. 5ml of this solution was diluted to 50ml 
with diluent. Further 5ml of this solution was diluted to 50ml with diluent (2.5µg/ml of 
olanzapine).Fig.2 
 
Fig.2: Chromatogram of diluted standard preparation 
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4.4 Impurity-1 stock solution:  
Accurately weighed and transferred 5 mg of olanzapine imp-1 standard in 100ml 
volumetric flask, 70ml of diluent was added to dissolve with aid of sonication and diluted 
to volume with diluent (50 µg/ml of olanzapine imp-1). 
 
4.5 Resolution solution 
Accurately weighed and transferred 25 mg of olanzapine reference/working 
standard in 50 ml volumetric flask, 30 ml of diluent was added to dissolve with aid of 
sonication, 5ml of Impurity 1 Stock solution was added and diluted to volume with 
diluent (500 µg/ml of Olanzapine and 5 µg/ml of olanzapine imp-1) chromatogram shown 
in fig 3. 
 
Fig.3: Chromatogram of resolution solution 
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4.6 Sample solution 
 
Thirty tablets were crushed to fine powder by mortar and pestle. Sample powder 
equivalent to about 50mg of olanzapine was weighed and transferred to 100 ml 
volumetric flask, 70ml of diluent was added and sonicated for 30 minute with intermittent 
swirling, diluted to volume with diluent (500µg/ml of olanzapine) and filtered with 0.45 
µm nylon membrane filter. As such sample preparation as per fig 4. 
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Fig.4: Chromatogram of sample solution (as such preparation) 
IM
PU
R
IT
Y
 1
 - 
8.
73
4
IM
PU
R
IT
Y
 2
 - 
10
.6
02
O
LA
N
ZA
P
IN
E 
- 2
7.
93
4
A
U
-0.005
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
0.050
Minutes
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00
 
 
5. Result and discussion 
 
5.1 Development and impurity identification 
Method development was started with olanzapine and olanzapine impurity 1 (Fig 
5) but during the coarse of product stability study an unknown impurity was found more 
than 0.1 % so, as per ICH guideline it needs to identify. It was an unknown but specified 
unknown by it’s RRT in terms of chromatography it was consistently observed at 
different station of drug product stability in increasing order. 
 
In order to identify unknown specified impurity, primary forced degradation data 
was focused whether any impurity in forced degradation is forming at the same RRT or 
not? And answer was yes it was observed that an unknown impurity at same RRT was 
present in acid as well as peroxide degradation study. Acid degradation was preferred for 
impurity isolation to identify it. As reaction enriched to about 30% of impurity of interest 
it was transferred to preparative scale to get pure impurity. Finally it was made as known 
as impurity 2 (Fig 6) with all required structural confirmation like Mass, NMR, IR and 
CHNS analysis. 
 
5.2 Separation for known impurities 
Impurity stock solution of Olanzapine and its impurity 1 and impurity 2 was used 
for method development parameters like column selection and gradient optimization 
(30µg/ml of olanzapine and its related impurity 1 and impurity 2). Once desired 
36 
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separation for known impurities and main component was achieved forced degradation 
was performed. Finally proposed method with chromatographic condition as per table 3 
was subjected to method validation as per ICH guideline with consideration of sample 
concentration to achieve LOQ below the reporting threshold of impurities [23]. 
 
Table 3: Chromatographic condition 
Buffer Buffer, 6.24 gm sodium dihydrogen orthophosphate dehydrate 
in 800 ml of water, pH was adjusted to 6.8 with dilute sodium 
hydroxide solution, filtered through 0.45µm membrane  
Mobile phase-A Buffer : Acetonitrile: Methanol, 500:200:300 (v/v/v) 
Mobile phase-B Water : Acetonitrile, 20:80 (v/v) 
Diluent Water : Acetonitrile, 20:80 (v/v) 
Column oven temp. 27°C 
Detection UV at 250 nm 
Injection volume 20 µl 
Time (min) Mobile phase-A (%) Mobile phase-B (%) 
0.01 100 0 
20 100 0 
25 70 30 
30 40 60 
35 20 80 
40 10 90 
45 10 90 
50 40 60 
55 100 0 
Gradient 
programme 
60 100 0 
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Fig. 5: Structure of olanzapine Impurity-1 
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Fig. 6: Structure of olanzapine Impurity-2 
 
5.3 Forced degradation study 
Forced degradation was performed on olanzapine OD tablets to achieve desired 
degradation and placebo as well as  olanzapine drug substance were treated with similar 
conditions as mentioned below, based on development trials optimized forced degradation 
conditions were established. Final sample concentration was achieved 5400µg/ml of 
olanzapine with diluent as proposed sample concentration. 
 
5.3.1 Oxidative degradation 
Olanzapine OD tablets powder equivalent to 50mg of 0lanzapine was subjected to 
oxidative stress condition by 5ml of 3% v/v H2O2 solution in 100ml volumetric flask and 
kept at room temperature for 30 min and sample solution was prepared as per procedure. 
 
5.3.2 Acidic degradation 
Olanzapine OD tablets powder equivalent to 50mg of Olanzapine was subjected to 
acidic stress condition by 5ml of 1N HCl solution in 100ml volumetric flask and heated 
on water bath at 60°C for 60 min and sample was neutralised with 1N NaOH and sample 
solution was prepared as per procedure. 
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5.3.3 Base degradation 
Olanzapine OD tablets powder equivalent to 50mg of Olanzapine was subjected to 
alkaline stress condition by 5ml of 1N NaOH solution in 100ml volumetric flask and 
heated on water bath at 60°C for 60 min and sample was neutralized with 1N HCl and 
sample solution was prepared as per procedure. 
 
5.3.4 Thermal degradation 
Olanzapine OD tablets were kept in temperature controlled oven at 105 °C for 72 
hours and sample solution was prepared as per procedure. 
 
5.3.5 Photolytic degradation 
Olanzapine OD tablets were kept in photo stability chamber to expose it for 1.2 
million lux hours and sample solution was prepared as per procedure. 
 
5.4 Method validation 
Method validation approach: 
The method for the determination of related impurities for olanzapine OD tablets 
of 2.5mg, 5mg, 7.5mg, 10mg, 15mg, and 20 mg is same. Sample concentration for all the 
strengths is same (500 µg/ml of olanzapine). Olanzapine OD tablets 2.5mg, 5mg , 
7.5mg,10mg ,15mg , 20mg are weight proportional formulations (scale up-down) so 
complete validation performed on highest strength (20 mg) only. Linearity was performed 
by 5 levels of concentration. Recovery was performed by 3 replicates x 3 concentration. 
Filter media interference study was covered in accuracy study. 
 
5.5.1Specificity  
Interference from blank was not observed at any peak of interest and peak purity 
of all known impurities in spiked sample (as per method precision) observed within the 
acceptance criteria and forced degradation data as discussed in section 5.3 summarized in 
table 5 and chromatograms are as shown in fig.7,(A) to 7(O). 
Table 5: Forced degradation data 
Stress condition Oxidative 
degradation 
Acid 
degradation 
Base 
degradation 
Thermal 
degradation 
Photolytic 
degradation
% of degradation 21.6 29.8 8.0 0.2 0.1 
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Fig.7 (A): Peroxide degradation blank 
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Fig.7 (B): Peroxide degradation placebo 
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Fig.7 (C): Peroxide degradation sample 
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Fig.7 (D): Acid degradation blank 
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Fig.7 (E): Acid degradation placebo 
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Fig.7 (F): Acid degradation sample 
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Fig.7 (G): Base degradation blank 
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Fig.7 (H): Base degradation placebo 
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Fig.7 (I): Base degradation sample 
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Fig.7 (J): Thermal degradation placebo 
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Fig.7 (K): Thermal degradation sample 
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Fig.7 (L): Photo degradation sample  
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Fig.7 (M): Olanzapine impurity-1 
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Fig.7 (N): Olanzapine impurity-2 
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Fig.7 (O): Sample spiked with impurities 
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5.5.2 Linearity 
 
Linearity and relative response factor determination 
 
The calibration curve for Olanzapine and its impurities were constructed over the 
absolute concentration range of 0.25-3.75 µg/ml i.e. 0.05% to 0.75% concentration with 
respect to sample solution concentration in five levels. Peak area of each impurities and 
Olanzapine versus respective concentration was plotted and linear regression analysis 
performed on resultant curves. Relative response factor (RRF) was calculated for each 
known impurities by taking the ratio of impurity slope to Olanzapine slope [24]. 
Statistical data summarized in table 6 and chromatograms mentioned in Fig.8 (A) to (E). 
 
Table 6: Linearity and RRF  
Impurity 1 Impurity 2 Olanzapine Sr. 
No. 
% 
Linearity
level 
Conc. 
(%) 
Average 
area 
Conc. 
(%) 
Average 
area 
Conc. 
(%) 
Average 
area 
1. LOQ 0.05 9990 0.05 21030 0.05 11038 
2. 50% 0.26 60541 0.24 107234 0.10 29453 
3. 80% 0.42 94993 0.39 175318 0.16 45530 
4. 100% 0.53 118357 0.48 214724 0.20 59325 
5. 150% 0.79 177964 0.72 316143 0.30 88925 
Correlation 
coefficient (r) 
0.99979 0.99980 0.99916 
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Slope of 
regression line  
225407 441128 308368 
Y-intercept              -47.82 1025.8 -3101.4 
Residual sum of 
squares  
6717283 19451918 5887483 
RRF 0.72 1.43 --- 
 
RRT = Relative retention time 
RRF = Relative response factor 
 
Fig.8 (A): Linearity level-1 
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Fig.8 (B): Linearity level-2 
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Fig.8 (C): Linearity level-3 
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Fig.8 (D): Linearity level-4 
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Fig.8 (E): Linearity level-5 
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5.5.3 Precision at LOQ 
The LOQ concentrations for all known impurities were determined 0.25 µg/ml as 
0.05 % with respect to sample solution concentration of Olanzapine by signal to noise 
ratio methodology . The reproducibility at LOQ was determined by six replicate 
injections of composite mixture of impurities and olanzapine solution as per table 7 and 
Fig.9. 
 
 
 
Fig. 9: Chromatogram of precision at LOQ 
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Table 7: Precision at LOQ 
Peak Area 
Injection Impurity-1 Impurity-2 Olanzapine 
1 9467 21057 11392 
2 9685 21043 11397 
3 9646 21152 11873 
4 9449 21023 11942 
5 9612 21236 11757 
6 9542 21056 11711 
MEAN 9567 21095 11679 
SD 96.7 82.4 234.9 
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RSD 1.01 0.39 2.01 
 
5.5.4 Precision 
Method precision was established by six sets of sample preparation. To 
demonstrate the method precision olanzapine impurity 2 was spiked at self life 
specification level to all six sample preparation while olanzapine impurity 1 was above 
the LOQ so, it was not spiked in the sample preparations as shown in fig 10. Data are 
summarized in table 8. 
 
 
Table 8: Summary of precision day-1 and day-2 
Day-1 
Set No. Imp-1 (%) Imp-2 (%) Unk imp (%) Total Imp (%) 
1 0.18 0.49 BQL 0.67 
2 0.18 0.49 BQL 0.67 
3 0.18 0.49 BQL 0.67 
4 0.18 0.49 BQL 0.67 
5 0.18 0.49 BQL 0.67 
6 0.18 0.49 BQL 0.67 
Mean 0.18 0.49 - 0.67 
SD 0.00 0.00 - 0.00 
%RSD 0.000 0.000 - 0.000 
95% CI 0.000 0.000 - 0.000 
Day-2 
Set No. Imp-1 (%) Imp-2 (%) Unk imp (%) Total Imp (%) 
1 0.18 0.50 BQL 0.68 
2 0.19 0.50 BQL 0.69 
3 0.19 0.51 BQL 0.70 
4 0.18 0.50 BQL 0.68 
5 0.18 0.50 BQL 0.68 
6 0.18 0.51 BQL 0.69 
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50 
Mean 0.18 0.50 - 0.69 
SD 0.005 0.005 - 0.008 
%RSD 2.82 1.03 - 1.19 
95% CI ±0.005 ±0.005 - ±0.009 
 
SD = Standard Deviation, %RSD = Relative Standard Deviation 
Unk imp = Unknown impurity, CI = confidence interval 
 
 
 
Fig. 10: Chromatogram of method precision 
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5.5.5 Accuracy (Recovery) 
The accuracy was evaluated by the recovery study for method which was 
established at three levels in the range of 0.25-3.75 µg/ml (0.05% to 0.75% relative to 
sample concentration, 3 levels x 3 preparations). Calculated amount of known impurities 
were added in form of solution to the sample preparation to attain lowest to highest level. 
Data summarized in table 9, chromatograms shown in Fig.11 (A) to (C). 
 
Fig.11 (A): Chromatogram of accuracy level-1 
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Fig.11 (B): Chromatogram of accuracy level-2 
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Fig.11 (C): Chromatogram of accuracy level-3 
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Table 9: Summary of recovery data 
Name Amount added a (mcg/ml) Recovery a (%) % RSD 
0.25 104.2 2.8 
2.5 102.4 1.75 Impurity-1 
3.75 102.8 0.39 
0.25 104.8 0.31 
2.5 99.5 0.10 Impurity-2 
3.75 99.6 0.15 
 a = Average of three determinations 
 
5.5.6 Solution stability 
 The solution stability at 25°C was studied at different time interval against fresh 
standard preparation at specified time interval. The results obtain for the solution stability 
study at different time intervals for standard and sample preparation shown in table 10(A) 
and 10(B). The results obtained are well within the acceptance criteria. Therefore, the 
diluted standard preparation and sample preparation are stable in solution form up to 59 
hours and 56 hours respectively at room temperature. 
         
Table 10(A): Sample solution stability 
For sample preparation  
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Time Condition % Impurity 
Absolute 
difference (%)
A)  For impurity-1 (%) 
Initial Room temperature 0.18 Not applicable 
After 44 hours Room temperature 0.19 0.01 
After 56 hours Room temperature 0.19 0.01 
B)  For impurity -2 (%) 
Initial Room temperature 0.50 Not applicable 
After 44 hours Room temperature 0.51 0.01 
After 56 hours Room temperature 0.51 0.01 
C) For any unknown impurity (%) 
Initial Room temperature BQL Not applicable 
After 44 hours Room temperature BQL 0.00 
After 56 hours Room temperature BQL 0.00 
D) For total impurities (%) 
Initial Room temperature 0.68 Not applicable 
After 44 hours Room temperature 0.70 0.02 
After 56 hours Room temperature 0.70 0.02 
 
 
 
Table 10(B): Standard solution stability 
 
For diluted standard preparation 
Time Condition % Assay 
Absolute 
difference (%)
Initial Room temperature 100.0 Not applicable 
After 47 hours Room temperature 99.8 0.2 
After 59 hours Room temperature 101.8 1.8 
 
5.3.6 Robustness:  
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The result of robustness study of the developed method has shown in Table 11(A) 
and 11(B). The results have shown that during all variance conditions value of related 
impurities for the test preparation was within the acceptance criteria. It was in accordance 
with that of accepted true value from method precision study. System suitability 
parameters were also found satisfactory; hence the analytical method would be concluded 
as robust.  
Table 11(A): System suitability summary of robustness study 
System suitability parameters 
Condition 
Resolution 
between  
imp-1 and 
imp-2 
Resolution 
between  
imp-2 and 
olanzapine 
% RSD for 
standard 
(NMT 2.0) 
A) Change in flow rate 
Normal condition 
(1.0 ml per minute) 
3.6 38.4 0.27 
0.9 ml per minute 3.8 39.0 1.52 
1.1 ml per minute 2.8 30.4 0.27 
B) Change in column temperature 
Normal condition (27°C) 3.1 33.6 0.33 
Oven temperature 32°C 2.4 34.2 0.51 
 
C) Change in buffer pH 
Normal condition pH 6.8 3.7 39.1 0.28 
Buffer pH 6.6 4.0 35.7 0.42 
Buffer pH 7.0 4.0 43.6 0.94 
D) Change in column lot* 
Normal:   YMC/OA/250-5/09 
Lot No: O425001079(W) 
3.1 33.6 0.33 
Changed: YMC/OA/250-5/06 
Lot No: O42586532(W) 
3.6 38.4 0.27 
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Table 11(B): System suitability summary of robustness study 
% Impurities 
Condition 
Imp-1 Imp-2 
Any 
single 
unknown 
imp (%) 
Total 
impurities (%) 
A) Change in flow rate 
Normal condition 
(1.0 ml per minute) 
0.18 0.50 BQL 0.68 
0.9 ml per minute 0.16 0.52 BQL 0.68 
Absolute difference 
from normal condition 
0.02 0.02 
Not 
applicable 
0.00 
Normal condition 
(1.0 ml per minute) 
0.18 0.49 BQL 0.67 
1.1 ml per minute 0.19 0.50 BQL 0.69 
Absolute difference 
from normal condition 
0.01 0.01 
Not 
applicable 
0.02 
B) Change in column temperature 
Normal condition 
27.0°C 
0.18 0.49 BQL 0.67 
Oven temperature 32°C 0.18 0.49 BQL 0.67 
Absolute difference 
from normal condition 0.00 0.00 
Not 
applicable 
0.00 
C) Change in buffer pH 
Normal condition pH-
6.8 
0.19 0.51 BQL 0.70 
Buffer pH 6.6 0.18 0.52 BQL 0.70 
Absolute difference 
from normal condition 
0.01 0.01 
Not 
applicable 
0.00 
Buffer pH 7.0 0.19 0.51 BQL 0.70 
 
 
Method development olanzapine OD tablets 
 
 
56 
Absolute difference 
from normal condition 
0.00 0.00 
Not 
applicable 
0.00 
D) Change in column lot* 
Lot No: 
O425001079(W) 
0.18 0.49 BQL 0.67 
Lot No: O42586532(W) 0.18 0.50 BQL 0.68 
Absolute difference 
from normal condition 
0.00 0.01 
Not 
applicable 
0.01 
 
6. Quantitation and calculation formulae 
 
6.1 Relative Standard Deviation (%) 
Relative Standard Deviation (%) =  X
100    SD ×  
 
6.2 Calculation formulae in linearity and RRF 
 Correlation coefficient (r) =   
]})([  ])(x{[
y)( x)(  -  )x(  
2222 yynxn
yn
∑−∑∑−∑
∑∑∑
 
 
Correlation coefficient (r) = CORREL (Array 1, Array 2) 
 
Slope of regression line = 22 x)( x
y)( x)(  -  )x(  
∑−∑
∑∑∑
n
yn
  
 
Slope of regression line = SLOPE (Array 1, Array 2) 
 
y- intercept = xB - y  =A  
y- intercept = INTERCEPT (Array 1, Array 2) 
 
Residual sum of squares =  ∑ 2calculated)Y - ( originalY
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Where, 
Y calculated =  A + Bx 
n = Number of measurements 
x = Individual concentration 
y = Individual area 
x   = Average concentration 
y  = Average area 
 
Residual sum of squares = SUMXMY2 (Array 1, TREND (Array 1, Array 2, Array2)) 
 
Relative Response Factor = 
standardfor  line regression of Slope
impurity for  line regression of Slope  
 
6.3 Accuracy (% Recovery) 
% Recovery = 100x 
added (mg) substance ofAmmount 
  found (mg) sbustance ofAmmount  
 
6.4 % Impurity in olanzapine Tablets 
% Impurity = such)(as%assayStd.
RRF
1
LC
Wt.Avg
WtSpl
Dilution
Dilution
 wtStd.
Astd
Asp ×××××  
 
e.g. 
% Impurity-1 = 72.99
0.72
1
20
320.2
806.21
100
50
5
50
5
100
25.91
165232
41362 ×××××××  
% Impurity-1 = 0.18  
% Impurity-2 = 72.99
1.43
1
20
320.2
806.21
100
50
5
50
5
100
25.91
165232
226953 ×××××××  
% Impurity-2 = 0.49  
 
% Total impurities = Total known impurities + Total unknown impurities 
% Total impurities = (0.18 + 0.49) + (0.00) 
% Total impurities = 0.67  
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Asp : Area of impurity in sample 
Astd : Mean area of diluted standard 
Std. wt : Std weight in mg 
Spl wt : Sample weight in mg 
Avg wt : Average weight in mg 
LC : Label claim per tablet (mg) 
 
6.5 95% Confidence Interval (CI) 
95% Confidence Interval (CI) = 
n
SD  t  ×± α  
Where, 
SD = Standard Deviation 
X   = Average concentration 
n = Number of measurements 
tα = t value at n-1 from t table (two tail) 
95% Confidence Interval (CI) = SD (2.57058)/SQRT (6) 
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 Section-II: HPLC Method development and validation for determination 
of related impurities in Quetiapine fumarate 
 
1. Introduction to quetiapine fumarate 
 
Quetiapine is chemically 2-[2-(4-dibenzo[b,f]thiazepin-11-yl-1-piperazinyl) 
ethoxy]ethanol (Fig.1A) is a dibenzothiazepine atypical antiscychotic and reported to 
have affinity for serotonin (5-HT2), histamine (H1), and adrenergic (α1 and α2) receptors 
as well as dopamine D2 receptors. Quetiapine is used in treatment of schizophrenia and of 
mania associated with bipolar disorder. Molecular formula of quetiapine fumarate (Fig. 
1B) is (C21H25N3O2S) 2 C4H4O4 with molecular weight 883.1 g/mole [1]. Its melting point 
is 172°C to 173°C [2-3]. Quetiapine fumarate is a weak acid with dissociation constant 
(pKa) 3.3 and 6.8 with moderate pH dependent solubility, 94.3 mg/mL to 2.37 mg/mL at 
pH values from 1 to 9 reported [4]. 
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Fig.1A: Quetiapine 
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Fig.1B: Quetiapine fumarate 
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Strengths: Quetiapine tablets are available in six strengths equivalent to 25 mg, 50 mg, 
100 mg, 150 mg, 200 mg, and 300 mg of Quetiapine in form of quetiapine fumarate as an 
active ingredient for oral administration. 
Innovator:  SEROQUEL tablets, AstraZeneca 
 
PHARMACOLOGY 
Pharmacodynamics 
Quetiapine is an atypical antipsychotic agent. Quetiapine and the human plasma 
metabolite, N-desalkyl quetiapine, interact with a broad range of neurotransmitter 
receptors. Quetiapine and N-desalkyl quetiapine exhibit affinity for brain serotonin 
(5HT2) and dopamine D1 and D2 receptors. It is this combination of receptor antagonism 
with a higher selectivity for 5HT2 relative to D2 receptors which is believed to contribute 
to the clinical antipsychotic properties and low extrapyramidal side effects (EPS) liability 
of SEROQUEL. Additionally, N-desalkyl quetiapine has high affinity at serotonin 5HT1 
receptors. Quetiapine and Ndesalkyl quetiapine also have high affinity at histaminergic 
and adrenergic α1 receptors, with a lower affinity at adrenergic α2 receptors. Quetiapine 
has no appreciable affinity at cholinergic muscarinic or benzodiazepine receptors. 
Quetiapine is active in tests for antipsychotic activity, such as conditioned avoidance. It 
also reverses the action of dopamine agonists, measured either behaviourally or 
lectrophysiologically, and elevates dopamine metabolite concentrations, a neurochemical 
index of D2 receptor blockade. The extent to which the N-desalkyl quetiapine metabolite 
contributes to the pharmacological activity of SEROQUEL in humans is not known. In 
pre-clinical tests predictive of EPS, quetiapine is unlike standard antipsychotics and has 
an atypical profile. Quetiapine does not produce dopamine D2 receptor supersensitivity 
after chronic administration. Quetiapine produces only weak catalepsy at effective 
dopamine D2 receptor blocking doses. Quetiapine demonstrates selectivity for the limbic 
system by producing depolarization blockade of the mesolimbic but not the nigrostriatal 
dopamine-containing neurons following chronic administration. Quetiapine exhibits 
minimal dystonic liability in haloperidol-sensitised or drug-naive Cebus monkeys after 
acute and chronic administration. The results of these tests predict that SEROQUEL 
should have minimal EPS liability, and it has been hypothesised that agents with a lower 
EPS liability may also have a lower liability to produce tardive dyskinesia. 
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Pharmacokinetics 
Absorption 
Quetiapine is well absorbed and the bioavailability of quetiapine is not 
significantly affected by administration with food [5]. 
 
Distribution 
The elimination half-lives of quetiapine and N-desalkyl quetiapine are 
approximately 7 and 12 hours respectively. Quetiapine is approximately 83% bound to 
plasma proteins. Steady state peak molar concentrations of the active metabolite N-
desalkyl quetiapine are 35% of that observed for quetiapine. The pharmacokinetics of 
quetiapine and N-desalkyl quetiapine are linear across the approved dosage range. The 
kinetics of quetiapine do not differ between men and women. 
 
Metabolism 
Quetiapine is extensively metabolised by the liver following oral administration, 
with parent compound accounting for less than 5% of unchanged drug related material in 
the urine or faeces, following the administration of radiolabelled quetiapine. The average 
molar dose fraction of free quetiapine and the active human plasma metabolite N-desalkyl 
quetiapine is <5% excreted in the urine. In vitro investigations established that CYP3A4 
is likely to be the primary enzyme responsible for cytochrome P450 mediated metabolism 
of quetiapine. N-desalkyl quetiapine is primarily formed and eliminated via CYP3A4. 
CYP2D6 and CYP2C9 are also involved in quetiapine metabolism. 
 
Quetiapine and several of its metabolites (including N-desalkyl quetiapine) were 
found to be weak to modest inhibitors of human cytochrome P450 3A4, 2C19,2D6, 1A2 
and 2C9 ctivities in vitro. In vitro CYP inhibition is observed only at concentrations 
approximately 5 to 50-fold higher than those observed at a dose range of 300 to 800 
mg/day in humans. Based on these in vitro results, it is unlikely that coadministration of 
quetiapine with other drugs will result in clinically significant drug inhibition of 
cytochrome P450 mediated metabolism of the other drug. From animal studies it appears 
that quetiapine can induce cytochrome P450 enzymes. In a specific interaction study in 
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psychotic patients, however, no increase in the cytochrome P450 activity was found after 
administration of quetiapine. 
 
1. The mean clearance of quetiapine in the elderly is approximately 30 to 50% lower 
than that seen in adults aged 18 to 65 years. 
2. Excretion 
3. Approximately 73% of the radioactivity is excreted in the urine and 21% in the 
4. Faeces. 
 
Use in renal impairment 
The mean plasma clearance of quetiapine was reduced by approximately 25% in 
subjects with severe renal impairment (creatinine clearance less than 30 mL/min/1.73m2), 
but the individual clearance values are within the range for normal subjects. 
 
Contraindications 
SEROQUEL is contraindicated in patients who are hypersensitive to any 
component of this product. 
 
2. Literature review 
The literature review regarding quetiapine fumarate suggest that various analytical 
methods were reported for drug substance as well as in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of Quetiapine are as under. 
 
2.1 Vijaya Kumar M., Muley have developed a stability indicating HPLC method for 
determination of quetiapine fumarate in bulk drug and solid dosage forms. In this 
method Puroshere STAR RP18e (C18 250mm x 4.6 mm, 5µm) column with mobile 
phase consisting of Methanol: Water: TEA in the ratio of 73:27:0.4 % v/v/v pH 3.0 
adjusted with phosphoric acid in isocratic mode. The detection wavelength is 289 nm 
and flow rate is 1.0 ml/min. In the range of 10-300 µg/ml, linearity of quetiapine 
shows a regression co efficient of 0.9996. The proposed method is sufficient selective 
to distinguish the parent drug and degradation products after hydrolysis, photolysis, or 
chemical oxidation and from excipients [6]. 
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2.2 Bharathi C.H., Prabahar K. J., Prasad C. H. S., Srinivasa Rao M.  
Trinadhachary G. N., Handa V. K., Dandala R., Naidu A have documented 
identification, isolation, synthesis and characterization of impurities of quetiapine 
fumarate and six unknown impurities and one known impurity (intermediate) were 
identified ranging from 0.05-0.15% by reverse-phase HPLC. These impurities were 
isolated from crude samples using reverse-phase preparative HPLC. Based on the 
spectral data, the impurities were characterized as 2-[4-dibenzo[b,f][1,4]thiazepine-
11-yl-1-piperazinyl]1-2-ethanol (impurity I, desethanol quetiapine), 11-[(N-formyl)-
1-piperazinyl]-dibenzo[b,f][1,4]thiazepine (impurity II, N-formyl piperazinyl 
thiazepine), 2-(2-hydroxy ethoxy)ethyl-2-[2-[4-dibenzo[b,f][1,4]thiazepine-11-
piperazinyl-1-carboxylate (impurity III, quetiapine carboxylate), 11-[4-ethyl-1-
piperazinyl]dibenzo[b,f][1,4] thiazepine (impurity IV, ethylpiperazinyl thiazepine), 2-
[2-(4-dibenzo[6,/][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]1 -ethyl ethanol [impurity 
V, ethyl quetiapine), 1,4-bis[dibenzo[b,f][1,4]thiazepine-11-yl] piperazine [impurity 
VI, bis(dibenzo)piperazine]. The known impurity was an intermediate, 11-
piperazinyldibenzo [b,f][1,4]thiazepine (piperazinyl thiazepine). The structures were 
established unambiguously by independent synthesis and co-injection in HPLC to 
confirm the retention times. To the best of our knowledge, these impurities have not 
been reported before. Structural elucidation of all impurities by spectral data (1H 
NMR, 13C NMR, MS and IR), synthesis and formation of these impurities are 
discussed in detail [7]. 
 
2.3 Julia Sachse, Johannes Köller Sebastian Härtter and Christoph Hiemke have 
developed an HPLC method with column switching is described for the determination 
of quetiapine, clozapine, perazine, olanzapine and metabolites in blood serum. After 
clean-up on silica C8 material (20 μm particle size) drugs were separated on ODS 
Hypersil C18 material (5 μm; column size 250 mm × 4.6 mm i.d.) within 25 min and 
quantified by ultraviolet (UV) detection at 254 nm. The limit of quantification ranged 
between 10 and 50 ng/ml. At therapeutic concentrations of the drugs, the inter-assay 
reproducibility was below 10%. Analyses of drug concentrations in serum of 75– 295 
patients treated with therapeutic doses of the antipsychotic drugs revealed 
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mean ± S.D. steady state concentrations of 139 ± 136 ng/ml for quetiapine, 
328 ± 195 ng/ml for clozapine, 48 ± 27 ng/ml for olanzapine and 71 ± 52 ng/ml for 
perazine The method was thus suitable for routine therapeutic drug monitoring and 
may be extended to other drugs [8]. 
 
2.4 B. Barrett and co-workers have developed validated HPLC–MS/MS method for 
determination of quetiapine in human plasma highly sensitive and selective high-
pressure liquid chromatography–tandem mass spectrometry (LC–MS/MS) methodwas 
developed for the quantitative determination of quetiapine (QUE) in human 
Na2EDTA plasma with mass spectrometry (MS) detection. Clozapine (CLO) was 
employed as an internal standard. Samples were extracted using solid phase extraction 
(SPE). Oasis HLB cartridges and the concentration of quetiapine was determined by 
isocratic HPLC–MS/MS. The SRM mode was used for MS/MS detection. The 
method was validated over a concentration range of 1.0–382.2 ng/mL. Inter- and 
intra-day precision and accuracy of the proposed method were characterized by 
relative standard deviation (R.S.D.) and the percentage of deviation, respectively; 
both were lower than 8%. The developed method was employed in the 
pharmacokinetic study of quetiapine [9]. 
 
2.5 Mandrioli R.; Fanali S.; Ferranti A.; Raggi M. A have developed a precise and 
feasible high- performance liquid chromatographic (HPLC) method for the analysis of 
the novel antipsychotic drug quetiapine in plasma. The analysis was carried out on a 
C8 (150 x 4.6 mm i.d., 5 μm) reversed-phase column, using a mixture of acetonitrile, 
methanol and pH 1.9 phosphate buffer as the mobile phase; triprolidine was used as 
the internal standard. Careful pretreatment of the biological samples was implemented 
by means of solid- phase extraction (SPE). A good linearity was found in the 4-400 ng 
ml-1 quetiapine plasma concentration range. The application to some plasma samples 
of patients treated with Seroquel® tablets gave satisfactory results. The accuracy was 
good (quetiapine mean recovery = 92%), as well as the precision (mean RSD = 3.3%). 
The method seems to be suitable for the clinical monitoring of patients treated with 
quetiapine [10]. 
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2.6 Vasil N, Atanasov, Kamen P. Kanev and Mariana Io. Mitewa have developed a 
method for detection and identification of atypical quetiapine metabolite in 
urine, Quetiapine fumarate (Seroquel®) is an atypical antipsychotic dibenzothiazepine 
derivative. Due to its extensive hepatic metabolism and low level of unchanged 
excretion (< 1%) the routine toxicological drug-screening analyses of urine often 
leads to false negative results. In the present study, we report that a newly identified 
metabolite of quetiapine, N-desalkylquetiapine, can be used as an indicative marker of 
quetiapine-intake in urine using common GC-MS screening procedure. The structure 
of the mentioned metabolite was solved from the mass-spectrum obtained and the 
quetiapine presence was proved by consequent HPLC plasma analysis [11]. 
 
2.7 Davis PC and Wong J Gefvert O have developed a method for sensitive and specific 
HPLC assay for the measurement of the antipsychotic compound quetiapine in human 
plasma and validated. The assay employs a three-step liquid liquid extraction of 
quetiapine and its 7-hydroxylated and 7-hydroxylated, N-dealkylated metabolites 
from human plasma, and utilizes ultraviolet (UV) detection of quetiapine and 
electrochemical detection of the metabolites. The method provides a linear response 
from a quantitation limit of 2.50 to 500 ng ml(-1) for each analyte using 0.4 ml 
plasma. The assay is applicable from 500 to 5000 ng ml(-1) by sample dilution with 
de-ionized water. The inter-assay precision of quetiapine in plasma calibration 
standards across 4 validation days averaged 11.9% relative standard deviation (RSD) 
over the range 2.50 to 500 ng ml(-1), with intra-assay precision averaging 16.0% RSD 
and mean accuracy of 98.6% of theory. Similarly, the inter-assay precision of the 7-
hydroxylated metabolite in plasma calibration standards across 4 validation days 
averaged 13.7% RSD over the range 2.50 to 500 ng ml(-1), with intra-assay precision 
averaging 17.6% RSD and mean accuracy of 109% of theory. The 7-hydroxylated, N-
dealkylated metabolite demonstrated inter-assay precision of 16.2% RSD, intra-assay 
precision of 19.9% RSD, and mean accuracy of 104% of theory over the range 2.50 to 
500 ng ml(-1). The present assay method was used to support a study comparing the 
pharmacokinetic profile of quetiapine with the time course of dopamine D2 and 
serotonin 5-HT2 receptor occupancy in the brain using positron emission tomography 
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(PET). We describe in this paper the bioanalytical method and the plasma 
concentrations of quetiapine and its metabolites resulting from this study [12]. 
 
2.8 Zhiling Zhou ; Xin Li  ; Kunyan Li ; Zhihong Xie ; Zeneng Cheng ; Wenxin Peng 
; Feng Wang ; Ronghua Zhu ; Huande Li  have developed method for simultaneous 
determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-
performance liquid chromatography-electrospray ionization mass spectrometry. 
Clozapine (CLZ), olanzapine (OLZ), risperidone (RIP) and quetiapine (QTP) have 
been widely used in the treatment of schizophrenia. However, no study (or little 
study) has been conducted to determine the four drugs simultaneously by the use of 
high-performance liquid chromatography-electrospray ionization mass spectrometry 
(HPLC-MS/ESI). Objective: To develop a sensitive method for simultaneous 
determination of CLZ, OLZ, RIP and QTP in human plasma by HPLC-MS/ESI. 
Methods: The analytes were extracted twice by ether after samples had been 
alkalinized. The HPLC separation of the analytes was performed on a MACHEREY-
NAGEL C18 (2.0 mm x 125 mm, 3 μm, Germany) column, using water (formic acid: 
2.70 mmol/l, ammonium acetate: 10 mmol/l)-acetonitrile (53:47) as mobile phase, 
with a flow-rate of 0.16 ml/min. The compounds were ionized in the electrospray 
ionization (ESI) ion source of the mass spectrometer and were detected in the selected 
ion recording (SIR) mode. Results: The calibration curves were linear in the ranges of 
20-1000 ng/ml for CLZ and QTP, 1-50 ng/ml for OLZ and RIP, respectively. The 
average extraction recoveries for all the four analysts were at least above 80%. The 
methodology recoveries were higher than 91% for the analysts. The intra- and inter-
day R.S.D. were less than 15%. Conclusion: The method is accurate, sensitive and 
simple for routine therapeutic drug monitoring (TDM) and for the study of the 
pharmacokinetics of the four drugs [13]. 
 
3. Aim of present work 
Literature reveals that the drug is not official in any pharmacopeia. An HPLC method 
for quetiapine assay using UV detector for drug substance and formulation is available 
[6]. A method with identification, isolation, synthesis and characterization of six 
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impurities for quetiapine fumarate was reported [7]. A method for quetiapine and it’s 
metabolite in serum is reported [8]. Many methods are available for quetiapine drug 
substance and it’s metabolite in plasma or urine [9-13]. But here seven known impurities 
are reported and for that method needs to developed and validated as per current regulated 
requirement with establishment of RRF and RRT for all known impurities (Fig. 1C). 
 
The aim and scope of the proposed work are as under 
? HPLC method development for determination of related impurities in Quetiapine 
fumarate drug substance. 
? Forced degradation study under stress condition 
? To resolve all known impurities and generated during the force degradation 
studies 
? Perform analytical method validation for the proposed method as per ICH 
guideline. 
 
Fig.1C: Quetiapine fumarate impurity A to G 
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4. Experimental 
 
4.1 Materials, chemicals and reagents 
Materials, chemicals and reagents were used as mentioned in Table 1 and Table 2. 
 
Table 1: Materials  
Sr.No  Material Name  Lot. No. / Batch 
no./Adl Cert. No. 
Potency / 
Purity 
1 Quetiapine fumarate standard OTV/2008/0203 99.60% 
2 Quetiapine fumarate sample QTP3/XIV/005 -- 
3 Impurity-A = Dibenzo [b,f] [1,4] thiazepine-11-(10H)-one  OTV/2007/758/01 99.53% 
4 Impurity-B = 11-Piperazinyl dibenzo[b,f] [1,4] thiazepine  OTV/2007/1502 82.79% 
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5 Impurity-C = 2-(4-dibenzo[b,f][1,4,]thiazepin-11-yl-1-
piperazinyl) ethanol) 
OTV/2007/1313 98.20% 
6 Impurity-D = 2-[2-(4-dibenzo[b,f][1,4,]thiazepin-11-yl-1-
piperazinyl)ethoxy]ethoxy]ethanol) 
OTV/2007/1314 88.95% 
7 Impurity-E = 11-(4-methylpiperazin-1-
yl)dibenzo[b,f][1,4]thiazapine) 
OTV/2007/893 87.72% 
8 Impurity-F = (1,4 Bis(dibenzo[b,f][1,4]thiazapine-11-yl 
piperazine ) 
OTV/2007/1503 98.35% 
9 Impurity-G = 1,2-Bis[2-(4-dibenzo[b,f][1,4]thiazepin-11-
yl-1-piperazinyl)ethoxy]ethane 
QTP/XII/022 83.59% 
 
 Table 2: Chemicals and reagents 
Sr. No. Chemical/Reagent Grade 
1 Methanol HPLC grade (Merck, India) 
2 Acetonitrile HPLC grade (Merck, India) 
3 Ammonia solution (25%v/v) AR grade (Rankem, India) 
4 Fumaric acid GR grade (Merck, India) 
5 Hydrochloric acid AR grade (Rankem, India) 
6 Sodium hydroxide pellets GR grade (Merck, India) 
7 Hydrogen peroxide solution (30%) Purified (Merck, India) 
8 Mill-Q-water By Milli-Q system (Millipore, USA) 
 
4.2 Instrumentation 
 
The HPLC system of alliance with Waters 2695, waters 2487 and waters 2996 
with Empower software was used for this entire study. Chromatographic separation was 
achieved on X terra RP -8 ,150 mm X 4.6mm 5µm (150 mm X 4.6mm 5µm) column as 
stationary phase with binary gradient mode. 
 
4.3 Blank preparation 
Diluent was used as a blank Fig. 2. 
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Fig.2: Chromatogram of blank 
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4.4 Standard solution 
Transferred about 15 mg of each of quetiapine fumarate standard into 100ml 
volumetric flask and 75ml diluent was added to dissolve with aid of sonication and 
diluted to volume with diluent. In a 200ml volumetric flask, 2 ml of this solution was 
diluted to volume with diluent (1.0 µg/ml of quetiapine fumarate) Fig [3]. 
 
Fig.3: Chromatogram of standard solution 
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4.5 Preparation of impurity –A stock solution 
Transferred about 2.5 mg of impurity –A into 10ml volumetric flask and 7ml 
diluent was added to dissolve with aid of sonication and diluted to volume with diluent. 
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4.6 Preparation of impurity –B stock solution 
Transferred about 2.5 mg of impurity –B into 10ml volumetric flask and 7ml 
diluent was added to dissolve with aid of sonication and diluted to volume with diluent. 
 
4.7 Preparation of impurity –D stock solution 
Transferred about 25 mg of impurity –D into 100ml volumetric flask and 70ml 
diluent was added to dissolve with aid of sonication and diluted to volume with diluent. 
 
4.8 Resolution solution 
Transferred about 50 mg of quetiapine fumarate into 50ml volumetric flask and 
35ml diluent was added to dissolve with aid of sonication and 1.0ml of each of impurity 
stock solution were added and diluted to volume with diluent Fig [4]. 
 
Fig.4: Chromatogram of resolution solution 
Im
p-
A 
- 1
4.
34
1
Im
p-
B 
- 2
0.
43
7
Q
ue
tia
pi
ne
 - 
33
.4
82
Im
p-
D
 - 
37
.6
13
AU
-0.002
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
0.016
0.018
0.020
Minutes
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00 65.00 70.00 75.00 80.00
 
4.9 Sample solution   
Transferred about 50 mg of sample into 50ml volumetric flask and 35ml diluent 
was added to dissolve with aid of sonication and diluted to volume with diluent (1000 
µg/ml of quetiapine fumarate) Fig[5]. 
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Fig.5: Chromatogram of sample solution (as such preparation) 
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5. Result and discussion 
 
5.1 Development and optimization of the LC method 
Method development was based on several considerations like diluent selection, 
column selection, and detection. 
 
5.1.1 Selection of diluent 
Initially method development was started with quetiapine fumarate standard 
preparation in methanol. But, it was observed that known impurities were not easily 
soluble in methanol. So, a mixture of acetonitrile and water in the ratio of 80:20 was 
chosen to achieve solubility of impurity-A to impurity-E. During the course of 
development an unknown impurity was observed in late eluting region of chromatogram 
and it was identified and made it known as an impurity-F. But, during the recovery stock 
solution preparation it was observed that impurity-F was also very less soluble in 
proposed diluent. So, again different pH diluents were employed in same composition of 
acetonitrile and water and finally 0.1 ml of perchloric acid in a mixture of 1000 ml of 
acetonitrile: water in ratio of 80:20 was optimized to achieve desired solubility and 
solution stability of QF and its known impurities. 
 
 
5.1.2 Selection of column 
A mobile phase consisting of buffer of pH 9.2 was explored to achieve adequate 
separation between impurity-D and QF peak fig [2]. So for such a higher pH X-terra RP-8 
column (150 mm x 4.6 mm, 5 µm) was used for chromatographic separation [14-15] 
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Table 3: Chromatographic condition 
Mobile phase-A Buffer : Acetonitrile : Methanol  70: 13: 17 (v/v/v) 
(Buffer, 40 mM ammoniaum acetate, pH was adjusted with 
ammonia  solution to 9.2, filtered through 0.45µm PVDF 
membrane) 
Mobile phase-B Acetonitrile 
Column X terra RP -8 ,150 mm X 4.6mm 5µm 
Column oven temp 45°C 
Detection UV at 250 nm  
Flow rate 1.5ml/min 
Injection volume 20µl 
Run time 80 min 
Time  
(min) 
Mobile phase-A  
(%) 
Mobile phase-B  
(%) 
0.0 100 0 
40 100 0 
65 50 50 
75 50 50 
76 100 0 
Gradient program 
80 100 0 
Diluent 0.1ml of perchloric acid (70%) in 1000 ml of mixture of water 
and Acetonitrile in ratio of 20:80 
 
5.1.3 Selection of detection 
A UV spectrum of QF and its impurities were recorded with the help of photo 
diode array detector, spectrum pattern was found similar for all components of interest 
with maxima at about 208 nm, 250 nm and 290 nm, but detection at 208 nm was not 
selected with consideration of UV cut-off of ammonium acetate buffer [16] and 250 nm 
was selected for adequate response at working concentration for intended application to 
reproduce the results of an impurity at reporting threshold [17-18] or at LOQ.  
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Impurities spiked sample solution was used for gradient optimization. Once 
desired separation for known impurities and main component was achieved forced 
degradation was performed. Finally proposed method with chromatographic condition as 
per table 3 was subjected to method validation as per ICH guideline. 
 
5.2 Forced degradation study 
Forced degradation was performed on Quetiapine fumarate drug substance to 
achieve desired degradation. Based on development trials optimized forced degradation 
conditions were established as mentioned below, Final sample concentration was 
achieved 1000µg/ml of Quetiapine fumarate with diluent as proposed sample 
concentration. 
 
5.2.1 Oxidative degradation 
Drug substance was subjected to oxidative stress condition by 5ml of 3% v/v 
H2O2 solution on water bath at 50°C for 5 min and sample solution was prepared as per 
procedure. 
 
5.2.2 Acidic degradation 
Drug substance was subjected to acid stress condition by 5ml of 1N HCl on water 
bath at 70°C for 8 hours in 50ml volumetric flask and sample was neutralized with 1N 
NaOH and sample solution was prepared as per procedure 
 
5.2.3 Base degradation 
Drug substance was subjected to base stress condition by 5ml of 5N NaOH on 
water bath at 70°C for 12 hours in 50ml volumetric flask and sample was neutralized with 
5N HCl and sample solution was prepared as per procedure 
 
5.2.3 Thermal degradation 
Drug substance was kept in temperature controlled oven at 105 °C for 72 hours 
and sample solution was prepared as per procedure. 
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5.3 Method validation 
Method validation approach was to establish performance characteristic of method 
for the requirements of intended analytical application. 
 
5.4.1  Specificity 
Interference from blank was not observed at any peak of interest and peak purity 
of all known impurities in spiked sample (as per method precision) observed within the 
acceptance criteria and forced degradation data as discussed in section 5.3 summarized in 
table 5 and chromatograms are as shown in fig.7,(A) to 7(L). 
 
Table 5: Forced degradation data 
Stress condition % of degradation  
Oxidative degradation 17.1 
Acid degradation 22.4 
Base degradation 5.0 
Photo degradation 0.2 
Thermal degradation 3.9 
 
Fig 7: Forced degradation chromatograms 
Fig.7 (A): Peroxide degradation 
AU
-0.002
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
0.016
0.018
0.020
Minutes
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00 65.00 70.00 75.00 80.00
 
 
 
 
76 
 
 
 
 
 
Method Development Quetiapine fumarate API 
 
un
k-
1 
- 2
.8
79
un
k-
2 
- 6
.3
64
un
k-
3 
- 8
.1
26
Im
p-
A 
- 1
4.
32
8
Im
p-
B 
- 1
9.
24
2
Im
p-
C 
- 2
6.
90
4
Q
ue
tia
pi
ne
 - 
33
.3
4 4
un
k-
4 
- 5
0.
58
6
Im
p-
G
 - 
64
.7
66
AU
-0.002
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
0.016
0.018
0.020
Minutes
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00 65.00 70.00 75.00 80.00
 
Fig.7 (B): Acid degradation 
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Fig.7 (C): Base degradation 
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Fig.7 (D): Thermal degradation 
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Fig.7 (E): Chromatogram of impurity-A 
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Fig.7 (F): Chromatogram of impurity-B 
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Fig.7 (G): Chromatogram of impurity-C 
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Fig.7 (H): Chromatogram of impurity-D 
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Fig.7 (I): Chromatogram of impurity-E 
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Fig.7 (J): Chromatogram of impurity-F 
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Fig.7 (K): Chromatogram of impurity-G 
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Fig.7 (L): Chromatogram of fumaric acid 
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5.5.2 Linearity 
Linearity and relative response factor determination were established by 
constructing the calibration curve for QF and its impurities over the concentration range 
of 0.5-2.25 µg/ml (LOQ to 150% of maximum allowable % known impurities Fig [8]. 
Peak area of each impurity and quetiapine fumarate versus concentration were plotted and 
linear regression analysis performed on resultant curves. Relative Response Factor (RRF) 
was calculated for each known impurities by taking the ratio of impurity slope to QF 
slope. % impurity was calculated based on RRF value [19]. Statistical data summarized in 
table 6. 
Table 6(A): Linearity and RRT and RRF  
Impurity-A Impurity –B Impurity -C QF 
Sr. 
No. 
Linearity 
Level 
Conc. 
(%) 
Area 
Conc. 
(%) 
Area 
Conc. 
(%) 
Area 
Conc. 
(%) 
Area 
1. 
LOQ 
(Level-1) 
0.05 22693 0.05 20338 0.05 15316 0.05 11488 
2. 
60% 
(Level-2) 
0.08 40516 0.09 34872 0.09 27976 0.06 14253 
3. 
80% 
(Level-3) 
0.11 53447 0.12 46942 0.11 38004 0.08 18598 
4. 
100% 
(Level-4) 
0.14 66147 0.15 58360 0.14 47941 0.10 25416 
5. 
150% 
(Level-5) 
0.21 100264 0.22 87225 0.22 70490 0.15 39229 
Correlation 
coefficient (r) 
0.99888 0.99968 0.99597 0.99879 
Slope of regression 
line 
475412 394495 326593 279105 
Y-intercept 514.78 -158.97 101.11 -2764.4 
Residual sum of 
squares 
7679461 1660951 14076936 1184090 
RRF 1.70 1.41 1.17 1.00 
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Table 6(B): Linearity and RRT and RRF  
Impurity-D Impurity –E Impurity -F Impurity-G 
Sr. 
No. 
Linearity 
level 
Conc. 
(%) 
Area 
Conc. 
(%) 
Area 
Conc. 
(%) 
Area 
Conc. 
(%) 
Area 
1. 
LOQ 
(Level-1) 
0.05 10748 0.05 14984 0.05 20030 0.05 12494 
2. 
60% 
(Level-2) 
0.09 15757 0.09 26815 0.08 36065 0.09 22729 
3. 
80% 
(Level-3) 
0.12 23599 0.12 35425 0.11 48050 0.12 32250 
4. 
100% 
(Level-4) 
0.15 28593 0.15 43742 0.14 59613 0.15 40037 
5. 
150% 
(Level-5) 
0.22 45870 0.22 65841 0.20 89500 0.22 60784 
Correlation 
coefficient (r) 
0.99382 0.99968 0.99858 0.99959 
Slope of 
regression line 
210189 297953 453460 285308 
Y-intercept -1570.4 -180.71 -1949.8 -2290.1 
Residual sum of 
squares 
9102257 941897 7782186 1108623 
RRF 0.75 1.07 1.62 1.02 
RRF = Relative response factor 
 
Fig 8: Linearity chromatograms 
Fig.8 (A): Linearity level-1 
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Fig.8 (B): Linearity level-2 
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Fig.8 (C): Linearity level-3 
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Fig.8 (D): Linearity level-4 
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Fig.8 (E): Linearity level-5 
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5.5.3 Precision at LOQ 
 
The LOQ concentrations for impurities were determined 0.5 µg/ml as 0.05 % with 
respect to sample concentration of QF. The reproducibility at LOQ was determined by six 
injections of composite mixture of impurities and quetiapine solution. % RSD of area for 
each impurities and quetiapine were determined as mentioned in table 7 and Fig.9. 
 
Fig 9: Chromatogram of precision at LOQ  
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Table 7: Precision at LOQ 
Peak Area 
Injection Imp A Imp B Imp C QF Imp D Imp E Imp F Imp G 
1 23275 19910 15773 11870 12209 15712 20223 12188 
2 23631 20121 15906 12571 12069 15192 20139 12005 
3 22990 20579 14778 12383 12442 15298 19984 11946 
4 23469 20410 14954 12118 12856 16039 20146 12062 
5 22531 20380 15439 12639 10758 16096 20321 12115 
6 22493 20287 15932 12168 11759 15996 20123 12099 
Mean 
Area 23064.8 20281.2 15463.7 12291.5 12015.5 15722.2 20156.0 12069.2 
SD 478.7 236.0 498.2 293.3 717.7 394.0 112.0 85.4 
%RSD 2.08 1.16 3.22 2.39 5.97 2.51 0.56 0.71 
 
5.5.4 Precision 
Method precision was established by calculating impurities in six sample 
preparations. To demonstrate the method precision all known impurities were spiked at 
0.15 % level to all six sample preparation fig 4. All impurities were calculated by formula 
fig 10 using the RRF value as established in linearity study. Method precision data are 
summarized in table 8. 
Table 8: Summary of precision  
Day-1 
Preparation 
Imp-A 
(%) 
Imp-B 
(%) 
Imp-C 
(%) 
Imp-D 
(%) 
Imp-E
(%) 
Imp-F
(%) 
Imp-G 
(%) 
Unk max 
imp (%) 
Total 
imps 
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(%) 
1 0.16 0.09 0.19 0.14 0.13 0.15 0.20 BQL 1.06 
2 0.16 0.09 0.19 0.14 0.13 0.15 0.19 BQL 1.05 
3 0.16 0.09 0.20 0.14 0.13 0.15 0.19 BQL 1.06 
4 0.16 0.09 0.19 0.14 0.13 0.15 0.19 BQL 1.05 
5 0.16 0.09 0.19 0.14 0.13 0.15 0.19 BQL 1.05 
6 0.16 0.09 0.20 0.14 0.13 0.15 0.19 BQL 1.06 
Mean 0.16 0.09 0.19 0.14 0.13 0.15 0.19 BQL 1.06 
SD 0.000 0.000 0.005 0.000 0.000 0.000 0.004 BQL 0.005 
%RSD 0.00 0.00 2.72 0.00 0.00 0.00 2.15 BQL 0.52 
95% 
confidence 
interval 0.000 0.000 ±0.005 0.000 0.000 0.000 ±0.004 BQL ±0.006 
Day-2 
Preparation 
Imp-A 
(%) 
Imp-B 
(%) 
Imp-C 
(%) 
Imp-D 
(%) 
Imp-E
(%) 
Imp-F
(%) 
Imp-G 
(%) 
Unk max 
imp (%) 
Total 
imps 
(%) 
1 0.15 0.09 0.19 0.14 0.13 0.15 0.19 BQL 1.04 
2 0.15 0.09 0.19 0.13 0.13 0.15 0.19 BQL 1.03 
3 0.15 0.09 0.19 0.14 0.13 0.15 0.18 BQL 1.03 
4 0.15 0.09 0.19 0.13 0.13 0.15 0.18 BQL 1.02 
5 0.15 0.09 0.19 0.14 0.13 0.15 0.18 BQL 1.03 
6 0.15 0.09 0.19 0.13 0.13 0.15 0.18 BQL 1.02 
Mean 0.15 0.09 0.19 0.14 0.13 0.15 0.18 BQL 1.03 
SD 0.000 0.000 0.000 0.005 0.00 0.00 0.005 BQL 0.008 
%RSD 0.00 0.00 0.00 3.91 0.000 0.000 2.87 BQL 0.73 
95% 
confidence 
interval 0.000 0.000 0.000 ±0.006 0.000 0.000 ±0.005 NA ±0.008 
SD = Standard Deviation, %RSD = Relative Standard Deviation 
Unk imp = Unknown impurity, CI = confidence interval 
Fig. 10: Chromatogram of method precision 
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5.5.5 Accuracy (Recovery) 
 
The accuracy of the method was established at three levels in the range of LOQ-
150% of specification limit. Calculated amount of known impurities were added in form 
of solution to the sample preparation to attain LOQ, 100% and 150% of specification 
limit as shown in fig 11(A) to 11(C). Sample preparations were prepared in triplicate for 
each level. Data summarized in table 9(A) to 9(G) 
 
Fig. 11(A): Chromatogram of accuracy level-1 
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Fig. 11(B): Chromatogram of accuracy level-2 
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Fig. 11(C): Chromatogram of accuracy level-3 
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Table 9(A): Summary of recovery data for impurity-A 
Level 
Amount added 
(ppm) 
Amount found 
(ppm) 
Recovery 
(%) 
Mean (%) 
Level-1 0.5176 0.5572 107.7 108.7 
 
89 
 
 
 
 
 
Method Development Quetiapine fumarate API 
 
 
90 
 
 
0.5176 0.5576 107.7 (LOQ) 
0.5176 0.5736 110.8 
 
1.5527 1.6588 106.8 
1.5527 1.6505 106.3 
Level-2 
(100%) 
1.5527 1.6466 106.0 
106.4 
2.3290 2.4806 106.5 
2.3290 2.4821 106.6 
Level-3 
(150%) 
2.3290 2.4653 105.9 
106.3 
Table 9(B): Summary of recovery data for impurity-B 
Level 
Amount added 
(ppm) 
Amount found 
(ppm) 
Recovery 
(%) 
Mean (%) 
0.5315 0.5827 109.6 
0.5315 0.5791 109.0 
Level-1 
(LOQ) 
0.5315 0.5882 110.7 
109.8 
1.5945 1.7289 108.4 
1.5945 1.7196 107.8 
Level-2 
(100%) 
1.5945 1.7246 108.2 
108.1 
2.3918 2.5759 107.7 
2.3918 2.5952 108.5 
Level-3 
(150%) 
2.3918 2.5362 106.0 
107.4 
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Table 9(C): Summary of recovery data for impurity-C 
Level 
Amount added 
(ppm) 
Amount found 
(ppm) 
Recovery 
(%) 
Mean (%) 
0.5284 0.5969 113.0 
0.5284 0.5843 110.6 
Level-1 
(LOQ) 
0.5284 0.6151 116.4 
113.3 
1.5851 1.7348 109.4 
1.5851 1.7564 110.8 
Level-2 
(100%) 
1.5851 1.7247 108.8 
109.7 
2.3777 2.5698 108.1 
2.3777 2.5961 109.2 
Level-3 
(150%) 
2.3777 2.5520 107.3 
108.2 
 
Table 9(D): Summary of recovery data for impurity-D 
Level 
Amount added 
(ppm) 
Amount found 
(ppm) 
Recovery 
(%) 
Mean (%) 
0.4543 0.3188 70.2 
0.4543 0.3275 72.1 
Level-1 
(LOQ) 
0.4543 0.3416 75.2 
72.5 
1.3628 1.1901 87.3 
1.3628 1.1670 85.6 
Level-2 
(100%) 
1.3628 1.1613 85.2 
86.0 
2.0442 1.9008 93.0 
2.0442 1.9575 95.8 
Level-3 
(150%) 
2.0442 1.8747 91.7 
93.5 
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Table 9(E): Summary of recovery data for impurity-E 
Level 
Amount added 
(ppm) 
Amount found 
(ppm) 
Recovery 
(%) 
Mean (%) 
0.4865 0.3468 71.3 
0.4865 0.3563 73.2 
Level-1 
(LOQ) 
0.4865 0.3673 75.5 
73.3 
1.4594 1.3581 93.1 
1.4594 1.3504 92.5 
Level-2 
(100%) 
1.4594 1.3590 93.1 
92.9 
2.1891 2.1795 99.6 
2.1891 2.1706 99.2 
Level-3 
(150%) 
2.1891 2.2050 100.7 
99.8 
 
Table 9(F): Summary of recovery data for impurity-F 
Level 
Amount added 
(ppm) 
Amount found 
(ppm) 
Recovery 
(%) 
Mean (%) 
0.5075 0.4909 96.7 
0.5075 0.4701 92.6 
Level-1 
(LOQ) 
0.5075 0.4870 96.0 
95.1 
1.5225 1.5378 101.0 
1.5225 1.5485 101.7 
Level-2 
(100%) 
1.5225 1.5357 100.9 
101.2 
2.2837 2.3408 102.5 
2.2837 2.3496 102.9 
Level-3 
(150%) 
2.2837 2.3274 101.9 
102.4 
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Table 9(G): Summary of recovery data for impurity-G 
Level 
Amount added 
(ppm) 
Amount found 
(ppm) 
Recovery 
(%) 
Mean (%) 
0.5255 0.5986 113.9 
0.5255 0.6025 114.7 
Level-1 
(LOQ) 
0.5255 0.6180 117.6 
115.4 
1.5765 1.8060 114.6 
1.5765 1.7650 112.0 
Level-2 
(100%) 
1.5765 1.8361 116.5 
114.4 
2.3648 2.6920 113.8 
2.3648 2.7917 118.1 
Level-3 
(150%) 
2.3648 2.6713 113.0 
115.0 
 
5.5.6 Solution stability 
The sample preparation of Quetiapine fumarate API was prepared and % related 
impurities were determined as per method. The diluted standard solution and sample 
preparation were stored upto 52 hours and 47 hours respectively at room temperature. The 
diluted standard solution was reanalyzed after 29 hours and 52 hours against freshly 
prepared diluted standard solution and results are shown in Table-10(A). The sample 
preparation was re-analyzed for impurities after 27 hours and 47 hours against freshly 
prepared diluted standard preparation. The impurity results obtained at different time 
intervals were compared with the initial value and shown in Table-10(B). 
Table 10(A): Standard solution stability 
For diluted standard preparation 
Time Condition % Assay Absolute difference (%) 
Initial Room temperature 100.0 Not applicable 
After 29 hours Room temperature 101.1 1.1 
After 52 hours Room temperature 98.2 1.8 
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Table 10(B): Sample solution stability 
For sample preparation  
Time Condition % Impurity Absolute diff. % Difference 
A)  For impurity-A (%) 
Initial Room temperature 0.16 Not applicable Not applicable 
After 27 hours Room temperature 0.16 Not applicable 0.0 
After 47 hours Room temperature 0.16 Not applicable 0.0 
B)  For impurity -B (%) 
Initial Room temperature 0.09 Not applicable Not applicable 
After 27 hours Room temperature 0.09 0.00 Not applicable 
After 47 hours Room temperature 0.09 0.00 Not applicable 
C)  For impurity -C (%) 
Initial Room temperature 0.19 Not applicable Not applicable 
After 27 hours Room temperature 0.19 Not applicable 0.0 
After 47 hours Room temperature 0.19 Not applicable 0.0 
D)  For impurity-D (%) 
Initial Room temperature 0.14 Not applicable Not applicable 
After 27 hours Room temperature 0.14 Not applicable 0.0 
After 47 hours Room temperature 0.15 Not applicable 7.1 
E) For impurity-E (%) 
Initial Room temperature 0.13 Not applicable Not applicable 
After 27 hours Room temperature 0.13 Not applicable 0.0 
After 47 hours Room temperature 0.13 Not applicable 0.0 
F) For impurity-F (%) 
Initial Room temperature 0.15 Not applicable Not applicable 
After 27 hours Room temperature 0.15 Not applicable 0.0 
After 47 hours Room temperature 0.15 Not applicable 0.0 
G) For impurity-G (%) 
Initial Room temperature 0.20 Not applicable Not applicable 
After 27 hours Room temperature 0.19 Not applicable 5.0 
After 47 hours Room temperature 0.19 Not applicable 5.0 
H) For any single maximum unknown impurity (%) 
Initial Room temperature BQL Not applicable Not applicable 
After 27 hours Room temperature BQL Not applicable Not applicable 
After 47 hours Room temperature BQL Not applicable Not applicable 
I) For total impurities (%) 
Initial Room temperature 1.06 Not applicable Not applicable 
After 27 hours Room temperature 1.05 Not applicable 0.9 
After 47 hours Room temperature 1.06 Not applicable 0.0 
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5.3.6 Robustness:  
Procedure: 
The robustness of the method was established by making deliberate minor variations in 
the following method parameters.   
1.  Change flow rate by ± 10% [i.e. flow rate 1.35mL/min and 1.65mL/min] 
2. Change the minor component in the mobile phase by ± 2 % absolute (i.e. Buffer:    
 Acetonitrile: Methanol:: 68:15:17 and Buffer: Acetonitrile: Methanol:: 72:11:17) 
3. Change column oven temperature by ± 5°C. [i.e. column oven temperature 40°C 
and 50°C] 
4. Change in buffer pH by ±0.2 unit (Use buffer pH 9.0 and 9.4) 
5. Change in column lot. 
 
Blank, resolution solution, diluted standard preparation and the sample preparation were 
prepared and injected. The effect of changes was observed on system suitability 
parameters and on impurities results and shown in table-11(A) & 11(B) respectively. 
 
Table 11(A): System suitability summary of robustness study 
System Suitability parameters 
Condition 
Resolution 
between imp-A 
and imp-B 
( NLT 2.5) 
Resolution between 
quetiapine and Imp-D  
( NLT 1.5) 
% RSD of six  
replicate 
injections of diluted 
standard preparation 
(NMT 5.0) 
A) Change in flow rate 
Normal Condition* 
(1.5 ml per minute) 
7.22 2.57 3.82 
1.35 ml per minute 5.76 2.42 2.30 
1.65 ml per minute 5.50 2.29 1.52 
B) Change in column oven temperature 
Normal condition**(45°C) 5.43 2.33 1.11 
oven temperature 40°C 5.50 2.28 1.03 
oven temperature 50°C 5.13 2.28 0.71 
C) Change in buffer pH 
Normal condition (pH-9.2)* 7.22 2.57 3.82 
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Buffer pH 9.0 4.38 2.40 1.44 
Buffer pH 9.4 6.51 2.51 3.05 
D) Change in column lot. 
Normal*Sr. No. 0126373161 7.22 2.57 3.82 
Changed** Sr. No. 0126380041 5.43 2.33 1.11 
E) Change in mobile phase composition 
Normal:   
Buffer: Acetonitrile: Methanol :: 
70:13:17** 
5.43 2.33 1.11 
Buffer: Acetonitrile: Methanol :: 
72:11:17 
7.03 2.47 3.59 
Buffer: Acetonitrile: Methanol :: 
68:15:17 
4.30 1.89 1.20 
 
* Data taken from the method precision. 
** Data taken from the intermediate precision. 
Table 11(B): System suitability summary of robustness study 
% Impurities 
Condition Imp-
A (%) 
Imp-
B (%) 
Imp-
C (%) 
Imp-
D (%) 
Imp-
E (%) 
Imp-
F (%) 
Imp-
G 
(%) 
Max 
Unk Imp 
(%) 
Total 
Imps 
(%) 
A) Change in flow rate  
Normal condition 
(1.50 ml per minute)* 
0.16 0.09 0.19 0.14 0.13 0.15 0.20 BQL 1.06 
 (1.35 ml /minute) 0.15 0.08 0.18 0.15 0.13 0.15 0.20 BQL 1.04 
Absolute difference 
from normal condition 
NA 0.01 NA NA NA NA NA NA NA 
% Difference from 
normal condition 
6.3 NA 5.3 7.1 0.0 0.0 0.0 NA 1.9 
 (1.65 ml / minute) 0.16 0.08 0.19 0.13 0.13 0.15 0.19 BQL 1.03 
Absolute difference 
from normal condition 
NA 0.01 NA NA NA NA NA NA NA 
% difference from 
normal condition 
0.0 NA 0.0 7.1 0.0 0.0 5.0 NA 2.8 
B) Change in column oven temperature 
Normal condition 
(45.0°C)** 
0.15 0.09 0.19 0.14 0.13 0.15 0.19 BQL 1.04 
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% Impurities 
Condition Imp-
A (%) 
Imp-
B (%) 
Imp-
C (%) 
Imp-
D (%) 
Imp-
E (%) 
Imp-
F (%) 
Imp-
G 
(%) 
Max 
Unk Imp 
(%) 
Total 
Imps 
(%) 
          
Change in oven 
temperature by + 
5°C(50.0°C) 
0.15 0.08 0.19 0.13 0.13 0.15 0.19 BQL 1.02 
Absolute difference 
from normal condition 
NA 0.01 NA NA NA NA NA NA NA 
% difference from 
normal condition 0.0 NA 0.0 7.1 0.0 0.0 0.0 NA 
 
1.9 
Change in oven 
temperature by  
- 5°C(40.0°C) 
0.15 0.08 0.18 0.13 0.22 0.15 0.18 BQL 1.09 
Absolute difference 
from normal condition 
NA 0.01 NA NA NA NA NA NA NA 
% difference from 
normal condition 
0.0 NA 5.3 7.1 69.2 0.0 5.3 NA 4.8 
C) Change in buffer pH 
Normal condition (pH-
9.2)* 
0.16 0.09 0.19 0.14 0.13 0.15 0.20 BQL 1.06 
Change in buffer pH 
by -0.2 unit (pH-9.0) 
0.15 0.08 0.18 0.13 0.14 0.15 0.19 BQL 1.02 
Absolute difference 
from normal condition 
NA 0.01 NA NA NA NA NA NA NA 
% Difference from 
normal condition 
6.3 NA 5.3 7.1 7.7 0.0 5.0 NA 3.8 
Change in buffer pH 
by +0.2 unit (pH-9.4) 
0.15 0.08 0.18 0.13 0.14 0.16 0.19 BQL 1.03 
Absolute difference 
from normal condition 
NA 0.01 NA NA NA NA NA NA NA 
% Difference from 
normal condition 
6.3 NA 5.3 7.1 7.7 6.7 5.0 NA 2.8 
D) Change in mobile phase composition  
 (Buffer: Acetonitrile: 
Methanol :: 
70:13:17)** 
0.15 0.09 0.19 0.14 0.13 0.15 0.19 BQL 1.04 
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% Impurities 
Condition Imp-
A (%) 
Imp-
B (%) 
Imp-
C (%) 
Imp-
D (%) 
Imp-
E (%) 
Imp-
F (%) 
Imp-
G 
(%) 
Max 
Unk Imp 
(%) 
Total 
Imps 
(%) 
Changed in minor 
component by 
-2% 
(Buffer: Acetonitrile: 
Methanol :: 72:11:17) 
0.14 0.07 0.17 0.23 0.13 0.14 0.20 BQL 1.08 
Absolute difference 
from normal condition 
NA 0.02 NA NA NA NA NA NA NA 
% Difference from 
normal condition 
6.7 NA 10.5 64.3 0.0 6.7 5.3 NA 3.8 
Changed in minor 
component by 
+2% 
(Buffer: Acetonitrile: 
Methanol :: 68:15:17) 
0.15 0.08 0.19 0.11 0.18 0.14 0.18 BQL 1.03 
Absolute difference 
from normal condition 
NA 0.01 NA NA NA NA NA NA NA 
% Difference from 
normal condition 
0.0 NA 0.0 21.4 38.5 6.7 5.3 NA 1.0 
E) Change in column lot  
Normal:   
XT/RP8/150-5/19 
Sr. No. 0126373161* 
0.16 0.09 0.19 0.14 0.13 0.15 0.20 BQL 1.06 
Changed: 
XT/RP8/150-5/23 
Sr. No. 0126380041** 
0.15 0.09 0.19 0.14 0.13 0.15 0.19 BQL 1.04 
Absolute difference  NA 0.00 NA NA NA NA NA NA NA 
% Difference from 
normal condition 
6.3 NA 0.0 0.0 0.0 0.0 5.0 NA 1.9 
 
6. Quantitation and Calculation formulae 
6.1 Relative Standard Deviation (%) 
Relative Standard Deviation (%) =  X
100    SD ×  
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By Microsoft excel  
Average = AVERAGE (Number 1) 
Standard Deviation = STDEV (Number 1) 
 
6.2 Calculation formulae in Linearity and RRF 
 Correlation coefficient (r) =   
]})([  ])(x{[
y)( x)(  -  )x(  
2222 yynxn
yn
∑−∑∑−∑
∑∑∑
 
 
Correlation coefficient (r) = CORREL (Array 1, Array 2) 
 
Slope of regression line = 22 x)( x
y)( x)(  -  )x(  
∑−∑
∑∑∑
n
yn
  
 
Slope of regression line = SLOPE (Array 1, Array 2) 
y- intercept = xB - y  =A  
 
y- intercept = INTERCEPT (Array 1, Array 2) 
 
Residual sum of squares =  ∑ 2calculated)Y - ( originalY
 
Where, 
Y calculated =  A + Bx 
n = Number of measurements 
x = Individual concentration 
y = Individual area 
x   = Average concentration 
y  = Average area 
 
Residual sum of squares = SUMXMY2 (Array 1, TREND (Array 1, Array 2, Array2)) 
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Relative Response Factor = 
standardfor  line regression of Slope
impurity for  line regression of Slope  
 
6.3 Accuracy (% Recovery) 
 
% Recovery = 100x 
added (mg) substance ofAmmount 
  found (mg) sbustance ofAmmount  
 
6.4 % Impurity in Quetiapine fumarate drug substance 
 
% Impurity = such)(as%assayStd.
RRF
1
WtSpl
Dilution
Dilution
 wtStd.
Astd
Asp ××××  
e.g. 
% Impurity-A  = 6.99
1.70
1
50.07
50
200
2
100
15.6
39225
66288 ×××××  
% Impurity-A = 0.15 
 
% Impurity-B  = 6.99
1.41
1
50.07
50
200
2
100
15.6
39225
30952 ×××××  
% Impurity-B = 0.09 
 
% Impurity-C  = 6.99
1.17
1
50.07
50
200
2
100
15.6
39225
56934 ×××××  
% Impurity-C = 0.19 
 
% Impurity-D  = 6.99
0.75
1
50.07
50
200
2
100
15.6
39225
26564 ×××××  
% Impurity-D = 0.14 
 
% Impurity-E  = 6.99
1.07
1
50.07
50
200
2
100
15.6
39225
35062 ×××××  
% Impurity-E = 0.13 
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% Impurity-F  = 6.99
1.62
1
50.07
50
200
2
100
15.6
39225
61764 ×××××  
% Impurity-F = 0.15 
 
% Impurity-G  = 6.99
1.02
1
50.07
50
200
2
100
15.6
39225
48586 ×××××  
% Impurity-G = 0.19 
 
% Total impurities = Total known impurities + Total unknown impurities 
% Total impurities = (0.15 + 0.09 + 0.19 + 0.14 + 0.13 +0.15 + 0.19) + (0.00) 
% Total impurities = 1.04 
Asp : Area of impurity in sample 
Astd : Mean area of diluted standard 
Std. wt : Std weight in mg 
Spl wt : Sample weight in mg 
 
6.5 95% Confidence Interval (CI) 
95% Confidence Interval (CI) = 
n
SD  t  ×± α  
Where, 
SD = Standard Deviation 
X   = Average concentration 
n = Number of measurements 
tα = t value at n-1 from t table (two tail) 
95% Confidence Interval (CI) = SD (2.57058)/SQRT (6) 
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Section-III: HPLC Method development and validation for assay of 
Pramipexole in Pramipexole tablets 
 
1. Introduction to pramipexole 
 Parkinson’s disease (PD) is a neurodegenerative disorder characterized by 
bradykinesia, rigidity, postural imbalance and tremor. The incidence of PD increases with 
age and on average, 2 to 3% of the population in western world will develop PD. The 
cause of the disease is still unknown. PD develops due to loss of neuronal functions 
within the basal ganglia and the substania nigra of the brain. More specifically, there is 
marked deficiency in the nigrostrital dopamine (DA) system due to degeneration of nigral 
DA neurons. Thus, restoration of the dopaminergic transmission forms the central 
strategy for the treatment of PD. 
 
Pramipexole is a synthetic amino-benzothiazole derivative. It has been shown to be 
a selective and specific full DA receptor agonist with high affinity and selectivity for the 
DA D2 receptor subfamily, and particularly the D3 receptor subtype [1].  
Innovator:  Boehringer Ingelheim, Germany. 
 
1.1 Physico-chemical properties 
Pramipexole is chemically (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino) 
benzothiazole. Commercially available tablets conations Pramipexole dihydrochloride 
monohydrate salt (Fig.1) in formulation (Sifrol®, Mirapex®, and Mirapexin®) [3]. 
Molecular formula of Pramipexole dihydrochloride monohydrate is C10H17N3S 2HCl H2O 
having molecular weight 302.28 g/mole. Its dissociation constants are pKa1 = 5.0 and 
pKa2 = 9.6, partition coefficient Log P (octanol water) is 0.87. Melting point is 296°C to 
301°C with decomposition [2]. 
N
SNH
H3C
H
NH2 2HCl H2O
S-isomer  
Fig.1: Chemical structure of pramipexole dihydrochloride monohydrate 
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1.2 Pharmaceutical and biological aspects 
Pramipexole tablets containing Pramipexole dihydrochloride monohydrate 
available in 5 strengths as Pramipexole base they are 0.088 mg, 0.18 mg, 0.35 mg, 0.7 
mg, 1.1 mg as an active ingredient. 
 
Active substance:  
Pramipexole is white to off-white crystalline powder, which is freely soluble in 
water in a pH independent way, soluble in methanol, slightly soluble in ethanol and 
insoluble in dichloromethane. At a relative humidity above 92% it liquefies but at lower 
relative humidity no absorption of water occurs. The active substance is not light sensitive 
itself, but has been found to degrade in the tablets matrix of binary mixtures with each 
excipient. A verity of degradation products have been identified but the mechanism of 
degradation is not known. By appropriate light protection during manufacture and by 
using a light protecting aluminium blister for packing, photo degradation is avoided. 
 
Stability:  
In the solid state, the active substance has shown good stability characteristics 
when tested under a number of different conditions. A 24-months shelf life is accepted 
when stored below 30°C and protected from light. 
 
1.3 Toxico - pharmacological aspects 
Pharmacodynamics:  
The pharmacodynamic action of pramipexole has been studied in vitro and in 
vivo. In brain homogenates or cell lines expressing cloned human receptors, pramipexole 
effectively bound to receptor of the DA D2 subfamily (i.e.D2, D3 and D4), with the 
highest affinity for D3 binding sited (Ki 0.5 nM). Binding to adrenergic alpha-2, 5HT1A 
and histamine-2 sited was weak to moderate (Ki > 240 nM). It lacked affinity for binding 
sites within the DA D1 subfamily (D1, D5) and for a large number of centrally acting 
neurotransmitters. Further in vitro studies (e.g. proton generation in a microphysometer 
assay, stimulation of CHO cell mitogenesis) showed that pramipexole was a full agonist 
for receptors within the DA D2 subfamily. In vivo studies, e.g. electrophysiology, 
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inhibition of prolactin release, DA turnover in specific brain region, indicated that 
pramipexole possessed full agonist activity. 
 
Pharmacokinetics:  
The pharmacokinetic profile of pramipexole was studied in mouse, rat, rabbit, 
minipig and monkey, the main species used in the preclinical program. Protein binding 
was low, <20% in all species including humans. Distribution study was conducted in rats 
with radiolablled compound. A wide tissue distribution was observed, with up to 9-fold 
higher tissue exposure to parent compound observed in brain compared to plasma. In 
pregnant rates, extensive placental transfer to fetuses was observed and in lacting females, 
levels of drug-related radioactivity in milk were up to 6 times higher than plasma. After 
oral administration, absorption was rapid and the bioavailability high (70-90%). 
 
1.4 Disposition in the body 
Pramipexole is readily, rapidly and completely absorbed from the gastro-intestinal 
tract. It is widely and extensively distributed throughout the body. Metabolism is 
minimal. More than 90% of the dose is excreted unchanged in urine via renal tubular 
secretion. Steady state is achieved by 2 days. No metabolites have been identified in 
plasma or urine. 
 
Absorption: 
• Rapid and complete. Absolute bioavailability is > 90 % 
• Linear Pharmacokinetics over the clinical dosage range  
• Cmax – 0.85 ng/ml ( 0.304 mg/ day), Tmax – 1-3 hrs 
• AUC – 10.43 ng.ml/hr ( 0.304 mg/ day) 
• Food dose not reduce the extent of pramipexole absorption, but the rate of 
absorption was reduced by around 1 hr. 
 
Half life: Men 11.6 hour; women, 14.1 hour; also reported as 8 to 12hours 
Volume of distribution: Men 7.34 L/kg; women 7.01 L/kg; also reported as 400L 
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Clearance:  
Total 500mL/min. Renal clearance is approx.400mL/min (3 times higher than the 
glomerular filtration rate) or 5.5 mL/min/kg. Clearance is about 30% lower in women as 
compared to men, elderly compared to young people and those with Parkinson’s disease 
compared to healthy people. It is about 75% lower for people with renal treatment. 
 
Distribution in Blood: The erythrocyte: plasma ratio is 2. 
Protein binding: 15% 
Dose: 125 to 500µg; three times daily. Maximum daily dose is 4.5 mg. 
 
1.5 Contraindications 
– Vascular disorders: Hypotension (dose limiting adverse effect). Beyond 0.25 mg 
not tolerated in healthy subjects. (RLD – 0.25 mg) 
– Psychiatric disorders: Insomnia, hallucinations, confusion  
– Nervous system disorders: Dizziness, dyskinesia, somnolence 
– Gastrointestinal disorders: Nausea, constipation  
– General disorders: Oedema peripheral  
 
2. Literature Review 
The literature reviews regarding pramipexole suggest that various analytical 
methods were reported for drug substance as well as in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of pramipexole are as under 
[3]. 
 
2.1 Srinubabu, K. Jaganbabu, B. Sudharani1, K. Venugopal, G. Girizasankar and J. 
V. L. N. S. Rao have developed method for determination of pramipexole in tablets. 
Chromatography was performed with mobile phase containing a mixture of 
acetonitrile/phosphate buffer (60/40; v/v) with a flow rate of 0.8 ml/min. Quantitation 
was accomplished with the internal standard method; the procedure was validated by 
linearity (correlation coefficient = 0.99892), accuracy, robustness and intermediate 
precision [4]. 
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2.2 AU YI LAU, SELENKA J. M., ANSON G. D., TALAAT R., ICHHPURANI N 
have developed a highly sensitive and selective HPLC-MS-MS method for the 
determination of pramipexole in human plasma. The analytes, pramipexole and BHT-
920 (internal standard), were extracted from plasma at basic pH with methyl tert.-
butyl ether (MTBE). MTBE was evaporated to dryness and reconstituted in 100 μl of 
(95:5) methanol-water. Chromatographic separation was achieved on a Zorbax SB-
CN column with a mobile phase of (15:5:80) water-0.1 M ammonium acetate-
methanol. The analytes were detected utilizing HPLC in conjunction with 
atmospheric pressure chemical ionization (APCI) tandem mass spectrometry (MS-
MS). The assay was linear in the concentration ranges from 50 to 5000 pg/ml [5]. 
 
2.3 Ramakrishna V. S. Nirogi, Vishwottam Kandikere, Wishu Shrivastava, 
Koteshwara Mudigonda, Santosh Maurya, Devender Ajjala have developed a 
high-performance liquid chromatography/electrospray ionization tandem mass 
spectrometry method and validated for the quantification of pramipexole in human 
plasma. Following liquid-liquid extraction, the analytes were separated using an 
isocratic mobile phase on a reverse-phase column and analyzed by MS/MS in the 
multiple reaction monitoring mode using the respective [M + H]+ ions, m/z 212/152 
for pramipexole and m/z 409/228 for the IS. The method exhibited a linear dynamic 
range of 200-8000 pg/ml for pramipexole in human plasma. The lower limit of 
quantification was 200 pg/ml with the RSD value less than 8% [6]. 
 
2.4 Biljana Janci, Mirjana Medenica, Darko Ivanovic, Anddelija Malenovic have 
developed method for its impurities as 2-amino benzothiazole and BI-II 546 CL and 
BI-II 751 xx using Zorbax Extended-C18 150 mm x 4.6 mm, 5 µ column with UV 
detection at 262 nm for pramipexole, BI-II 751 xx and 2-amino benzothiazole and at 
326 nm for BI-II 546 CL. The flow rate was 1.0 ml/min. Column temperature 25°C 
and 20 µl was injection volume. Mobile phase was water, TEA pH adjusted to 7.0 
with orthophosphoric acid [7]. 
 
2.5 A Pathare DB, Jadhav AS, Shingare MS have developed a chiral liquid 
chromatographic method for the enantiomeric resolution of pramipexole 
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dihydrochloride monohydrate, (S)-2-amino-4,5,6,7-tetra-hydro-6-(propylamino) 
benzothiazole dihydrochloride monohydrate, a dopamine agonist in bulk drugs. The 
enantiomers of pramipexole dihydrochloride monohydrate were resolved on a 
Chiralpak AD (250 mm x 4.6 mm, 10 microm) column using a mobile phase system 
containing n-hexane:ethanol:diethylamine (70:30:0.1, v/v/v). The resolution between 
the enantiomers was found not less than eight. The presence of diethylamine in the 
mobile phase has played an important role in enhancing chromatographic efficiency 
and resolution between the enantiomers. The developed method was extensively 
validated and proved to be robust. The limit of detection and limit of quantification of 
(R)-enantiomer were found to be 300 and 900 ng/ml. ng/ml. respectively for 20 
microl injection volumes. The percentage recovery of (R)-enantiomer was ranged 
from 97.3 to 102.0 in bulk drug samples of Pramipexole dihydrochloride 
monohydrate. Pramipexole dihydrochloride monohydrate sample solution and mobile 
phase were found to be stable for at least 48 h. The proposed method was found to be 
suitable and accurate for the quantitative determination of (R)-enantiomer in bulk 
drugs [8]. 
 
3. Aim of present work 
As per discussion in the literature review it is not official in pharmacopeia [9-14], 
method for assay by UV was reported with internal standard preparation. Methods for 
pramipexole in human plasma, chiral purity by normal phase and related impurities 
method were reported. So, a simple assay method without any internal standard 
preparation is the aim of present work. Hence, the method is recommended for routine 
quality control analysis and also stability sample analysis. 
 
The aim and scope of the proposed work are as under 
? To developed suitable HPLC assay method for Pramipexole in formulation 
? Forced degradation study of Pramipexole tablets under stress condition 
? To resolve all major impurities generated during the force degradation studies of 
Pramipexole tablets  
? Perform analytical method validation for the proposed method as per ICH 
guideline. 
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4. Experimental 
4.1 Materials, chemicals and reagents 
 
 A) Materials required:  
Sr. No. 
Material Name 
Lot. No./  
Batch no. 
Mfg.by Potency/ 
Purity 
1 Pramipexole 
dihydrochloride 
monohydrate reference 
standard 
OTV/2007/112 TRC,Bhat 99.8% 
2 
 
Pramipexole 
dihydrochloride 
monohydrate API 
PRA/015/005 TRC,Bhat -- 
3 Pramipexole impurity A OTV/2007/123 TRC,Bhat 98.99% 
4 Pramipexole impurity B OTV/2007/114 TRC,Bhat 98.53% 
5 Pramipexole impurity C OTV/2007/113 TRC,Bhat 99.56% 
 
B) Chemicals and Reagents:  
Sr. No. Chemical/Reagent Grade 
1 Acetonitrile HPLC 
2 Ammonia solution (25% v/v) AR 
3 Methanol HPLC 
6 Water  Milli-Q-water 
7 Hydrogen peroxide AR 
8 Hydrochloric acid AR 
9 Sodium hydroxide AR 
 
4.2 Instrumentation 
Shimadzu LC 2010C with Class VP software and Waters alliance 2996 and 2487 
with empower software HPLC systems were used. 
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4.3 Mobile phase preparation 
The mobile phase consisted of 0.1 % v/v ammonia solution: acetonitrile: methanol          
(70: 15: 15, v/v/v). To prepare the 0.1 % v/v ammonia solution 1ml concentrated 
ammonia solution (25% v/v) was diluted to 1000 ml with HPLC grade water. Mobile 
phase was degassed by sonication with an ultrasonic bath. 
 
4.4 Diluent preparation  
Mixed both the solvents Methanol : water, 50:50. 
 
4.5 Standard preparation  
A pramipexole standard solution containing 0.1 mg/ml, was prepared in a 250 ml 
volumetric flask by dissolving 25 mg of Pramipexole dihydrochloride monohydrate in 50 
ml of diluent by sonication and then diluted to volume with diluent. 
 
4.6 Test preparation  
Sample tablets were weighed and transferred to the volumetric flask as per below 
the table, after addition of about 70 % of total volume of volumetric flask sonication was 
done with intermittent swirling, content was brought back to room temperature and 
diluted to volume to achieve about 0.1 mg/ml Pramipexole concentration as of standard 
preparation. The preparation was filtered through 0.45µm PVDF membrane disk filter. 
 
4.7 Chromatographic conditions  
Chromatographic analysis was performed on X-TERRA RP-8 (150mm ×  4.6mm , 
5 μm) column with oven temperature of 25˚C. The flow rate of the mobile phase was 
adjusted to 1.0 ml/min and the injection volume was 10 µl. Detection was performed at 
260nm. 
 
5. Result and Discussion 
 
5.1 Development and optimization of the HPLC method 
Proper selection of the methods depends upon the nature of the sample (ionic or 
ionisable or neutral molecule) its molecular weight and solubility. Pramipexole 
dihydrochloride monohydrate is dissolved in polar solvent hence RP-HPLC was selected 
for it’s estimation in formulation. To develop a rugged and suitable HPLC method for the 
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quantitative determination of pramipexole, the analytical condition were selected after the 
consideration of different parameters such as diluent, buffer, buffer concentration, organic 
solvent for mobile phase and mobile phase composition and other chromatographic 
conditions. Preliminary trials were taken with different composition of buffer and organic 
phase of mobile phases with pH range of 2-7 but pramipexole peak was appear in early 
eluting region even at certain composition there was double peak phenomena.  
 
Pramipexole is basic compound with amine groups in its structure so, peak 
retention can be achieved above it’s pKa in alkaline pH and further optimized with 
organic phase. Based on this fact just 0.1 % ammonia solution as aqueous part with 
different composition with acetonitrile as well as with methanol were tried to achieve 
desired chromatography. Finally 0.1 % ammonia solution-acetonitrile-methanol 
(70:15:15, v/v/v) was optimized with consideration of peak shape and pump pressure. 
Here, X-terra RP-8 column was used due to its higher pH stability of mobile phase 
(pH=10 to 11). Detection at 260 nm was selected based on its UV spectrum. For sample 
preparation water-methanol (50:50, v/v) was chosen based on solubility of drug and to get 
easy dispersion of tablet formulation. Moreover this diluent gave good solution stability 
for sample as well as standard preparation. Here, acetonitrile was also tried along with 
water as a diluent but somewhat that diluent is not able to give reproducible result for 
assay value even peak area of standard preparation, Hence, selected diluent was best 
among the all trials by many aspects.  Fig.1 to Fig.3 represents the chromatogram of 
standard preparation, sample preparation and blank respectively.  
Fig.1: Chromatogram of standard preparation 
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Fig.2: Chromatogram of sample preparation 
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Fig.3: Chromatogram of blank preparation 
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5.2 Degradation study 
 
The degradation samples were prepared by transferring intact tablets, samples 
were employed for acidic, alkaline and oxidant media and also for thermal and photolytic 
conditions. After the degradation treatments were completed, the stress content solutions 
were diluted with diluent to attain about 0.1 mg/ml concentration. Specific conditions 
were described as follows. 
 
5.2.1 Acidic degradation 
 
Acidic degradation study was performed by refluxing the content in 30 ml of 5 N 
HCl at about 100˚ C for 12 hrs and after cooling to room temperature it was neutralized 
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with 5 N NaOH solution. Pramipexole degradation was found by 1 % in this acidic 
condition (Fig.4). 
 
Fig.4: Chromatogram of acidic forced degradation study 
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5.2.2 Base degradation 
 
Alkali degradation study was performed by heating the content in 30 ml of 5 N 
NaOH at about 80˚ C for 45 min and after cooling to room temperature it was neutralized 
with 5 N HCl solution. Pramipexole degradation was found by 23.4 % in this alkaline 
condition (Fig.5). 
 
Fig.5: Chromatogram of alkali forced degradation study 
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5.2.3 Oxidative degradation 
 
 Oxidation degradation study was performed by heating the drug product in 30ml 
of 30% v/v H2O2 at 80˚ C for 15 minutes. Pramipexole degradation was found by 27.9 % 
in this oxidative condition (Fig.6). 
 
Fig.6: Chromatogram of oxidative forced degradation study 
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5.2.4 Thermal degradation 
 
Thermal degradation was performed by exposing solid drug product at 105˚ C for 
72 hrs. Pramipexole degradation was found by 14.5 % in this thermal condition (Fig.7). 
 
Fig.7: Chromatogram of thermal degradation study 
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5.2.5 Photolytic degradation 
 
Photolytic degradation study was performed by exposing the drug product to UV 
light for 1.2 million lux hours. Pramipexole degradation was found by 7.7 % in this 
photolytic condition (Fig.8). 
 
Fig.8: Chromatogram of UV-light degradation study 
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5.3 Method Validation 
 
Method validation approach 
The assay method is same for all the strength. The standard concentration for 
0.125mg, 0.25mg, 0.5mg, 1mg, 1.5mg are 100 ppm and sample concentration for 
0.125mg, 0.25mg, 0.5mg, 1mg are 100 ppm and for 1.5mg is 90 ppm. Pramipexole 
dihydrochloride tablets 0.125 and 0.25mg are weight proportional formulations (scale up-
down) and pramipexole dihydrochloride tablets 0.5, 1.0 and 1.5mg are also weight 
proportional formulations (scale up-down). Complete validation will be performed on 
higher strength (1.5 mg) and specificity (Part-A) and accuracy also performed on 0.125 
mg strength by 3 replicate x 3 concentration and Linearity with 5 levels of concentration 
range [15]. Filter media interference study was covered in accuracy study. 
 
5.3.1 Specificity 
 
The specificity of the method was determined by checking the interference of 
placebo with analyte and the proposed method was evaluated by checking the peak purity 
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of pramipexole during the force degradation study. The peak purity was found 
satisfactory (>0.9999) under different stress condition. There was no interference of any 
peak of degradation product with drug peak and peak purity was also found satisfactory in 
impurity spiked sample (Fig.9). 
 
 
 
 
Fig.9: Chromatogram of impurity spiked sample 
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Here, known pramipexole impurity-A was eluted before  the pramipexole which 
can process cum degradation product while late eluting impurity was not eluted but as it 
is process impurity and controlled at API level it self and at proposed concentration of 
pramipexole for assay that impurity can be at below quantitation limit for proposed 
chromatography. 
 
5.3.2 Linearity 
 
Seven points calibration curve were obtained in a concentration range from 0.045-
0.15 mg/ml for pramipexole. The response of the drug was found linear for entire 
concentration range and the linear regression equation was y = 23524x + 21527 with 
correlation coefficient 0.99998. (Fig.10) Chromatograms obtain during linearity study is 
shown in fig.11-15. 
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Fig.10: Linearity curve for pramipexole 
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Fig.11: Linearity study chromatogram of level-1 (45%) 
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Fig.12: Linearity study chromatogram of level-2 (80%) 
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Fig.13: Linearity study chromatogram of level-3 (100%) 
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Fig.14: Linearity study chromatogram of level-4 (120%) 
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Fig.15: Linearity study chromatogram of level-5 (150%) 
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5.3.3 Precision 
 The result of repeatability and intermediate precision study are shown in Table 1. 
The developed method was found precise as the %RSD values for the method precision 
and intermediate precision studies were < 0.81 % and < 1.23 %, respectively. 
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Table 1: Evaluation data of precision study 
Set Day-1 (n = 6) Day-2 (n = 6) 
1 102.5 101.6 
2 103.8 102.1 
3 101.3 103.1 
4 102.3 103.3 
5 102.5 104.8 
6 101.9 104.5 
Mean 102.4 103.2 
Standard deviation 0.83 1.27 
% RSD 0.81 1.23 
95% Confidence Interval (CI) 0.66 1.02 
 
5.3.4 Accuracy 
The accuracy of the method was established at three levels in the range of 50% to 
150% of specification limit for 0.125 mg and 1.5 mg strengths. Above levels were 
prepared in triplicate. Each solution was injected in singlet.  % Recovery was calculated 
at each level and recorded in Table-2 and 3 respectively for 0.125 mg and 1.5 mg 
strengths. The supporting chromatograms shown in fig.16-21. 
 
Table 2: Evaluation data of accuracy study Part-A (with placebo of 0.125 mg) 
Amount Recovery 
Added Found Recovery Level Replicate 
(ppm) (ppm) % 
Mean 
% 
%RSD 
1 52.5946 52.9263 100.6 
2 52.4748 53.2075 101.4 
Level-1 
(50%)      
3 52.5547 53.3170 101.5 
101.2 0.5 
1 104.7900 106.7151 101.8 
2 105.0894 106.8262 101.7 
Level-2 
(100%) 
3 104.8698 106.6460 101.7 
101.7 0.1 
1 157.9235 159.3557 100.9 
2 158.1830 159.5583 100.9 
Level-3 
(150%) 
3 157.6640 159.2088 101.0 
100.9 0.1 
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Table 3: Evaluation data of accuracy study Part-B (with placebo of 1.5 mg) 
Amount Recovery 
Added Found Recovery Level Replicate 
(ppm) (ppm) % 
Mean 
% 
%RSD 
1 51.8002 52.4149 101.2 
2 50.9140 51.7041 101.6 
Level-1 
(50%)     
3 50.9200 51.1906 100.5 
101.1 0.6 
1 101.7880 103.6629 101.8 
2 100.7980 101.2128 100.4 
Level-2 
(100%) 
3 100.8060 101.2919 100.5 
100.9 0.8 
1 150.3088 151.3185 100.7 
2 150.3228 150.0967 99.8 
Level-3 
(150%) 
3 150.5024 150.7100 100.1 
100.2 0.5 
 
Fig.16: Chromatogram of accuracy study Part-A level-1 (50%) 
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Fig.17: Chromatogram of accuracy study Part-A level-2 (100%) 
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Fig.18: Chromatogram of accuracy study Part-A level-3 (150%) 
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Fig.19: Chromatogram of accuracy study Part-B level-1 (50%) 
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Fig.20: Chromatogram of accuracy study Part-B level-2 (100%) 
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Fig.21: Chromatogram of accuracy study Part-B level-3 (150%) 
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5.3.5 Solution stability study 
 
Table 4 and 5 shows the results obtain in the solution stability study at different time 
intervals for standard and sample preparation. It was concluded that the standard and 
sample preparation solution were found stable up to 60 hours at 25 ˚C. 
 
Table 4: Solution stability for standard preparation 
Standard Preparation 
Time % Assay Absolute Difference (%) 
Initial* 100.0 N/A 
After 25 hours 100.1 0.1 
After 60 hours 100.5 0.5 
 
Table 5: Solution stability for sample preparation 
Sample Preparation 
Time % Assay Absolute Difference (%) 
Initial* 101.6 N/A 
After 25 hours 100.8 0.8 
After 60 hours 100.2 1.4 
* Data taken from system suitability and Test preparation-1 injected for 
Intermediate precision respectively. 
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5.3.6 Robustness 
 
The result of robustness study of the developed assay method was shown in Table 
6 and 7. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of accepted true 
value from method precision study. System suitability parameters were also found 
satisfactory; hence the analytical method would be concluded as robust.  
Table 6: System suitability summary of robustness study 
System suitability parameters 
Condition Theoretical 
plates 
Asymmetry 
% RSD
 
A) Change in flow rate 
Normal condition (1.0 ml per minute) 4480 0.98 0.46 
 (0.9 ml per minute) 4589 1.03 0.20 
 (1.1 ml per minute) 4111 1.02 0.13 
B) Change in minor component in the mobile phase 
Normal condition 
Buffer : Methanol : Acetonitrile(70:15:15) 
4480 0.98 0.46 
Buffer : Methanol : Acetonitrile(72:14:14 4360 1.03 0.23 
Buffer : Methanol : Acetonitrile(68:16:16) 4261 1.03 0.11 
C) Change in column temperature  
Normal condition 25°C 4480 0.98 0.46 
Column temperature 30°C 4516 1.04 0.12 
D) Change in column Lot* 
Normal condition  
Column S/N 012437289133 24 
4279 1.00 0.03 
Changed condition 
Column S/N 012337101120 02 
4139 1.13 0.14 
* This parameter was studied as part of precision (method precision and intermediate 
precision). 
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Note: 
 i) Theoretical plates, asymmetry and retention time values are from the first injection of 
the system suitability set. 
ii)  RSD was calculated for the five replicate injections of standard preparation. 
iii) Normal condition data taken from the method precision (Repeatability). 
 
Table 7: % Assay summary of robustness study 
Condition % Assay 
A) Change in flow rate 
Normal condition (1.0 ml per minute) 100.7 
Change in flow rate (0.9 ml per minute) 99.7 
Absolute difference from normal condition = 1.0% 
Change in flow rate (1.1 ml per minute) 98.9 
Absolute difference from normal condition = 1.8% 
B) Change in minor component in the mobile phase 
Normal condition 
Buffer : Methanol : Acetonitrile (70:15:15) 
100.7 
Change in methanol composition  
by – 2% absolute  
Buffer : Methanol : Acetonitrile(72:14:14) 
98.8 
Absolute difference from normal condition = 1.9% 
Change in methanol composition  
by + 2% absolute  
Buffer : Methanol : Acetonitrile(68:16:16) 
98.8 
Absolute difference from normal condition = 1.9% 
D) Change in column oven temperature 
Normal condition: (25°C) 100.7 
Change in oven temperature by + 5°C: (30°C) 99.1 
Absolute difference from normal condition = 1.6% 
C) Change in column lot* 
Normal column S/N 012437289133 24 102.4 
Changed column S/N 012337101120 02 103.2 
Absolute difference from normal condition = 0.8% 
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5.3.7 System suitability 
 
A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. 
Acceptance criteria for system suitability, asymmetry not more than 2.0, theoretical plate 
not less then 2000 and % RSD of peak area not more then 2.0, were full fill during each 
validation parameter as shown in table 8. 
 
Table 8: System suitability summary 
Parameter 
Theoretical 
plates 
Asymmetry %RSD 
Limits: 
Not less than 
2000 
Not more than 
2.0 
Not more than 
2.0% 
Specificity-Part A 4530 1.15 0.12 
Accuracy 5293 1.19 0.19 
Method precision 4279 1.00 0.03 
Specificity –Part B 3187 1.11 0.25 
Intermediate precision and 
Solution stability-initial 
4139 1.13 0.14 
Robustness 4480 0.98 0.46 
Linearity 4084 1.13 0.10 
Solution stability after 25 hours 4288 1.05 0.08 
Solution stability after 60 hours 4199 1.02 0.09 
Specificity (Photo degradation) 3756 1.30 1.74 
 
6. Quantitation and Calculation formulae 
 
6.1 Relative Standard Deviation (%) 
 
Relative Standard Deviation (%) =  X
100    SD ×  
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By Microsoft excel  
Average = AVERAGE (Number 1) 
Standard Deviation = STDEV (Number 1) 
 
6.2 Calculation formulae in Linearity 
 Correlation coefficient (r) =   
]})([  ])(x{[
y)( x)(  -  )x(  
2222 yynxn
yn
∑−∑∑−∑
∑∑∑
 
Correlation coefficient (r) = CORREL (Array 1, Array 2) 
Slope of regression line = 22 x)( x
y)( x)(  -  )x(  
∑−∑
∑∑∑
n
yn
  
Slope of regression line = SLOPE (Array 1, Array 2) 
 
y- intercept = xB - y  =A  
y- intercept = INTERCEPT (Array 1, Array 2) 
Residual sum of squares =∑ 2calculated)Y - ( originalY  
Where, 
Y calculated =  A + Bx 
n = Number of measurements 
x = Individual concentration 
y = Individual area 
x   = Average concentration 
y  = Average area 
 
Residual sum of squares = SUMXMY2 (Array 1, TREND (Array 1, Array 2, Array2)) 
 
6.3 Accuracy (% Recovery) 
 
% Recovery = 100x 
added (mg) substance ofAmmount 
  found (mg) sbustance ofAmmount  
  
 
 
Method Development Pramipexole Tablets 
 
 
 126  
 
 
6.4 % Assay 
% Assay = such)(as%assayStd.
LC
Wt.Avg
WtSpl
Dilution
Dilution
 wtStd.
Astd
Asp ××××  
 
e.g. Method precision Set-1: 
% Assay of Pramipexole 2HCl H2O = 8.99
1.5
300
9025.67
500
250
25.80
2236837
2003071 ××××  
% Assay of pramipexole 2HCl H2O = 102.5 
Asp : Peak area in sample 
Astd : Mean peak area of standard 
Std. wt : Std weight in mg 
Spl wt : Sample weight in mg 
Avg wt : Average weight in mg 
LC : Label claim per tablet (mg) 
 
6.5 95% Confidence Interval (CI) 
95% Confidence Interval (CI) = n
SD  t  ×± α  
Where, 
SD = Standard Deviation 
X   = Average concentration 
n = Number of measurements 
tα = t value at n-1 from t table (two tail) 
or 
95% Confidence Interval (CI) = SD (2.57058)/SQRT (6) 
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 INTRODUCTION TO CHIRAL CHROMATOGRAPHY 
 
INTRODUCTION 
 
A chiral molecule is defined as a molecule that is not superimposible on its mirror 
image. The two mirror image forms of a chiral molecule are called enantiomers.A chiral 
molecule has one or more stereogenic centers, which are typically carbons. These 
steriogenic carbon atoms are attached to four different substituents [1], e.g. 
chlorobromomethanol fig.1. 
 
C
Cl
OH
BrHC
Cl
OH
HBr
 
Fig.1: Chlorobromomethanol 
 
 The biological activity of chiral substances often depends upon their 
stereochemistry, since the living body is a highly chiral environment. A large percentage 
of commercial and investigational pharmaceutical compounds are enantiomers, and many 
of them show significant enantioselective differences in their pharmacokinetics and 
pharmacodynamics. The importance of chirality of drugs has been increasingly 
recognized, and the consequences of using them as racemates or as enantiomers has been 
frequently discussed in the pharmaceutical literature during recent years.  With increasing 
evidence of problems related to stereoselectivity in drug action, enantioselective analysis 
by chromatographic methods has become the focus of intensive research of separation 
science. Most of the pharmaceutical and pharmacological studies of stereoselectivity of 
chiral drugs before the mid eighties involved pre-column derivatization of the 
enantiomers with chiral reagents, forming diastereomers. The diastereomers were 
subsequently separated in the normal or reversed phase mode of chromatography [2-5]. 
 
The majority of separation of enantiomers reported in old literature were based on 
an initial reaction of chiral molecule with an enantiomerically pure, chiral derivatizing 
agent. The reaction yields two diastereomers, one for each of the two enantiomeric 
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analytes in the starting sample. The resulting two diastereomers could than be separated 
by conventional HPLC. This overall procedure referred to as the indirect method of chiral 
analysis. The use of chiral stationary phases (CSPs) without derivatization is referred to 
as the direct method of chiral analysis. A method is to be considered to be direct if it 
involves the actual chromatographic separation of molecules that are enantiomerically 
related to each other (not converted to covalent diastereomerically related derivatives), 
and regardless of whether they are derivatized with an achiral reagent or not. Another 
type of direct method uses a chiral mobile phase additive (CMPA), which forms a 
transient diastereomeric complex with the analytes. Resolution of these diasereomeric 
complexes is then possible by HPLC [1]. 
 
Principle of chiral recognition 
 
Chiral recognition referes to the ability of the CSP to interact differently with two 
enantiomers, leading to their HPLC separation. The nature of chiral recognition has been 
examines in several studies and depends on the different interactions as summarized in 
table 1. The ability of the analyte and CSP to form transient-diastereomeric complexes 
utilizing hydrogen bonding, À@À  interactions, dipole stacking, inclusion complexing, and 
steric bulk is the driving force behind enantioseparation.   
 
General considerations for chiral method development 
Sample information: 
-Solubility in different solvents 
-À   or hydrogen bonding capability 
- pKa 
-Functional groups 
-UV spectrum 
-Bulky substituents 
-Inclusion-complexing capability 
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Table 1: Chiral stationary phases 
 
Type of CSP Chiral recognition 
mechanism 
Analyte requirement Mobile phase 
requirement 
Protein based Hydrophobic and 
electrostatic 
interactions 
Ionizable groups (e.g. 
amide or acid); aromatic 
group helpful 
Reversed phase only 
Cyclodextrin Inclusion 
complexation,  
H-bonding 
Polar and aromatic 
group 
Reversed and normal 
phase and polar 
organic mode 
Polymer based 
carbohydrates 
Inclusion 
complexation, 
attractive interactions 
Ability to H bond; steric 
bulk near chiral center 
helps 
Reversed and normal 
phase 
Pirkle type H-bonding, À@À  
interactions, dipole 
stacking 
Ability to À   or H bond, 
aromatic group helpful 
Mostly normal phase; 
reversed phase usually 
less resolution 
Ligand exchange Coordination 
complexes to metals 
α-amino and α-hydroxy 
amino acids 
Reversed phase 
Macrocyclic 
antibiotics 
H-bonding, À@À  
interactions, dipole 
stacking; steric, 
hydrophobic pocket 
Ability to À   or H bond 
or dipole bond; steric 
bulk near chiral center 
assists 
Reversed and normal 
phase 
 
All of these characteristics may help a role in determining the ability of a CSP to 
resolve the sample enantiomers. The two most important considerations are the type of 
substituent groups present in the analyte molecule and their ability to either (1) À  or H 
bond (attractive interaction) or (2) sterically interfere with bonding. The arrangement in 
space of these substituent groups (relative to the analyte chiral center) plays an important 
role in enantiomer separations. In most cases, the closer a group is to the chiral center, the 
more likely to chiral recognition and enantioselectivity. If there are no analyte groups that 
can bind to stationary support, derivatization of the analyte may be necessary. 
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Selecting chiral column 
Over 100 CSP columns are commercially available, although many of these 
column are similar in structure and enantioselectivity. Some columns are better able to 
separate a wide range of sample types. A very rough order of CSP universality is; 
Protein > carbohydrate > pirkle > cyclodextrin. 
 
1. PROTEIN-BASED CHIRAL COLUMN 
One of the most appealing types of chiral stationary phases for pharmaceutical 
analysis involves the use of protein immobilized to the surface of silica gel, or other 
support. Many protein based stationary phases have been proposed, six materials with 
somewhat different characteristics now have been commercialized in columns for chiral 
separations: bovine and human serum albumin, α1-acid glycoprotein (orosomucoid), 
ovomucoid, cellobiohydrolase (cellulose) and pepsin. These proteins have been 
covalently bonded to wide pore silica and polymeric support for rapid HPLC separations 
that are suited for routine analytical methods. A special advantage of immobilized protein 
columns is that they are compatible with the aqueous buffered mobile phases widely used 
in many applications. Protein based chiral columns are less suited for preparative 
applications because of limited sample capacity and relative high column cost. Some 
commercially available protein based chiral columns are listed in table 2. 
Table 2: Commercially available protein based chiral columns 
Protein Trade Name Manufacturer Support Particle size 
(µm) 
Pore size 
(A°) 
AGP Enantiopak Pharmacia LKB Silica 10 250 
AGP Chiral AGP ChromTech AB Silica 5 120 
HSA Chiral Protein-2 ASTEC Silica 7 300 
HSA Chiral HSA ChromTech AM Silica 5 120 
BSA Resolvosil Machery Nagel Silica 7 100 
BSA BSA column ASTEC Silica 7 300 
BSA BA Showa Denko KK Polymer 15-20 500 
OVM Ultron ES-OVM Shinwa chemicals Silica 5 120 
OVM OV Shinwa chemicals Polymer 15-20 500 
CELL Chiral-CBH ChromTech AB Silica 5 120 
Pepsin Ultron ES-PEP Shinwa chemicals Silica 5 120 
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Human Serum Albumin (HSA): 
 
Human Serum Albumin has about the same molecular weight as bovine serum 
albumin, but immobilized form of HSA exhibit some what different selectivity for many 
analytes. HSA covalently bonded to diol activated silica based support forms the basis for 
one commercial column. For many years, HSA has been used to study the binding of 
drugs to protein in solution, reflecting its utility in investigating drugs to be used in the 
human body. 
 
α1-Acid Glycoprotein (AGP) 
 
α1-Acid glycoprotein or orosomucoid is made up of a polypeptide containing 181 
amino acid residues and sialic acid residues incorporated in the carbohydrate portion of 
the molecule. Salic acid has been suggested to be associated with binding of basic 
compounds at neutral pH. Two different commercial columns of immobilized AGP are 
available, and the variation in performance characteristics for these two products probably 
is the result of different immobilization chemistry. 
 
Ovomucoid (OVM) 
 
Ovomucoid is a trypsin inhibitor obtained from the egg white of chickens. This 
protein is known to undergo strong hydrophobic interactions with hydrophobic aromatic 
solutes. Ovomucoid protein is immobilized onto aminopropyl silica, and the amount of 
protein bound to the support apparently influences the degree of sample resolution. 
Recent studies have identified the active component of OVM column as an 
ovoglycoprotein. 
 
Cellobiohydrolase (CBH; cellulose) 
 
Cellobiohydrolase forms the basis for a diol silica-based commercial column that 
uses this stable covalently bound enzyme produced by the fungus Trichoder ma reesei. 
Pepsin is distinctive among enzymes for having a low isoelectric point (pI <1). The 
chromatographic packing is prepared by bonding this protein to aminopropyl silica via 
N,N’-disuccinimidyl carbonate [1]. 
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2. POLYSACCHARIDE (CARBOHYDRATE) BASED CHIRAL COLUMNS  
 
The naturally occurring polysaccharides form the basis for an important group of 
columns designed for chiral separations. Derivatives of these polymers, especially 
cellulose and amylose, exhibits excellent properties as stationary phases for HPLC. 
Commercially available columns of these materials now are used extensively for both 
analysis and preparative separations of a wide range of enantiomers. Although most 
columns used in normal phase mode, columns are also available for applications with 
aqueous reversed mobile phases. Some commercially available polysaccharide based 
chiral columns are shown in table 3.Non-ionic or moderately ionic samples generally are 
compatible with normal phase chromatography. Experience with many compound types 
shown that a decreasing order of successful separations with polysaccharide-based 
column is  
OD > AD > OJ > OG > AS > OF > OB > OC > OK > OA. Statistically, the top four in 
this list are successful in separating more than 80% of unknown samples. 
Table 3: Commercially available polysaccharide based chiral columns 
Polysaccharide Derivative Trade Name Distributor 
Microcrystalline cellulose triacetate* Chiralcel CA-1 Daicel 
 Cellolose triacetate Merck 
 Celolose Cel-AC-40XF Macherey-Nagel 
Cellolose triacetate  Chiralcel OA Daicel 
Cellolose tribenzoate  Chiralcel OB Daicel 
Cellolose trisphenylcarbamate Chiralcel OC Daicel 
Cellolose tris(3,5-dimethylphenyl-carbamate) Chiralcel OD 
Chiralcel OD-R 
Daicel 
Cellolose tris(4-chlorophenyl-carbamate) Chiralcel OF Daicel 
Cellolose tris(4-methylphenyl-carbamate) Chiralcel OG Daicel 
Cellolose tris(4-methylbenzoate) Chiralcel OJ Daicel 
Cellolose tricinnamate Chiralcel OK Daicel 
Amylose tris(3,5-dimethylphenyl-carbamate)  Chiralpak AD Daicel 
Amylose tris[(S)-1-phenylethyl-carbamate)  Chiralpak AS Daicel 
*other than this columns are coated on silica gel 
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3. DONOR- ACCEPTOR (PIRKLE) CHIRAL COLUMN 
 
Separation of these CSPs is based on the three point rule. For chiral recognition to 
occur, a minimum of three simultaneous points of interactions is necessary between the 
solute and the CSP, with at least one interaction being strereochemically dependent. 
These interactions can be either attractive or repulsive in nature. The pioneering work of 
Pirkle had such an impact on the field that the whole category of donor-acceptor type 
stationary phases was named after him.  The structure of these types of stationary phases 
is based on single strands of chiral selectors, connected via amidic linkage onto 
aminopropyl silica as of napthylaniline CSP, a À -electron donor CSP as shown in Fig.2 
and Chemical structure of 3,5-dinitrophenyl phenylglycine (3,5-DNBPG) CSP, a À-
electron acceptor CSP in fig.3. 
 
CH3
CH3
O
O
Si
(CH2)11
OCH2CH3
O
O
NH
CH3 H
 
Fig.2: Napthylaniline CSP, a À -electron donor CSP 
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Fig.3: Dinitrophenyl phenylglycine (3,5-DNBPG) CSP, a À-electron acceptor CSP 
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Table 4: Commercially available Pirkle-type chiral columns 
À-electron donor or acceptor CSP Trade Name Distributor 
D or L Phenylglycine DNBPG Regis, J.T.Baker, ES 
Industries, E. Merck, Serva 
D or L Leucine Leucine Regis, J.T.Baker, ES 
Industries, Serva 
(R,R) or (S,S)-β-Gem 1 β-Gem 1 Regis 
(R) or (S) α-Burke 1 α-Burke 1 Regis 
D or L N-2-Naphthylamine Naphthylamine Regis 
(S) N-1-Naphthylleucine Naphthylleucine Regis 
Whelk-O 1 Whelk-O 1 Regis 
Sumimoto OA Series  OA-2000, 2500, to 
5000 
Regis, HPLC technology, 
LTD, Sumimoto 
Phenomenex-Chirex  Chirex CSPs Phenomenex 
DNB-phenylethylamine Nucleosil chiral 2 Machery Nagel 
Phenylmethyl urea Spherisorb chiral 1 Phase-Sep 
(R)-Naphthyl urea Spherisorb chiral 2 Phase-Sep 
(R)-Naphthylethylamine YMC-Pack-K-Series YMC, Inc. 
α- Naphthyl urea Bakerbond  
α- naphthyl urea 
J. T. Baker 
(R) Phenethyl urea Chromegabond-(R)-
phenethyl urea 
E. S. Industries 
 
4. CAVITY TYPE CHIRAL COLUMNS 
Cavity type CSP allows inclusion of one or both enantiomers into a chiral cavity, 
thereby providing enhanced chiral discrimination between the two enantiomers. 
Cyclodextrin bonded phases (CD) comprise most cavity CSPs, but synthetic chiral 
polymers have also been used for inclusion complexation. Cyclodextrin CSPs make use 
of interactions such as H-bonding and inclusion complexation. These interactions require 
that the analyte contain at least a hydrophobic portion that fits into the CD cavity. If the 
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analyte also contains polar groups that can hydrogen bond to the CD hydroxyls, 
enantioselectivity can be enhanced. Cyclodextrin are available in α-, β-, γ-CD types that 
are formed from 6(α), 7(β), or 8(γ) glucopyranose units connected by α-(1,4)-glycosidic 
linkages as shown in fig.4 and its mechanism shown in fig.5. Some commercially 
available cyclodextrin columns are mentioned in table 5. 
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Fig.4:  Alpha-Beta- Gamma Cyclodextrin 
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Fig.5: Cyclodextrin cavity and inclusion mechanism 
Table 5: Commercially available cyclodextrin columns* 
Trade Name Support 
Cyclobond I 2000 β - Cyclodextrin 
Cyclobond II 2000 γ - Cyclodextrin 
Cyclobond III 2000 α – Cyclodextrin 
Cyclobond I Ac 2000 Acetylated β-CD 
Cyclobond I SP 2000 Hydroxypropyl ether β-CD 
Cyclobond I RSP 2000 Hydroxypropyl ether β-CD 
Cyclobond I RN 2000 R-Naphthylmethyl carbamate β-CD 
Cyclobond I SN 2000 S-Naphthylmethyl carbamate β-CD 
Cyclobond I DMP 2000 3,5-Dimethylphenyl carbamate β-CD 
Cyclobond I PT 2000 p-toluoyl ester β-CD 
* Manufacturer and supplier : Astec , with 5µm particle size. 
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Section-I: Chiral RP-HPLC method development and validation for 
determination of R-isomer in Pramipexole 
 
1. Introduction to pramipexole 
 
Pramipexole is chemically (S)-2-amino-4,5,6,7-tetrahydro-6-benzothiazole. 
Commercially available tablets conations pramipexole dihydrochloride monohydrate salt 
(Fig.1A) in formulation (Sifrol®, Mirapex®, and Mirapexin®). Molecular formula of 
pramipexole dihydrochloride monohydrate is C10H17N3S 2HCl H2O having molecular 
weight 302.28 g/mole. Its dissociation constants are pKa1 = 5.0 and pKa2 = 9.6, partition 
coefficient Log P (octanol water) is 0.87. Melting point is 296°C to 301°C with 
decomposition [1-3]. R-Isomer of pramipexole dihydrochloride monohydrate salt is an 
impurity of drug substance (Fig.1B). Detail information is described in section of 
pramipexole assay method development for formulation tablets. 
 
N
SNH
H3C
H
NH2 2HCl H2O
S-isomer  
Fig.1A: Pramipexole dihydrochloride monohydrate (S-isomer) 
 
N
SNH
H3C
H
NH2 2HCl H2O
R-isomer  
Fig.1B: Pramipexole dihydrochloride monohydrate (R-isomer) 
 
2. Literature review 
 
2.1 A Pathare DB, Jadhav AS, Shingare MS have developed a chiral liquid 
chromatographic method for the enantiomeric resolution of Pramipexole 
dihydrochloride monohydrate, (S)-2-amino-4,5,6,7-tetra-hydro-6-(propylamino) 
benzothiazole dihydrochloride monohydrate, a dopamine agonist in bulk drugs. The 
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enantiomers of pramipexole dihydrochloride monohydrate were resolved on a 
Chiralpak AD (250 mm x 4.6 mm, 10 microm) column using a mobile phase system 
containing n-hexane:ethanol:diethylamine (70:30:0.1, v/v/v). The resolution between 
the enantiomers was found not less than eight. The presence of diethylamine in the 
mobile phase has played an important role in enhancing chromatographic efficiency 
and resolution between the enantiomers. The developed method was extensively 
validated and proved to be robust. The limit of detection and limit of quantification of 
(R)-enantiomer were found to be 300 and 900 ng/ml. ng/ml. respectively for 20 microl 
injection volumes. The percentage recovery of (R)-enantiomer was ranged from 97.3 
to 102.0 in bulk drug samples of Pramipexole dihydrochloride monohydrate. 
Pramipexole dihydrochloride monohydrate sample solution and mobile phase were 
found to be stable for at least 48 h. The proposed method was found to be suitable and 
accurate for the quantitative determination of (R)-enantiomer in bulk drugs [4]. 
 
3. Aim of present Work 
Pramipexole dihydrochloride monohydrate is identical as S-isomer or basically it 
is the salt form of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino) benzothiazole. From 
the structure at the position of 6th carbon all attached groups and / or atom is different. So, 
there is one chiral center is present in the basic molecule part of the API. Hence, as per 
the chiral theory two isomers are possible for this structure. Out of them S-isomer is the 
identified and reported as an active pharmaceutical ingredient for the treatment of 
Parkinson’s disease. Finally R-isomer needs to be control as per ICH guideline [5]. 
 
As per discussion in the literature review it is not official in pharmacopeia [6-11], 
method for Assay by UV was reported with internal standard preparation. Methods for 
pramipexole in human plasma and related impurities method were reported. A method for 
chiral purity by normal phase also reported [4] but eco friendly and simple reversed 
phase method for chiral purity is the aim of present work. 
 
The aim and scope of the proposed work are as under 
? Method development for chiral purity / R-isomer content for Pramipexole drug 
substance by HPLC. 
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? Resolution optimization for R-isomer and S-isomer (Drug substance) 
? Perform analytical method validation for the proposed method as per ICH 
guideline [12]. 
 
4. Experimental 
 
4.1 Materials, chemicals and reagents 
 
A) Materials : 
 All the materials are manufactured and provided by Torrent Research Center 
Sr. No. Material Name Lot No. / Batch no. Potency /Purity 
1 R-Isomer (+) 2,6-diamino -4,5,6,7-tetrahydro 
benzothiazole reference standard 
OTV/2007/238 99.62 
2 Pramipexole dihydrochloride monohydrate 
API 
PRA/015/005 -- 
3 Pramipexole impurity A 
 [2,6-Diamino-4,5,6,7-tetrahydro-
benzothiazole] 
OTV/2007/123 98.99% 
4 Pramipexole impurity B 
[ (6S)-N2,N6-dipropyl 4,5,6,7 tetrahydro 1,3 
benzothiazole 2,6 diamino ]  
OTV/2007/114 98.53% 
5 Pramipexole impurity C 
[ (6S)-N6,N6-dipropyl 4,5,6,7 tetrahydro 1,3 
benzothiazole 2,6 diamino ] 
OTV/2007/113 99.56% 
 
B) Chemicals and reagents:  
Sr. No. Chemical/Reagent Grade Sr. No. Chemical/Reagent Grade 
1 Acetonitri le HPLC 6 Boric acid AR 
2 Ammonia solution AR 7 Hydrogen peroxide AR 
3 Methanol HPLC 8 Hydrochloric acid AR 
4 Water Milli-Q 9 Sodium hydroxide AR 
5 Borax AR    
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4.2 Instrumentation 
Shimadzu LC 2010C with Class VP software HPLC systems were used. 
 
4.3 Mobile phase preparation 
Buffer: Acetonitrile in ratio of 70: 30 (v/v) were mixed and sonicated to degas. 
 
Buffer: pH of Buffer 1 adjusted to 8.5 with Buffer 2. 
 
Buffer 1: 7.44 g of borax dissolved in 1000 ml of water. 
 
Buffer 2: 13.66 g of boric acid dissolved in 1000 ml of water. 
 
4.4 Diluent preparation  
Methanol: 0.1% v/v ammonia solution, 40:60 mixed. 
 
4.5 Resolution preparation 
Accurately weighed and transferred each of about 2.5 mg of R-isomer of 
pramipexole working/reference standard and Pramipexole dihydrochloride monohydrate 
into 50 ml volumetric flask, 35 ml of diluent was added and dissolved it with aid of 
sonication, diluted to volume with diluent, mix. 5 ml of this solution was diluted to 50 ml 
with diluent. 
 
4.6 Standard preparation  
Accurately weighed and transferred about 2.5 mg of R-isomer of pramipexole 
working/reference standard into 50 ml volumetric flask, 35 ml diluent was added to 
dissolve with aid of sonication and diluted to volume with diluent. 5 ml of this solution 
was diluted to 50 ml with diluent. Further 5 ml of this solution was diluted to 50 ml with 
diluent. 
 
4.7 Test preparation  
Accurately weighed and transferred about 25 mg of test sample into 50 ml 
volumetric flask, 35 ml of diluent was added to dissolve with aid of sonication, diluted to 
volume with diluent. 
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4.8 Chromatographic conditions  
 
Chromatographic separation of both the isomers achieved on CHIRAL PACK AD-
RH 150 mm x 4.6 mm column with 10 x 4 mm guard cartridge as of same CSP in gourd 
holder [13], column oven temperature was 25˚C. The flow rate of the mobile phase was 
adjusted to 0.6 ml/min and the injection volume was 20 µl. Detection was performed at 
260nm. 
 
5. Result and discussion 
 
5.1 Development and optimization of the HPLC method 
 
Initially development was started with solution of mixture of R-isomer and S-
isomer of Pramipexole. Mobile phase with buffer pH 4.5, 20mM potassium dihydrogen 
phosphate and methanol in binary isocratic mode at different compositions were tried but 
even at higher aqueous composition peaks were not separated or it gave ‘M’ shape peak. 
For the purpose of quantitation base line separation was the primary goal before method 
validation and a mobile phase with higher pH gave the base line resolution so, buffer with 
higher pH was explored but as a known fact that at higher pH phosphate buffers reduces 
the column life. Hence, borate buffer with higher pH was explored to increase the column 
life and buffer and acetonitrile composition was optimized to get desired separation for 
both the isomers. Before any sample analysis or study system was qualified with the 
resolution solution and standard solution as a part of system suitability. 
 
5.2 Method validation 
 
5.3.1 Specificity:  
 
Interference from blank and impurities: 
A blank, resolution solution, standard preparation and sample preparation were 
injected and peak purity index for analyte peak in each preparation were the observed 
within the acceptance criteria as mentioned in table 1 and chromatogram shown in fig.1 to 
fig.3. There was no peak at the retention time of any of isomer’s retention time of peak. 
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Table 1: Peak purity in specificity study 
Solution Peak purity index for R-Isomer 
Standard preparation 0.99597 
Resolution 0.99999 
Sample preparation (as such) Not detected 
Sample preparation spiked with R-isomer 0.99227 
 
Fig.1: Chromatogram of blank preparation 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
Fig.2: Chromatogram of resolution preparation 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.47
S-ISOMER PRAMIPEXOLE  24.61
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Fig.3: Chromatogram of R-isomer standard preparation 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.49
  
Interference from degradation products by stress study 
 
The Pramipexole dihydrochloride monohydrate was subjected to thermal, water 
hydrolysis and photo degradation while other chemical stress conditions were not applied 
to avoid probable chiral column damage. For each stress conditions a corresponding blank 
was prepared. 
 
A blank, unstressed and stressed pramipexole dihydrochloride monohydrate 
sample solutions were prepared and injected 
 
 
 
 
5.3.2 Linearity: 
 
Linearity was determined at five levels over the range of LOQ to 150% of 
specification limit. A standard stock solution was prepared and further diluted to attain 
concentration at LOQ (0.05%), 80%, 100%, 120% and 150% of working concentration. 
Each preparation was injected in singlet. A graph of area versus concentration was 
plotted. The correlation co-efficient (r), y- intercept, slope of regression line, residual sum 
of squares were calculated and mentioned in Table 2. Supporting plot and chromatograms 
shown in fig.3 to fig.5. 
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Table 2: Linearity data for pramipexole R-isomer 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3: Linearity curve for pramipexole R-isomer 
 
 
 
 
 
Sr.No. Concentration 
(% of working 
concentration) 
Area 
1 49.80 18851 
2 79.80 29169 
3 99.60 37571 
4 
119.60 45874 
5 149.40 58005 
Correlation coefficient (r) 0.99917 
Slope of regression line 396.76 
Y-intercept -1639 
Residual sum of squares 1496806 
Pramipexole R- isomer linearity
y = 396.76282x - 1639.44776
R 2 = 0.99835
0 
20000 
40000 
60000 
80000 
0 20 40 60 80 100 120 140 160 
CONCENTRATION (%)
A 
R 
E 
A 
 
 
 
Chiral Method development for Pramipexole API 
  
 
 146  
 
 
Fig.4: Linearity study chromatogram of level-1 
 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.60
 
 
 
 
Fig.5: Linearity study chromatogram of level-2 
 
Minutes
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0.000
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R-ISOMER PRAMIPEXOLE  6.59
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Fig.6: Linearity study chromatogram of level-3 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.59
 
 
Fig.7: Linearity study chromatogram of level-4 
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lts
0.000
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R-ISOMER PRAMIPEXOLE  6.60
 
 
 
 
 
 
 
Chiral Method development for Pramipexole API 
  
 
 148  
 
 
Fig.8: Linearity study chromatogram of level-5 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.60
 
5.3.3 Precision 
Method precision was established by determining the R-isomer of six sample 
preparations under same conditions. Six replicate of samples were prepared by spiking the 
solution of R-isomer at the target concentration and injected. Mean, %RSD and 95% 
confidence interval for % of R-isomer result were calculated as mentioned in Table 3 and 
chromatogram shown in fig.9 and fig.10. 
  Table 3: Data of precision study 
Day-1 Day-2 
Sample preparation 
% R-isomer % R-isomer 
1. 0.10 0.10 
2. 0.10 0.11 
3. 0.10 0.10 
4. 0.10 0.10 
5. 0.11 0.10 
6. 0.10 0.10 
Mean 0.10 0.10 
SD  0.0041 0.0041 
% RSD (n= 6) 4.02 4.02 
95% Confidence 
interval (CI) 0.003 0.003 
Overall % RSD (n =12) = 3.83 
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Fig.9: Chromatogram for method precision sample (spiked) 
 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.56
   22.82
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig.10: Chromatogram for method precision sample (as such) 
 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
S-ISOMER PRAMIPEXOLE  22.88
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5.3.4 Accuracy:  
The accuracy of the method was established at three levels in the range of LOQ to 
150% of specification limit. Above levels were prepared in triplicate. Each solution was 
injected in singlet. % Recovery was calculated at each level and recorded in table 4 and 
supporting chromatograms shown in fig.11 to fig.13. 
Table 4: Recovery study  
Level 
Amount 
found 
(mg/ml) 
Amount 
added  
(mg/ml) 
Recovery 
(%) 
Mean 
(%) 
% RSD 
0.2519 0.2500 100.8 
0.2560 0.2500 102.4 
Level-1 
(LOQ) 
0.2549 0.2500 102.0 
101.7 0.82 
0.5053 0.5001 101.0 
0.5103 0.5001 102.0 
Level-2 
(100%) 
0.5237 0.5001 104.7 
102.6 1.87 
0.7724 0.7501 103.0 
0.8004 0.7501 106.7 
 
Level-3 
(150%) 0.8038 0.7501 107.2 
105.6 2.17 
 
Fig.11: Chromatogram of accuracy study level-1 (LOQ) 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.72
S-ISOMER PRAMIPEXOLE  22.87
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Fig.12: Chromatogram of accuracy study level-2 (100%) 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.71
   22.86
Fig.13: Chromatogram of accuracy study level-3 (150%) 
Minutes
0 5 10 15 20 25 30 35 40 45
Vo
lts
0.000
0.005
0.010
0.015
0.020
R-ISOMER PRAMIPEXOLE  6.71
   22.93
 
5.3.5 Solution stability study: 
 
The standard and sample preparations were prepared at test concentration and 
initial % R-isomer content was determined. Standard and sample preparations were stored 
up to 74 hours at room temperature and at 2 -8°C. The % R-isomer content obtained at 
different time interval were compared with the initial % R-isomer content value and 
recorded. The results are recorded in table 5 and table 6. 
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Table 5: Solution stability for standard  
  
Standard Preparation 
Time Condition 
% R-isomer 
content 
Absolute 
difference (%)
Initial Room temperature 100.0 Not applicable 
After 30 hours Room temperature 100.4 0.40 
After 74 hours Room temperature 100.9 0.90 
 
 
Table 6: Solution stability for sample 
 
Sample Preparation 
Time Condition 
% R-isomer 
content 
Absolute 
difference (%)
Initial Room temperature 0.10 Not applicable 
After 27 hours Room temperature 0.10 0.00 
After 71 hours Room temperature 0.10 0.00 
  
5.3.6 Robustness:  
The robustness of the method was established by making deliberate minor 
variations in the   following method parameters.   
 
(A) Change in flow rate by  ± 10% (0.54 ml/min and 0.66 ml/min) 
(B) Change in the minor components in the mobile phase by ± 2% absolute or 30% 
relative whichever is lower (Buffer: Acetonitrile, 68:32 and Buffer: Acetonitrile, 
72:28) 
(C) Change in column oven temperature + 5°C (Column temperature 30°C) 
(D) Change in buffer pH by ± 0.2 (pH 8.3 and 8.7)  
(E) Change in column lot. 
 
Sample was prepared by spiking the R-isomer at specification level 
The effect of changes was observed on system suitability and recorded in table 7. 
The effect of changes was observed on % R-isomer content and recorded in table 8. 
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Table 7: Robustness and system suitability 
System suitability 
parameters Condition 
%RSD Resolution 
Limits: NMT 5.0 NLT 2.0 
A) Change in flow rate 
Normal condition 
(0.6 ml per minute) 1.54 7.72 
Change in flow rate by 10%  
(0.54 ml per minute) 2.28 7.75 
Change in flow rate by 10%  
(0.66 ml per minute) 2.29 7.00 
B) Change in minor component in the mobile phase 
Normal condition 
(Buffer:Acetonitrile (70:30)) 1.54 7.72 
Change in Acetonitrile composition  
by + 2% absolute  
 (Buffer:Acetonitrile (68:32)) 
0.5 7.39 
Change in Acetonitril composition  
by - 2% absolute  
(Buffer:Acetonitrile (72:28)) 
2.02 7.52 
C) Change in column oven temperature 
Normal condition 
(25°C) 1.54 7.72 
Change in oven temperature by + 5°C 
(30°C) 1.3 8.65 
D) Change in pH of mobile phase 
Normal condition 
(pH 8.5) 1.75 7.71 
Change in pH of buffer by + 0.2units 
(pH 8.7) 2.22 8.88 
Change in pH of buffer by - 0.2units 
(pH 8.3) 2.35 7.51 
E) Change in column lot 
Normal column lot: 
CH/AD-RH/150-4.6/03 4.44 8.02 
Changed column lot: 
CH/AD-RH/150-4.6/02 2.26 7.80 
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Table 8: Robustness and system suitability 
 
Condition % R-isomer 
A) Change in flow rate 
Normal condition 
(0.6 ml per minute) 0.10 
Change in flow rate by – 10%  
(0.54 ml per minute) 
0.11 
 
Absolute difference from normal condition 0.01% 
Change in flow rate by + 10% 
(0.66 ml per minute) 0.11 
Absolute difference from normal condition 0.01% 
B) Change in minor component in the mobile phase 
Normal condition 
(Buffer: Acetonitrile (700:300)) 0.10 
Change in Acetonitrile composition  
by – 2% absolute  
 (Buffer: Acetonitrile (720:280)) 
0.12 
Absolute difference from normal condition 0.02% 
Change in acetonitrile composition  
by + 2% absolute  
 (Buffer: Acetonitrile (680:320)) 
0.11 
Absolute difference from normal condition 0.01% 
C) Change in buffer pH by  ±  0.2 units 
Normal condition 
(buffer pH-8.5) 0.10 
Change in buffer pH by +0.2 unit 
(pH-8.7) 0.11 
Absolute difference from normal condition 0.01% 
Change in buffer pH by -0.2 unit 
(pH-8.3) 0.11 
Absolute difference from normal condition 0.01% 
D) Change in column  oven temperature 
Normal condition 
(25°C) 0.10 
Change in oven temperature by + 5°C 
(30°C) 0.11 
Absolute difference from normal condition 0.01% 
E) Change in column lot 
CH/AD-RH/150-4.6/03 
Lot no. ADRHCD-FE053 0.10 
CH/AD-RH/150-4.6/02 
Lot no. ADRHCD-KE019 0.10 
Absolute difference from normal condition 0.0% 
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6. Quantitation and calculation formulae 
 
6.1 Relative Standard Deviation (%) 
 
Relative Standard Deviation (%) =  X
100    SD ×  
By Microsoft excel  
Average = AVERAGE (Number 1) 
Standard Deviation = STDEV (Number 1) 
 
6.2 Calculation formulae in linearity 
 
 Correlation coefficient (r) =   
]})([  ])(x{[
y)( x)(  -  )x(  
2222 yynxn
yn
∑−∑∑−∑
∑∑∑
 
 
Correlation coefficient (r) = CORREL (Array 1, Array 2) 
 
Slope of regression line = 22 x)( x
y)( x)(  -  )x(  
∑−∑
∑∑∑
n
yn
  
 
Slope of regression line = SLOPE (Array 1, Array 2) 
 
y- intercept = xB - y  =A  
 
y- intercept = INTERCEPT (Array 1, Array 2) 
 
Residual sum of squares =∑ 2calculated)Y - ( originalY  
 
 
 
 
 
Chiral Method development for Pramipexole API 
  
 
 156  
 
 
Where, 
Y calculated =  A + Bx 
n = Number of measurements 
x = Individual concentration 
y = Individual area 
x   = Average concentration 
y  = Average area 
 
Residual sum of squares = SUMXMY2 (Array 1, TREND (Array 1, Array 2, Array2)) 
 
6.3 Accuracy (% Recovery) 
 
% Recovery = 100x 
added (mg) substance ofAmmount 
  found (mg) sbustance ofAmmount  
 
6.4 % R-isomer in pramipexole 
 
% R-isomer = such)(as%assayStd.
WtSpl
Dilution
Dilution
 wtStd.
Astd
Asp ×××  
 
% R-isomer = 62.99
25.02
50
50
5
50
5
50
2.501
38682
39940 ×××××  
 
% R-isomer = 0.10 
 
Asp : Area of R-isomer in sample 
Astd : Mean area of diluted standard 
Std. wt : Std weight in mg 
Spl wt : Sample weight in mg 
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6.5 95% Confidence Interval (CI) 
 
95% Confidence Interval (CI) = n
SD  t  ×± α  
Where, 
SD = Standard Deviation 
X   = Average concentration 
n = Number of measurements 
tα = t value at n-1 from t table (two tail) 
95% Confidence Interval (CI) = SD (2.57058)/SQRT (6) 
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INTRODUCTION TO UPLC 
 
History of chromatography can give an idea about improvement in technology 
from conventional column chromatography to high performance liquid chromatography 
and finally at this stage an ultra performance liquid chromatography or in other way a 
combination of pressurized chromatographic technology and sub 2 (two) micron particle 
size of stationary phase technology leads to advance Ultra Performance Liquid 
Chromatography (UPLC) or Rapid Resolution Liquid Chromatography (RRLC) 
technology. 
 
Technology of sub 2 (two) micron particle size leads many modifications in 
hardware part of the system like reduction of system volume, higher pump pressure 
capacity, injector and needle part, and cell volume of detector as well as in software area, 
data acquisition rate or capacity was increased for sufficient data collection. 
 
In brief detail, small particle size columns leads to increase in pump pressure so 
that area was improved and for accurate and precise injection volume needle in needle 
technology with teflon material was came into the picture. Detector cell volume was 
reduced for better signals and resolution. 
 
Smaller particle size of 2 micron technology altered the machine and its 
application for faster way of analysis in current scenario of separation science. 
Requirement of this technology can be explained by van deemter equation [1,4] and plot 
as shown in fig 1. From this plot it reveals that there is minimum HETP against the linear 
velocity with the almost constant relation or maximum the theoretical plates can be 
achieved with particle size less than 2 micron. Finally as a known fact increasing in N 
leads to increase in Resolution as shown in formula; 
 
Rs  =  N 
 4 ( 
α -1
  α )       k     k+1 (     )
RetentivitySelectivitySystem 
Efficiency 
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Fig.1: Van Deemter plots-influence of particle size 
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Now, for method conversion from HPLC to UPLC or for comparison of both the 
technology following aspects needs to take in consideration [2-3]. 
 
? Ratio of column length to particle size (L/dp) needs to keep constant. 
i.e. 150 mm/5 µm = 30,000 is closest to 50mm/1.7 µm = 29,500 
 
? Column selection should be based on same basic column chemistry 
i.e. C18 column should be replaced by C18 column 
 
? 5 µm to 1.7 µm particle size leads to increase in speed of 9X along with 9X 
pressure 
? 3 µm to 1.7 µm particle size leads to increase in speed of 3X along with 3X 
pressure 
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? 5 µm to 1.7 µm particle size leads to increase in peak height of 1.7X 
? 3 µm to 1.7 µm particle size leads to increase in peak height of 1.3X 
 
? 5 µm to 1.7 µm particle size leads to decrease in peak width of 0.6X 
? 3 µm to 1.7 µm particle size leads to decrease in peak width of 0.8X 
 
? Column efficiency (N) is inversely proportional to dp 
 
 
 
i.e. 5 µm to 1.7 µm particle size leads to increase in column efficiency (N) 3X but 
dp
N 1∝
  NRs ∝
 
So, resolution also increase by 1.7X 
Based on above fact practically an example for chromatogram comparison against 
column dimension for rune time and resolution is shown in fig 2. 
 
Remark 
Here, X is used to express the mathematical relation in multi fold. 
e.g. pressure increased by 3X i.e. pressure increase by three times 
 
Method Development 
 
Method development in UPLC remains same as of HPLC but few areas of 
chromatographic conditions are different e.g. for gradient elution column equilibration 
time is very less as compare to HPLC due to lower column volume. 
 
Advance technology in column filled material for HPLC as well as UPLC allows 
higher pH and temperature stability for column for wider choice of mobile phase for 
different applications. e.g. pH of mobile phase or its buffer can selected based on 
compound chemical nature and that can be explain by fig.3 for reversed phase retention 
plot. 
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Fig.2 Chromatogram comparison against column dimension 
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Fig.3 Reversed phase retention plot  
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From the above plot and fundamental theory of solvent gives following 
information for development consideration. 
 
Facts for basic compound  
1. Alkaline pH increases retention of basic analytes 
2. Methanol increases retention of all components compared to acetonitrile 
3. Similar basic analytes differ little in selectivity, respective to one another, when 
they are either fully charged or uncharged 
4. Largest selectivity differences between bonded phases occur with methanol and 
analytes in their unionized state 
 
Facts for acid compound  
1. Acidic pH increases retention of acidic analytes 
2. Methanol increases retention of all components compared to acetonitrile 
3. Large differences in selectivity are observed when change in pH alters charge 
state 
4. Largest selectivity differences between bonded phases occur with methanol and 
analytes in their unionized state 
Column chemistry for known columns UPLC are shown in fig 4. 
 
Fig.4: Column chemistry of UPLC column 
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By many recent research and development, UPLC presents the ability to 
extend and expand the utility of separation science at a time when many scientists have 
reached separation barriers, pushing the limits of conventional HPLC. New chemistry and 
instrumentation technology can provide more information per unit of work as UPLC 
begins to fulfil the promise of increased speed, resolution, and sensitivity predicted for 
liquid chromatography. As this is the concept for the scientist many of industries may 
take time to use in routine but it can be the future of the liquid chromatography. Hence 
present research work includes the extended area of HPLC to UPLC as a part of 
technology updating or a balance form of present HPLC and improved LC or UPLC for 
future scope for separation science. 
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Section-I: UPLC Method development and validation for determination of 
related impurities in Torsemide tablets 
 
1. Introduction to torsemide tablets 
 
Torsemide is a diuretic of the pyridine-sulfonylurea class. Its chemical name is 1-
isopropyl-3-[(4-m-toludino-3-pyridyl)sulfonyl]urea, and N-[[(1-methylethyl)amino] 
coarbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide. Torsemide is a loop 
diuretic used for oedema associated with heart failure, including pulmonary oedema and 
with renal and hepatic disorders. It is also used in the treatment of hypertention, either 
alone or with other antihypertensive.Its molecular weight is 348.43 g/mole with 
molecular formula of C16H20N4O3S. Its dissociation constant (pKa) reported is 7.1 in 
Demadex® complete product information while in Merck index pKa = 6.44 is reported. 
Its melting point is 163°C to 164°C with decomposition [1-3] 
 
CH3
CH3
N
H
N
H
O
S
O O
N
NH
CH3  
Fig.1: Torsemide 
 
Innovator:  Roche pharmaceuticals, USA 
 
Strengths: Torsemide tablets are available in four strengths as 5 mg, 10 mg, 20 mg, and 
100 mg of Torsemide as an active ingredient for oral administration. 
 
1.1 Clinical pharmacology 
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Mechanism of Action: Micro puncture studies in animals have shown that 
Torsemide from within the lumen of the thick ascending portion of loop of Henle, where 
it inhibits the Na+/K+/2Cl- carrier system. Clinical pharmacology studies have confirmed 
this site of action in humans, and effects in other segments of the nephron have not been 
demonstrated. Diuretic activity thus correlates better with the rate of drug excretion in the 
urine than with the concentration in the blood. 
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Torsemide increases the urinary excretion of sodium, chloride and water but it 
does not significantly alter the glomerular filtration rate, renal plasma flow or acid base 
balance. 
 
1.2 Pharmacokinetic and metabolism 
 
The bioavailability of Demadex® tablets is approximately 80% with little 
intersubject variation: the 90% confidence interval is 75% to89%. The drug is absorbed 
with little first pass metabolism and the serum concentration reaches its peak (Cmax) 
within 1 hour after oral administration. Cmax and area under the serum concentration-time 
curve(AUC) after oral administration are proportional to dose over the range of 2.5 mg to 
200 mg. Simultaneous food intake delays the time to Cmax by about 30 minutes but overall 
bioavailability (AUC) and diuretic activity are unchanged. Absorption is essentially 
unaffected by renal or hepatic dysfunction. 
 
The volume of distribution in adult is 12 liters to 15 liters in adults or in patients 
with mild to moderate renal failure or congestive heart failure. In patient with hepatic 
cirrhosis, the volume of distribution is approximately doubled. 
 
1.3 Contraindications 
Demadex® is contraindicated in patients with known hypersensitivity to Demadex® 
or sulfonylureas.  
 
2. Literature review 
 
The literature reviews regarding Torsemide suggest that various analytical 
methods were reported for drug substance as well as in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of torsemide are as under. 
 
2.1 Begona Barroso M., Alonso R.M., Jimenez R.M have developed a high 
performance liquid chromatographic method with amperometric detection for the 
determination of the loop diuretic 1-Isopropyl-3-[4-(3-methylphenylamino)-3-
pyridinesulphonyl] urea, torsemide, using a μ-Bondapak C18 column and a mobile 
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phase water :acetonitrile (65 :35), 5 mM in potassium dihydrogen phosphate/ 
dipotassium hydrogen phosphate at pH 5.3. Eluant is monitored at +1300 mV with an 
amperometric detector equipped with a glassy carbon working electrode. The method 
showed a determination limit of 8 ppb and reproducibility in terms of relative 
standard deviation lower than 2% in intra-day assays and 5 % in inter-day assays. The 
HPLC-EC method was applied to urine samples obtained from a healthy volunteer. 
Concentration levels of torsemide at different time intervals were monitorized and 
results were in agreement with the pharmacokinetic parameters of this diuretic. The 
determination of torsemide in urine required a liquid-liquid extraction prior to 
chromatographic analysis due to the interferences found in urine matrix. With this 
simple clean-up procedure, recoveries around 70% were achieved. Torsemide was 
directly determined in tablets after dissolution of the powder in a methanolic solution. 
 
2.2 Marothu Vamsi Krishna and Dannana Gowri Shankar have developed a simple 
and cost effective spectrophotometric method for the determination of torsemide in 
pure form and in pharmaceutical formulations. The method is based on the formation 
of blue colored chromogen when the drug reacts with Folin-Ciocalteu (F-C) reagent in 
alkaline medium. The colored species has an absorption maximum at 760 nm and 
obeys beer?s law in the concentration range 30-150 µg mL-1. The absorbance was 
found to increase linearly with increasing concentration of TSM, which is 
corroborated by the calculated correlation coefficient value of 0.9999(n=8). The 
apparent molar absorptivity and sandell sensitivity were 1.896x103 L mol-1 cm-1 and 
0.183 µg cm-2, respectively. The slope and intercept of the equation of the regression 
line are 5.4x10-3 and 1.00x10-4 respectively. The limit of detection was 0.94. The 
optimum experimental parameters for the reaction have been studied. The validity of 
the described procedure was assessed. Statistical analysis of the results has been 
carried out revealing high accuracy and good precision. The proposed method was 
successfully applied to the determination of TSM in pharmaceutical formulations. 
 
2.3 Kwang-Hyeon Liu1 and et al have established a rapid and sensitive method to assay 
torsemide in plasma was developed using a simple liquid-liquid extraction technique 
followed by HPLC. Torsemide and the internal standard furosemide were extracted 
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from 0.5 mL of plasma using ethyl acetate in the presence of 0.1M HCl. The analysis 
of the extracts was performed on a monolithic silica column with ultraviolet 
spectrophotometric detection. The calibration curve was linear over the concentration 
range of 0.05-5 µg mL–1 in plasma. Recoveries were reasonable for routine analyses 
(>80%); the limit of quantification was 0.05 µg mL–1 with a signal-to-noise ratio of 5. 
The coefficient of variation of the assay precision was less than 6.1%, and the 
accuracy exceeded 98%. This method was used to measure the torsemide 
concentration in plasma from healthy subjects after a single 20-mg oral dose of 
torsemide. This method provides a very simple, sensitive, and accurate way to 
determine torsemide concentrations in plasma. 
 
2.4 Dragica Zendelovska, Trajce Stafilov have developed a reverse phase high-
performance liquid chromatography (RP-HPLC) methods for determination of 
diuretics in different human body fluids (whole blood, plasma, serum or urine). 
Sample preparation procedures, including solid-phase extraction, liquid-liquid 
extraction, dilution, precipitation as well as automated RP-HPLC procedures, are 
discussed in order to present the advantages and disadvantages of each type of sample 
preparation. Also, values of analytical recovery of each procedure used for sample 
preparation are summarized. The most important RP-HPLC parameters detection 
mode, stationary phase, mobile phase, sensitivity, etc.) are also summarized and 
discussed. 
 
2.5 H-J Guchelaarl, L. chandil, O. Schoutenl, W.A. van den Brandl have developed a 
simple and adequate HPLC method for screening of human urine for the following 17 
diuretic drugs: acetazolamide, bendrofluazide, bumetanide, canrenoic acid, 
chlorothiazide, chlorthalidone, clopamide, epitizide, etacrynic acid, furosemide, 
hydrochlorothiazide, indapamide, mefruside, piretanide, spironolactone, torasemide, 
and triamterene. The assay involves extraction from two 2 mL urine samples with 
ethyl acetate at pH = 5, washing with a phosphate buffer at pH = 6 and analysis by 
HPLC using a reversed phase C18 column and ultraviolet detection with a diode array 
detector for all drugs (except triamterene) using two eluents consisting of water, 
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triethylamine, phosphoric acid and acetonitrile at different ratios and different pH 
values. Triamterene is determined by direct injection of diluted urine onto the column 
and is measured by fluorescence detection. The recoveries of the diuretic drugs were 
determined at two different concentrations and ranged from 43–110% (median: 87%) 
which is sufficient to detect abuse of these drugs. The repeatability of the assay 
ranged from 1–12% (median: 5.5%). 
 
3. Aim of present work 
 
Literature reveals that the torsemide drug substance is official in US 
pharmacopeia as well as in British pharmacopeia but its tablet formulation is not official 
[4, 5]. An assay method has been described for determination of torsemide in tablet 
formulation by HPLC EC method [6]. A spectrophotometric method reported for 
determination of torsemide in bulk drug and formulation using Folin-Ciocalteu reagent as 
color forming reagent [7]. Some methods are also available for determination of 
torsemide in urine and biological fluids [8-10]. But none of method available for 
determination of related impurities for torsemide tablets. The present communication 
describes method for determination of related impurities for Torsemide tablets with 
established relative response factor (RRF) and relative retention time (RRT) for known 
impurities. Moreover, analytical column with sub 2-micron particle size technology was 
explored for better chromatography. 
 
Simple and precise analytical method for determination of related impurities for 
torsemide tablets was developed and validated as per ICH guideline. Hence, this faster 
LC method could be of use for formulation development and stability testing as well as at 
quality control laboratory for routine use. 
 
The aim and scope of the proposed work are as under  
? LC method development for determination of related impurities in torsemide 
tablets formulation 
? Forced degradation study under stress condition 
? To resolve all known impurities and generated during the force degradation 
studies 
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? Perform analytical method validation for the proposed method as per ICH 
guideline and method applicability to market samples including IFF. 
 
4. Experimental 
4.1 Materials, chemicals and reagents 
 
Materials, chemicals and reagents were used as mentioned in Table 1 and Table 2. 
 Table 1: Materials 
Name B.No./Lot No Potency / Strength 
Torsemide related compound A, USP RS (imp A) 
[4-[(3-methylphenyl)amino]-3-pyridinesulfonamide] 
F0B071 100.0 % 
Torsemide related compound B, USP RS (imp B) 
[N-[(n-butylamino)-carbonyl]-4-[(3-
methylphenyl)amino]-3-pyridinesulfonamide] 
F0B083 100.0 % 
Torsemide related compound C, USP RS (imp C) 
[N-[(ethylamino)carbonyl]-4-[(3-
methylphenyl)amino]-3-pyridinesulfonamide] 
F0B078 100.0 % 
Torsemide , USP RS G0E293 99.6 % 
Torsemide working standard, TRC, India TO 0011005 99.5 % 
Placebo, TRC, India 001 -- 
Torsemide tablets, TRC, India 003 5 mg 
Torsemide tablets, Tide-10, TPL India  C8938003 10 mg 
Torsemide tablets, Demadex, Roche Lab, USA E6772 10 mg 
Torsemide tablets, Torsinex-10, Micro lab, India TNXH0020 10 mg 
Torsemide tablets, Dytor-10, Cipla, India D82152 10 mg 
 
Table 2: Chemicals and reagents 
Sr. No. Chemical/Reagent Grade 
1 Potassium dihydrogen phosphate AR grade (Rankem, India) 
2 Ortho-phosphoric acid GR grade (Merck, India) 
3 Methanol HPLC grade (Merck, India) 
4 Acetonitrile HPLC grade (Merck, India) 
5 Mill-Q-Water By Milli-Q system (Millipore, USA) 
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4.2 Instrumentation 
The LC system of Waters acquity UPLC with PDA was used for this entire study 
and chromatographic separation was achieved on Zorbax SB-C18 (50 mm X 4.6mm 
1.8µm) column as stationary phase with binary gradient mode. 
 
4.3 Standard stock solution 
Transferred about 1.5 mg of each of Torsemide USP reference standard and USP 
Torsemide related compound A, Torsemide related compound B and Torsemide related 
compound C reference standard into 50ml volumetric flask and 25ml methanol was added 
to dissolve with aid of sonication and diluted to volume with diluent (30µg/ml of 
Torsemide and its related compound A, B and C) Fig.2. 
 
4.4 Standard solution 
In a 25ml volumetric flask, 1 ml of standard stock solution was diluted to volume 
with diluent (1.2 µg/ml of torsemide and its related compound A, B and C) Fig.3. 
 
4.5 Diluted standard solution 
Transferred about 2.0 mg of torsemide USP working standard into 100ml 
volumetric flask and 50ml methanol was added to dissolve with aid of sonication and 
diluted to volume with diluent. In a 50ml volumetric flask, 1 ml of standard stock solution 
was diluted to volume with diluent Fig.4. 
 
4.6 Resolution solution 
Transferred about 20 mg of torsemide working standard into 50ml volumetric 
flask, 25ml of diluent was added and sonicated to dissolve, 2 ml of standard stock 
solution was added and diluted to volume with diluent (400µg/ml of Torsemide and 1.2 
µg/ml of Torsemide related compound A, B and C] Fig.5. 
 
4.7 Sample solution 
Twenty tablets were crushed to fine powder by mortar and pestle. Sample powder 
equivalent to about 40mg of torsemide was weighed and transferred to 100 ml volumetric 
flask, 50ml of diluent was added and sonicated for 25 minute with intermittent swirling, 
diluted to volume with diluent (400µg/ml of torsemide) and filtered with 0.22 µm PVDF 
membrane filter. As such sample preparation as per fig.6. 
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Fig.2: Chromatogram of standard stock preparation 
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Fig.3: Chromatogram of standard preparation 
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Fig.4: Chromatogram of diluted standard preparation 
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Fig.5: Chromatogram of resolution solution 
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Fig.6: Chromatogram of sample solution (as such preparation) 
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5. Result and discussion 
5.1 Development and optimization of the LC method 
Method development was started with same mobile phase as mentioned in the 
monograph of torsemide USP as a part of chromatographic conditions but peak of 
impurity B was eluted in very late eluting region so, run time is little high for analysis and 
flow rate can not be increased further more as due to buffer and methanol gave high pump 
pressure. So, on this fact methanol was replaced by acetonitrile with composition 
optimization or in other words, torsemide USP related substances method for its 
chromatographic condition can of use but it is of very long run time of about 40 minutes 
[Fig.7A]. While instead of methanol in mobile phase acetonitrile gives better peak shape 
with its sharpness and run time also reduced and chromatographic separation can 
achieved in 25 minutes [Fig.7B].  
 
But scientist is always looking for better technology for betterment or for 
improved chromatography. As a part of that UPLC method with Zorbax column of sub 2 
micron particle size technology was explored to reduce the run time to 6 minutes 
[Fig.7C]. 
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Fig.7A: HPLC Chromatogram with Torsemide USP HPLC method 
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Fig.7B: HPLC Chromatogram with modified HPLC method 
 
 
Fig.7C: UPLC Chromatogram 
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5.2 Separation for known impurities 
Impurity stock solution of torsemide and its USP related compound A, B and C 
was used for method development parameters like column selection and gradient 
optimization (30µg/ml of torsemide and its related compound A, B and C). Once desired 
separation for known impurities and main component was achieved forced degradation 
was performed. Finally proposed method with chromatographic condition as per table no. 
3 was subjected to method validation as per ICH guideline with consideration of sample 
concentration to achieve LOQ below the reporting threshold of impurities [11]. 
 
Table 3: Chromatographic condition 
 
Buffer Buffer, 20 mM potassium dihydrogen phosphate, pH was 
adjusted to 3.5 with orthophosphoric acid, filtered through 
0.22µm PVDF membrane 
Mobile phase-A Buffer : Acetonitrile, 90:10 (v/v) 
Mobile phase-B Buffer : Acetonitrile, 50:50 (v/v) 
Diluent Buffer : Acetonitrile : Methanol, 25:25:50 (v/v/v) 
Column oven temp. 30°C 
Detection UV at 288 nm 
Injection volume 6 µl 
Time (min) Mobile phase-A (%) Mobile phase-B (%) 
0.0 75 25 
2.5 65 35 
4.0 25 75 
4.6 25 75 
5.0 75 25 
Gradient programme 
6.0 75 25 
 
5.3 Forced degradation Study 
Forced degradation was performed on torsemide tablets to achieve desired 
degradation and placebo as well as  Torsemide drug substance were treated with similar 
conditions as mentioned below, based on development trials optimized forced 
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degradation conditions were established. Final sample concentration was achieved 
400µg/ml of torsemide with diluent as proposed sample concentration. 
 
5.3.1 Oxidative degradation 
 
Torsemide sample powder equivalent to 40mg of torsemide was subjected to 
oxidative stress condition by 5ml of 3% v/v H2O2 solution in 100ml volumetric flask and 
heated on water bath at 100°C for 30 min and sample solution was prepared as per 
procedure. 
 
5.3.2 Acid degradation 
 
Torsemide sample powder equivalent to 40mg of torsemide was subjected to 
acidic stress condition by 5ml of 1N HCl solution in 100ml volumetric flask and heated 
on water bath at 100°C for 30 min and sample was neutralised with 1N NaOH and sample 
solution was prepared as per procedure. 
 
 
5.3.3 Base degradation 
 
Torsemide sample powder equivalent to 40mg of torsemide was subjected to 
alkaline stress condition by 5ml of 1N NaOH solution in 100ml volumetric flask and 
heated on water bath at 100°C for 30 min and sample was neutralized with 1N HCl and 
sample solution was prepared as per procedure. 
 
5.3.4 Thermal degradation 
 
Torsemide tablets were kept in temperature controlled oven at 100 °C for 30 hours 
and sample solution was prepared as per procedure. 
 
5.3.5 Photolytic degradation 
 
Torsemide tablets were kept in photo stability chamber to expose it for 1.2 million 
lux hours and sample solution was prepared as per procedure 
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5.4 Method  applicability to market samples  
Method was success fully applicable to market samples for evaluation of known 
impurities with their UV spectral confirmation as mentioned in table 4.  
 
Table 4: Impurity profile for different make samples 
 Sample Name B.No./Lot No Expiry 
Date 
Imp A 
(%) 
Imp B 
(%) 
Imp C 
(%) 
Torsemide tablets, Tide-10, 
TPL India  
C8938003 Feb 2010 0.09 BQL BQL 
Torsemide tablets, Demadex, 
Roche Lab, USA 
E6772 Apr 2009 0.37 BQL BQL 
Torsemide tablets, Torsinex-
10, Micro lab, India 
TNXH0020 Apr 2009 0.09 BQL BQL 
Torsemide tablets, Dytor-10, 
Cipla, India 
D82152 Mar 2011 0.07 BQL BQL 
BQL = Below Quantitation Limit  
(Limit of quantitation = 0.025%) 
 
5.5 Method Validation 
 
Method validation approach: 
The method for the determination of related impurities for torsemide tablets of 5 
mg, 10 mg, 20 mg, and 100 mg is same. Sample concentration for all strength is 400 
µg/ml of torsemide and complete validation was performed on lower strength (5 mg) and 
linearity was performed by 5 levels of concentration. Recovery was performed by 3 
replicates x 3 concentration. Filter media interference study was covered in accuracy 
study. 
 
5.5.1 Specificity 
Interference from blank was not observed at any peak of interest and peak purity 
of all known impurities in spiked sample (as per method precision) observed within the 
acceptance criteria and forced degradation data as discussed in section 5.3 summarized in 
table 5 and chromatograms are as shown in fig.8(A) to 8(J). 
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Table 5: Forced degradation data 
Stress condition % of degradation  
Oxidative degradation 15.40 
Acid degradation 10.81 
Alkali degradation 0.42 
Thermal degradation 6.35 
Photolytic degradation 0.45 
 
Fig.8 (A): Peroxide degradation 
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Fig.8 (B): Acid degradation 
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Fig.8 (C): Base degradation 
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Fig.8 (D): Thermal degradation 
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Fig.8 (E): Photolytic degradation 
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Fig.8 (F): Chromatogram of impurity-A 
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Fig.8 (G): Chromatogram of impurity-B 
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Fig.8 (H): Chromatogram of impurity-C 
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Fig.8 (I): Chromatogram of blank/diluent 
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Fig.8 (J): Chromatogram of placebo 
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5.5.2 Linearity 
 
Linearity and relative response factor determination 
The calibration curve for Torsemide and its impurities were constructed over the 
absolute concentration range of 0.1-4.0 µg/ml. So, 0.025% to 1% concentration with 
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respect to sample solution concentration in five levels. Peak area of each impurities and 
Torsemide versus respective concentration was plotted and linear regression analysis 
performed on resultant curves. Relative response factor (RRF) was calculated for each 
known impurities by taking the ratio of impurity slope to Torsemide slope [12]. Statistical 
data summarized in table 6 and chromatograms mentioned in Fig.9 (A) to 9 (E). 
 
Table 6: Linearity and RRT and RRF  
Name Slope Intercept r2 RRT RRF 
Imp-A 17365 71 0.9996 0.587 1.357 
Imp-B 12107 -19 0.9999 1.229 0.946 
Imp-C 13316 8 0.9996 0.683 1.041 
Torsemide 12793 -29 0.9997 1.000 1.000 
RRT = Relative retention time 
RRF = Relative response factor 
 
Fig.9: Linearity chromatograms 
 
Fig.9 (A): Linearity level-1  
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Fig.9 (B): Linearity level-2 
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Fig.9 (C): Linearity level-3 
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Fig.9 (D): Linearity level-4 
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Fig.9 (E): Linearity level-5 
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5.5.3 Precision at LOQ 
 
The LOQ concentrations for all known impurities were determined 0.1 µg/ml as 
0.025 % with respect to sample solution concentration of Torsemide by signal to noise 
ratio methodology [13]. The reproducibility at LOQ was determined by six replicate 
injections of composite mixture of impurities and Torsemide solution as per table 7 and 
Fig.10. 
Fig.10: Chromatogram of Precision at LOQ 
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Table 7: Precision at LOQ 
 
Name RSD (%) Day-1 RSD (%) Day-2 
Imp-A 1.10 0.73 
Imp-B 1.02 0.84 
Imp-C 0.87 0.89 
Torsemide 0.92 0.76 
 
5.5.4 Precision 
 
Method precision was established by six sets of sample preparation. To 
demonstrate the method precision all known impurities were spiked at 0.3 % level to all 
six sample preparation fig.11. Data are summarized in table 8. 
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Table 8: Summary of precision day-1 and day-2 
Day-1 
Set No. Imp-A (%) Imp-B (%) Imp-C (%) Unk imp (%) Total Imp (%)
1 0.32 0.30 0.30 0.05 0.97 
2 0.32 0.31 0.31 0.05 0.99 
3 0.31 0.31 0.31 0.05 0.98 
4 0.32 0.30 0.31 0.05 0.98 
5 0.31 0.30 0.30 0.05 0.96 
6 0.31 0.30 0.30 0.05 0.96 
Mean 0.32 0.30 0.31 0.05 0.97 
SD 0.005 0.005 0.005 0.000 0.012 
%RSD 1.739 1.702 1.796 0.000 1.244 
95% CI 0.0057 0.0054 0.0057 0.0000 0.0127 
Day-2 
Set No. Imp-A (%) Imp-B (%) Imp-C (%) Unk imp (%) Total Imp (%)
1 0.30 0.31 0.31 0.05 0.97 
2 0.31 0.30 0.31 0.05 0.97 
3 0.30 0.31 0.30 0.05 0.96 
4 0.31 0.30 0.31 0.05 0.97 
5 0.30 0.30 0.30 0.05 0.95 
6 0.31 0.30 0.31 0.05 0.97 
Mean 0.31 0.30 0.31 0.05 0.97 
SD 0.005 0.005 0.005 0.000 0.008 
%RSD 1.796 1.702 1.684 0.000 0.867 
95% CI 0.0057 0.0054 0.0054 0.0000 0.0088 
 
SD = Standard Deviation, %RSD = Relative Standard Deviation 
Unk imp = Unknown impurity, CI = confidence interval 
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Fig.11: Chromatogram of method precision 
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5.5.5 Accuracy (Recovery) 
The accuracy was evaluated by the recovery study for method which was 
established at three levels in the range of 0.1-4.0 µg/ml (0.025% to 1% relative to sample 
concentration, 3 levels x 3 preparations). Calculated amount of known impurities were 
added in form of solution to the sample preparation to attain lowest to highest level. Data 
summarized in table 9, Chromatograms shown in Fig.12 (A) to (C). 
 
Fig.12 (A): Chromatogram of accuracy level-1 
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Fig.12 (B): Chromatogram of accuracy level-2 
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Fig.12 (C): Chromatogram of accuracy level-3 
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Table 9: Summary of recovery data 
 
Name 
Amount added a 
( mcg/ml) 
Recovery a (%) % RSD 
0.1 98.6 1.37 
1.2 100.7 1.04 Imp A 
4.0 99.8 1.26 
0.1 99.7 0.79 
1.2 100.6 1.24 Imp B 
4.0 99.8 0.80 
0.1 98.6 0.83 
1.2 101.3 1.67 Imp C 
4.0 99.6 1.15 
 
a = Average of three determinations 
 
5.5.6 Solution Stability 
The solution stability at 25°C was studied at different time interval against fresh 
standard preparation at specified time interval. The results obtain for the solution stability 
study at different time intervals for standard and sample preparation shown in table 10(A) 
and 10(B). It was concluded that the standard and sample preparation solution were found 
stable up to 48 hours at 25 ˚C. 
 
Table 10(A): Sample solution stability 
Sample solution stability  
Time (Hours) Imp-A (%) Imp-B (%) Imp-C (%) Unk imp (%) Total Imp (%)
Initial* 0.32 0.30 0.30 0.05 0.97 
24 0.30 0.31 0.31 0.05 0.97 
48 0.31 0.30 0.31 0.05 0.97 
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Table 10(B): Standard solution stability 
Standard solution stability 
Time (Hours) Imp-A (µg/ml) Imp-B (µg/ml) Imp-C (µg/ml) Torsemide 
Initial* 1.2024 1.2036 1.2012 1.2010 
24 # 1.2025 1.2030 1.2008 1.2015 
48 # 1.2028 1.2034 1.2011 1.2007 
 
* Data taken from test preparation-1 and system suitability from method precision. 
# Concentration of component obtained against fresh standard preparation. 
 
5.3.6 Robustness:  
The result of robustness study of the developed method was shown in Table 11(A) 
and 11(B). The results have shown that during all variance conditions value of related 
impurities for the test preparation was within the acceptance criteria. It was in accordance 
with that of accepted true value from method precision study. System suitability 
parameters were also found satisfactory; hence the analytical method would be concluded 
as robust.  
 
Table 11(A): System suitability summary of robustness study 
 
System suitability parameters 
Condition 
Asymmetry % RSD 
A) Change in flow rate 
Flow rate 1.0 ml/minute 1.02 0.62 
Flow rate 0.9 ml/minute 1.00 0.28 
Flow rate 1.1 ml/minute 1.01 0.45 
B) Change in minor component in the mobile phase 
MP-A, Buffer : Acetonitrile (90:10) 1.02 0.62 
MP-A, Buffer : Acetonitrile (88:12) 1.09 0.35 
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MP-A, Buffer : Acetonitrile (92:8) 1.13 0.21 
C) Change in column temperature  
Column temperature 30°C 1.02 0.46 
Column temperature 25°C 1.14 0.80 
Column temperature 35°C 1.08 0.71 
D) Change in column Lot No # 
Method precision 1.02 0.46 
Intermediate precision 1.05 0.36 
 
# = this parameter was studied as part of precision (method precision & intermediate 
precision). 
 
Table 11(B): System suitability summary of robustness study 
 
% of Impurities 
Condition 
A B C Unk Total 
A) Change in flow rate 
Flow rate 1.0 ml/minute 0.32 0.30 0.30 0.05 0.97 
Flow rate 0.9 ml/minute 0.31 0.30 0.31 0.05 0.97 
Flow rate 1.1 ml/minute 0.30 0.31 0.32 0.05 0.98 
B) Change in minor component in the mobile phase 
MP-A, Buffer : Acetonitrile (90:10) 0.32 0.30 0.30 0.05 0.97 
MP-A, Buffer : Acetonitrile (88:12) 0.32 0.30 0.30 0.05 0.97 
MP-A, Buffer : Acetonitrile (92:8) 0.31 0.30 0.30 0.05 0.96 
C) Change in column temperature  
Column temperature 30°C 0.32 0.30 0.30 0.05 0.97 
Column temperature 25°C 0.31 0.32 0.33 0.05 1.01 
Column temperature 35°C 0.31 0.31 0.31 0.05 0.98 
D) Change in column Lot No* 
Method precision 0.32 0.30 0.31 0.05 0.97 
 
 
 
UPLC Method Development Torsemide Tablets 
 
Intermediate precision 0.31 0.30 0.31 0.05 0.97 
 
6. Quantitation and calculation formulae 
 
6.1 Relative Standard Deviation (%) 
 
Relative Standard Deviation (%) =  X
100    SD ×  
By Microsoft excel  
Average = AVERAGE (Number 1) 
Standard Deviation = STDEV (Number 1) 
 
6.2 Calculation formulae in Linearity and RRF 
 
 Correlation coefficient (r) =   
]})([  ])(x{[
y)( x)(  -  )x(  
2222 yynxn
yn
∑−∑∑−∑
∑∑∑
 
 
Correlation coefficient (r) = CORREL (Array 1, Array 2) 
 
Slope of regression line = 22 x)( x
y)( x)(  -  )x(  
∑−∑
∑∑∑
n
yn
  
 
Slope of regression line = SLOPE (Array 1, Array 2) 
 
y- intercept = xB - y  =A  
y- intercept = INTERCEPT (Array 1, Array 2) 
 
Residual sum of squares =  ∑ 2calculated)Y - ( originalY
 
Where, 
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Y calculated =  A + Bx 
n = Number of measurements 
x = Individual concentration 
y = Individual area 
x   = Average concentration 
y  = Average area  
Residual sum of squares = SUMXMY2 (Array 1, TREND (Array 1, Array 2, Array2)) 
 
Relative Response Factor = 
standardfor  line regression of Slope
impurity for  line regression of Slope  
 
6.3 Accuracy (% Recovery) 
 
% Recovery = 100x 
added (mg) substance ofAmmount 
  found (mg) sbustance ofAmmount  
 
6.4 % impurity in Torsemide Tablets 
 
% Impurity = such)(as%assayStd.
RRF
1
LC
Wt.Avg
WtSpl
Dilution
Dilution
 wtStd.
Astd
Asp ×××××  
e.g. 
% Impurity-A = 5.99
1.357
1
5
75.7
605.6
100
50
1
100
2.001
5048
22115 ××××××  
% Impurity-A = 0.32 
 
% Impurity-B = 5.99
0.946
1
5
75.7
605.6
100
50
1
100
2.001
5048
14403 ××××××  
% Impurity-B = 0.30 
 
% Impurity-C = 5.99
1.041
1
5
75.7
605.6
100
50
1
100
2.001
5048
15927 ××××××  
% Impurity-C = 0.30 
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% unknown = 5.99
1
1
5
75.7
605.6
100
50
1
100
2.001
5048
2579 ××××××  
% unknown = 0.05 
% Total impurities = Total known impurities + Total unknown impurities 
% Total impurities = (0.32 + 0.30 + 0.30) + (0.05) 
% Total impurities = 0.97 
Asp : Area of impurity in sample 
Astd : Mean area of diluted standard 
Std. wt : Std weight in mg 
Spl wt : Sample weight in mg 
Avg wt : Average weight in mg 
LC : Label claim per tablet (mg) 
 
6.5 95% Confidence Interval (CI) 
 
95% Confidence Interval (CI) = n
SD  t  ×± α  
Where, 
SD = Standard Deviation 
X   = Average concentration 
n = Number of measurements 
tα = t value at n-1 from t table (two tail) 
95% Confidence Interval (CI) = SD (2.57058)/SQRT (6) 
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GLOSSARY 
SPECIFICITY 
 
 Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically these might include 
impurities, degradants, matrix, etc. 
 
 Lack of specificity of an individual analytical procedure may be compensated by 
other supporting analytical procedure(s). 
This definition has the following implications: 
 
Identification: To ensure the identity of an analyte. 
 
Purity Tests:  
 To ensure that all the analytical procedures performed allow an                    
accurate statement of the content of impurities of an analyte, i.e. related substances test, 
heavy metals, residual solvents content, etc. 
 
Assay (content or potency):  
 To provide an exact result which allows an accurate statement  on the content or 
potency of the analyte in a sample. 
 
ACCURACY 
 
The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. 
This is sometimes termed trueness. 
 
PRECISION  
 
The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple sampling of 
the same homogeneous sample under the prescribed conditions. Precision may be 
considered at three levels:  repeatability, intermediate precision and reproducibility. 
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Precision should be investigated using homogeneous, authentic samples. 
However, if it is not possible to obtain a homogeneous sample it may be investigated 
using artificially prepared samples or a sample solution. 
 
The precision of an analytical procedure is usually expressed as the variance, 
standard deviation or coefficient of variation of a series of measurements. 
 
Repeatability 
 
Repeatability expresses the precision under the same operating conditions over a 
short interval of time. Repeatability is also termed intra-assay precision . 
Intermediate precision 
Intermediate precision expresses within-laboratories variations: different days, different 
analysts, different equipment, etc. 
 
Reproducibility 
 
Reproducibility expresses the precision between laboratories (collaborative studies, 
usually applied to standardization of methodology). 
 
DETECTION LIMIT  
 
The detection limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be detected but not necessarily quantitated as an exact 
value. 
 
QUANTITATION LIMIT 
 
The quantitation limit of an individual analytical procedure is the lowest amount 
of analyte in a sample which can be quantitatively determined with suitable precision and 
accuracy. The quantitation limit is a parameter of quantitative assays for low levels of 
compounds in sample matrices, and is used particularly for the determination of 
impurities and/or degradation products. 
 
 
 
 
Glossary 
 
 
 199 
 
LINEARITY 
 
The linearity of an analytical procedure is its ability (within a given range)  to 
obtain test results which are directly  proportional to the concentration (amount) of 
analyte in the sample. 
 
RANGE 
 
The range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. 
 
ROBUSTNESS 
 
The robustness of an analytical procedure is a measure of its capacity to remain 
unaffected by small, but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. 
 
Retention time   tR   Time from injection to appearance of peak 
maximum 
tR = tm (1+k) 
 
Column dead time  tm   Time for elution of earliest possible band 
   (or mobile phase molecules);  
also symbolized as t0. 
tm = Vm/F  
 
Retention factor   k   Fraction of a sample compound distributed 
into stationary phase divided by fraction in  
mobile phase; also symbolized as k 
k = (tR - tm) / tm 
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Column dead volume   Vm   Volume of mobile phase inside column 
Vm = tm F 
Vm » 0.7 (p/4) L dc2
» 0.5 L dc2
(F is the mobile phase flow rate in mL/min; 
t0 is in minutes; dc is the column i.d. in cm; 
and Vm is in mL) 
 
Reversed-phase separation    Separation that uses an aqueous mobile 
phase (with added organic) and a column 
with alkyl-bonded-phase packing such as C8 
or C18. 
 
Normal-phase separation    Separation with silica or polar-bonded phase 
Column 
 
Column plate number  N   A column parameter that measures column 
efficiency or the narrowness of sample 
bands 
N = 16 (tR / W)2 
(W is baseline bandwidth) 
 
Column plate height   H  A column parameter that measures column 
(HETP value)     efficiency per unit length of column 
H = L / N 
 
Resolution    Rs   A separation parameter that measures how 
well two adjacent bands are separated 
Rs = (t2 - t1) / (1/2)(W1 + W2) 
Separation factor   α   Ratio of k values for two adjacent bands 
α = k2 / k1 
 
 
 
Glossary 
 
Separation selectivity    Relative band separation (value of α) 
provided by some combination of mobile 
phase and column packing. 
 
Separation efficiency     Relative bandwidths (value of N) provided  
by some column and separation conditions 
(flow rate, column length, and temperature) 
 
Column pressure   P   Pressure drop across column during 
separation (psi) 
Retention Time tR
 
Column dead-time tM
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Estimating tM 
1 by the chromatogram: 
 
 
2. By injecting an non-retained solute (uracil, NaNO3, etc.) 
3. By calculation: 
internal volume, VM » 0.5 L dC
2 (» 0.1 x L for 4.6-mm i.d.) 
L is column length, dC is column i.d. (both in cm) 
VM is column volume in mL, F is flow in mL/min 
tM = VM / F 
 
Retention factor k 
Retention factor, defined as the ratio of amount of X in the stationary phase to 
amount of X in the mobile phase, can be computed by dividing the corrected retention 
time (tR - tm) by tm.  
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Retention factor can be estimated quickly by using tm as a ruler and measuring 
retention time from tm in units of tm. k does not change with flow rate or column 
dimensions, but is influenced by column chemistry and mobile phase composition. 
 
Selectivity α 
Selectivity, α is defined as the ratio of k-values for adjacent peaks. By convention α 
≥1.0.Thes shortcoming of using α to measure separation is that it does not take the band 
width into account. 
 
α n= (2.15 / 1.95) = 1.10 
k =1.95 k =2.15
Column plate number N 
 
Band width is measured as the column plate number. The easiest way to measure 
N is using the half-height method. Alternatively, the baseline technique can be used to 
determine N. N is an expression of the standard deviation of a peak. 
 
N for commercial columns tested under ideal conditions (e.g., using toluene) will 
be in the range of 80,000 plates/meter for 5 μm columns and 100,000 plates/meter for 3 
μm columns.In practical use, however, the plate number often will be much lower. This 
equation allows us to estimate practical expectations for N in real applications. For 
example, a 25 cm, 5 μm column would be expected to generate about 15,000 plates (vs a 
test value of perhaps N =20,000). 
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Estimating N 
N » 3000 L / dp 
where: 
L = column length (cm) 
dp = particle diameter (mm) 
 
 
Whereas k, N, and α give us measurements of peak characteristics, we’re most 
interested in whether our peaks are separated. The upper left chromatogram is too-well 
separated; time is wasted. The upper right one looks good. The lower left separation is 
insufficient for many purposes, but may be adequate for qualitative analysis or chiral 
assays. The lower right separation is too poor for any use except determining that two 
compounds are present. The requirements of each method dictate the resolution required 
for satisfactory results. 
 
Resolution Rs 
 Resolution can be calculated by; 
Rs = (tr2 - tr1)/ 0.5(Wb1 + Wb2) 
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Another way to look at resolution is to express Rs in terms of N, α, and k. k 
measures retention, and is influenced mainly by solvent strength.  An α is most strongly 
affected by chemical changes in the column or mobile phase. N is a "physical" (kinetic) 
rather than "chemical" (thermodynamic) parameter and changes resolution only in 
relation to its square root. 
 
Here we see the influence of each factor independently expressed. 
 
 
 
 
 
Glossary 
 
How resolution varies with N, α, k 
 
Resolution depends on the efficiency of the chromatographic system (as measured 
by the plate number, N), on the selectivity of the chromatographic system (as measured 
by the separation factor, a) and on the retention of the chromatographic system (as 
measured by the retention factor, k) for the analytes of interest. Overall, efficiency and 
retention (or range of retentions for various analytes) determine the number of peaks 
which can be separated. The selectivity determines whether a specific pair of peaks can 
be separated. 
 
If α and N are held constant, then the relationship between Resolution and 
retention becomes Rs α k/(1 + k). At low k-values, resolution is poor. As k is increased, a 
point is reached at which resolution is only marginally increased for further increases in 
k. Sensitivity (peak height) becomes poorer as peaks get broader and are more strongly 
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retained. The factor k/(1+k) can be thought of as the fraction of analyte molecules which 
interact with the column packing at any given time. 
 
The best place to work to obtain significant changes in resolution with reasonable 
changes in retention (or solvent strength) is in the 1 < k < 20 or better yet, 2 < k < 5 
region. 
 
Resolution depends on efficiency, selectivity and retention 
RS = (1/4) N1/2 (α - 1)   [k / (1 + k)] 
Efficiency    selectivity       retention 
? The number of peaks that can be resolved depends on efficiency and retention. 
? Whether specific compounds can be resolved depends on selectivity. 
